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Glycosylphosphatidylinositols (GPIs) are a family of complex glycolipids that are ubiquitous 
in eukaryotic cells. GPIs are added as a post-translational modification at the C-terminus of 
proteins or can be found as free glycolipids displayed on the outer leaflet of the cell 
membrane. GPI contains a conserved pseudo-pentasaccharide glycan core and a phospholipid, 
(Man(1→2)Man(1→6)Man(1→4)GlcN(1→6)-myo-Inositol-1-PO4-lipid). GPIs and 
GPI-anchored proteins participate in diverse biological and pathological events and activate 
the host immune system during parasitic infections. These glycolipids are difficult to isolate 
in pure and homogeneous form, therefore, to date, chemical synthesis has remained the best 




Figure 1: Summary of the thesis describing the investigation of the role of GPIs in biological and biophysical aspects.   
In malaria, GPIs act as a toxin during the progress of the disease and may be responsible for 
the strong symptoms of the infection. Therefore, the development of an antitoxic GPI-
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glycoconjugate vaccine represents a promising approach to preventing malaria pathogenesis. 
In this work, chemical synthesis was applied to obtain GPIs and GPI-derivatives from the GPI 
of Plasmodium spp. to investigate the role of GPIs in three aspects; the design and evaluation 
of CRM197-GPI glycoconjugates as antimalarial vaccine candidates, the semi-synthesis of 
GPI-anchored proteins to understand the role of GPIs on the protein function and structure, 
and for the evaluation of the biophysical properties of GPI fragments in monolayers as model 
membranes (figure 1).   
 
Starting with the use of GPI as an anti-toxin vaccine, Chapter 2 comprises the design, 
synthesis and immunological evaluation of six structurally distinct GPI fragments from the 
GPI of P. falciparum. These fragments were designed to cover different components of the 
glycan moiety of the P. falciparum GPI structure. The GPI fragments were synthesized using 
a convergent synthetic strategy bearing a thiol linker that was used for their conjugation to the 
carrier protein without compromising the amine functionality of the glucosamine and 
phosphoethanolamine units. Benzyl ethers were used as a permanent protecting group and 
acetyl ester, TIPS and allyl ethers were used as orthogonal temporary protecting groups. Birch 
reduction was used for global deprotection and products were obtained as a mixture of thiol 
and disulfide oligosaccharides which were reduced and purified using size exclusion 
chromatography. The synthesised glycans were conjugated to the CRM197 carrier protein 
using N-succinimidyl-3-(bromoacetamido)propionate (SBAP)  activation of protein followed 
by reaction with the thiol-glycans. 
The CRM197-GPI glycocojugates were tested for immunogenicity and efficacy as antimalarial 
vaccine candidates using C57BL/6JRj as experimental cerebral malaria (ECM) model. A 
structureactivity relationship of different synthetic GPIs with respect to immunogenicity by 
glycan array analysis was established. All the glycoconjugate immunized mice showed an 
increased survival compared to the control group. Cross-reactivity revealed that the length of 
the mannose backbone is an important epitope for immune recognition. The 
phosphoethanolamine present on the ManIII residue and myo-inositol also represent important 
immunogenic epitopes. This study added to current evidence that a GPI-antitoxic vaccine 
offers protection against Plasmodium GPI-induced ECM. The protection is dependent on both 
the antibody and cellular immune response. Furthermore, this study demonstrated that GPI 







The participation and role of GPIs of parasitic GPI-anchored proteins involved in 
proteinprotein interactions mediating the attachment of Plasmodium parasites to the host 
cells and further infection of erythrocytes is unknown. To evaluate the biological function of 
GPIs and its effect on proteins involved in the infection process during malaria infection, 
chapter 3 describes the synthesis of a lipidated GPI containing a cysteine residue for ligation 
reactions with proteins. The synthesis of this GPI was successfully achieved using a [3+1+2] 
glycosylation strategy with trichloroacetimidate glycosyl donors to obtain the glycan moiety 
and late-stage phosphorylations. The challenging removal of the protecting groups was 
completed using a palladium catalysed hydrogenolysis followed by acid treatment in the 
presence of mercury salts. 
The synthetic GPI glycolipid and Cys-Biotin were ligated to the 19 kDa fragment of the 
MSP1 protein, which is considered to be essential for the infection by the parasite. This 
process was carried out by using intein trans-splicing reactions to deliver pure MSP119-GPI 
and MSP119-Biotin. The protein structure of the ligation products MSP119-GPI and MSP119-
Biotin were evaluated using analysis by circular dichroism (CD).  CD spectra for both 
modified proteins, with and without GPI, were similar showing that these C-terminal 
modifications do not affect the overall structure of the MSP119 protein in solution.  
Evaluation of the biological activity of MSP119-GPI and MSP119-Biotin for the activation of 
antigen presenting cells was completed by stimulating dendritic cells in vitro. This dendritic 
cell stimulation assay showed that both MSP119-Biotin and MSP119-GPI are able to activate 
the T-cells and induce the release of the cytokines TNF-α and IL-12. However, very high 
level of both cytokines, TNF-α and IL-12, were only observed using the MSP119-GPI 
conjugate. This study is the first immunological and structural evaluation of a homogeneous 
synthetic MSP119-GPI and showed that the GPI anchor is an important and dominant 
immunogenic factor in the immune response against GPI-anchored proteins from 
Plasmodium. Furthermore, this study shows the MSP119-GPI is a potential target for vaccine 
development. 
The lipid chains present on GPIs are highly variable and contribute to the heterogeneity of 
GPIs. These chains interact through van der Waals forces with other lipids chains of the 
bilayer and participate in the formation of membrane microdomains. The presence of the large 
hydrophilic oligosaccharide head group in GPI distinguishes these glycolipids from other 
phospholipids by providing flexibility and additional hydrogen bonding that can dominate the 
lipid interactions. Studies of the structural arrangement of GPIs in a model membrane can 
provide insight into the relationship between the glycolipid composition of and its behavior in 
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model membranes. To evaluate the correlation between the GPI lipid components and the 
structural arrangement of GPI in model membranes that could explain their biological 
function, chapter 4 presents the synthesis of GPI fragments bearing linear, branched and 
unsaturated lipid chains and the results of their affinity towards the formation of substructures 
in monolayers at the water/air interface. 
Four GPI fragments were synthesized containing the pseudo-disaccharide glycan and a 
diacylglycerol bearing either saturated, unsaturated or branched fatty acids chains. 
Monolayers of the glycolipids were generated and their structural parameters were determined 
by using IR and GIXD measurements to obtain the tilt angle of the alkyl chains and determine 
the change in the packing mode and lattice. GIXD patterns and contour plots of the 
monolayers depicted different substructures that depend on the lipid composition and the 
polar head group. The monolayer structures showed a correlation between an increase in 
zwitterionic character of the glycolipid and a reduction in the flexibility of the head group of 
the GPI fragment. GPI fragments containing an acetylated glucosamine were more flexible 
and demonstrated a reduced packing compared to the non-acetylated glycolipid. This 
confirmed the importance of this amine in the hydrogen bonding and electrostatic interaction 
for the formation of ordered structures in the membrane. These results can be directly 
correlated to GPI biosynthesis with the deacetylation of the glucosamine as a crucial step. The 
presence of branching and unsaturation at the lipid induces a similar effect and are responsible 
for the fluidity of the membrane. These findings suggest that the lipids play a crucial role in 
the organization of the GPIs in the membrane and are responsible for many cellular functions.  
Altogether, this work was able to demonstrate the applicability of chemical synthesis to obtain 
better insight into the structural and immunological properties of GPIs and GPI-anchored 
protein from Plasmodium. Furthermore, the results of this thesis show the importance of GPIs 
in parasitic infection and why these glycolipids should be considered as an important 










Glykosylphosphatidylinositole (GPIs) sind eine Familie von komplexen Glykolipiden, die in 
eukaryotischen Zellen ubiquitär vorkommen. GPIs werden als posttranslationale Modifikation 
am C-Terminus von Proteinen hinzugefügt oder sind als freie Glykolipide auf der äußeren 
Oberfläche der Zellmembran zu finden. GPIs enthalten einen konservierten Pseudo-
Pentasaccharid-Glykankern und ein Phospholipid, (Man(1→2)Man(1→6)Man(1→4) 
GlcN-myo-Inositol-1-PO4-lipid). GPIs und GPI-verankerte Proteine sind an verschiedenen 
biologischen und pathologischen Ereignissen beteiligt und wirken unter Anderen für die 
Aktivierung des Immunsystems des Wirtes bei parasitären Infektionen. GPI Glykolipide sind 
schwer in reiner und homogener Form aus natürlichen Quellen zu isolieren und die chemische 
Synthese ist der effizienteste Weg, sie für biologische Studien zu erhalten. 
 
 
Abbildung 1: Zusammenfassung der Arbeit, die die Untersuchung der Funktion von GPIs in biologischen und biophysikalischen  Studien beschreibt. 
 
In Malaria wirken die parasitäre GPIs während des Krankheitsverlaufs als Toxine und können 
für die schweren Symptome der Infektion verantwortlich sein. Daher stellt die Entwicklung 
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eines antitoxischen GPI-Glykokonjugat-Impfstoffs einen vielversprechenden Ansatz zur 
Verhinderung der Malariapathogenese dar. In dieser Arbeit wurde die chemische Synthese 
benutzt, um GPIs und GPI-Derivate aus dem GPI von Plasmodium spp. zu erhalten und die 
Rolle von GPIs in drei funktionelle Studien zu untersuchen: die Aktivität von CRM197-GPI-
Glykokonjugaten als Antimalaria-Impfstoffkandidaten, als Bausteine für die Semisynthese 
von GPI-verankerten Proteinen zur Untersuchung des Effekts von GPIs in die Funktion und 
Struktur des Protein, und für die Analyse der biophysikalischen Eigenschaften von GPI-
Fragmenten in Monoschichten als Modellmembranen (Abbildung 1).   
Beginnend mit der Verwendung von GPI als Anti-Toxin-Impfstoff umfasst Kapitel 2 das 
Design, die Synthese und die immunologische Untersuchung von sechs strukturell 
unterschiedlichen GPI-Fragmenten aus dem GPI von P. falciparum. Diese Fragmente wurden 
entwickelt, um verschiedene Komponenten des Glykanteils der P. falciparum GPI-Struktur 
abzudecken. Die GPI-Fragmente wurden mit einer konvergenten synthetischen Strategie 
synthetisiert und tragen einen Thiol-Linker für ihre Konjugation mit dem Trägerprotein ohne 
die Aminogruppen von Glucosamin und den Phosphoethanolamineinheiten zu 
beeinträchtigen. Benzylether wurden als permanente Schutzgruppe benutzt und Acetylester, 
TIPS Ether und Allylether wurden als orthogonale temporäre Schutzgruppen verwendet. Die 
globale Entschützung wurde durch eine Birch-Reduktion durchgeführt und die Produkte 
wurden als Mischung aus Thiol- und Disulfidoverbindungen erhalten, die mittels TCEP 
reduziert wurden und durch Größenausschlusschromatographie gereinigt wurden. Die 
synthetisierten Glykane wurden mit dem CRM197-Trägerprotein unter Verwendung der N-
Succinimidyl-3-(bromoacetamido)propionat (SBAP)-Aktivierung des Proteins konjugiert, 
gefolgt von der Reaktion mit den Thiol-Glykanen.  
Die CRM197-GPI-Glykokojugate wurden auf Immunogenität und Wirksamkeit als 
Antimalaria-Impfstoffkandidaten getestet, wobei C57BL/6JRj als ECM-Modell 
(Experimental Cerebral Malaria) verwendet wurde. Eine Struktur-Aktivitäts-Beziehung 
verschiedener synthetischer GPIs in Bezug auf die Immunogenität durch Glykan-Array-
Analyse wurde etabliert. Alle mit Glykokonjugaten immunisierten Mäuse zeigten ein erhöhtes 
Überleben im Vergleich zur Kontrollgruppe. Die Kreuzreaktivität ergab, dass die Länge des 
Mannose-Rückgrats ein wichtiges Epitop für die Immunerkennung ist. Das am ManIII-Rest 
vorhandene Phosphoethanolamin und das Myo-Inositol stellen ebenfalls wichtige 
immunogene Epitope dar. Diese Studie fügte den aktuellen Erkenntnissen hinzu, dass ein 





ist sowohl vom Antikörper als auch von der zellulären Immunantwort abhängig. Darüber 
hinaus zeigte diese Studie, dass die GPI-Zusammensetzung und Präsentation auf dem 
Trägerprotein eine wichtige Rolle bei der Auslösung einer Immunantwort spielt. 
Die Beteiligung und Rolle von GPIs in der Aktivität parasitärer GPI-verankerter Proteine, die 
an Protein-Protein-Wechselwirkungen beteiligt sind und die Bindung von Plasmodium-
Parasiten an die Wirtszellen sowie die weitere Infektion von Erythrozyten vermitteln, ist 
unbekannt. Um die biologische Funktion von GPIs und ihre Wirkung auf Proteine zu 
bewerten, die während einer Malaria-Infektion und am Infektionsprozess beteiligt sind, 
beschreibt Kapitel 3 die Synthese eines lipidierten GPIs, das mit einem Cysteinrest für 
Ligationsreaktionen mit Proteinen ausgestattet war. Die Synthese des GPIs wurde erfolgreich 
mit einer [3+1+2] Glykosylierungsstrategie mit Verwendung von Trichloracetimidat-
Glykosyl-Donatoren, um den Glykananteil zu erhalten, und folgenden Phosphorylierungen 
mit H-Phosphonate durchgeführt. Die anspruchsvolle Entschützung der Schutzgruppen wurde 
mit einer palladiumkatalysierten Hydrogenolyse und anschließender Säurebehandlung in 
Gegenwart von Quecksilbersalzen abgeschlossen. 
Das synthetische GPI-Glykolipid und Cys-Biotin wurden an das 19 kDa-Fragment des MSP1-
Proteins gebunden, das während der Infektion durch den Parasiten als wesentlich angesehen 
wird. Dieser Prozess wurde unter Verwendung von Intein-Transspleißreaktionen 
durchgeführt, um reines MSP119-GPI und MSP119-Biotin zu liefern. Die Proteinstruktur der 
Ligationsprodukte MSP119-GPI und MSP119-Biotin wurde durch eine Analyse mittels 
Zirkulardichroismus (CD) bewertet.  CD-Spektren für beide modifizierten Proteine, mit und 
ohne GPI, zeigten einheitlich, dass diese C-terminalen Modifikationen die Gesamtstruktur des 
MSP119-Proteins in Lösung nicht beeinflussen.  
Eine Untersuchung der biologischen Aktivität von MSP119-GPI und MSP119-Biotin zur 
Aktivierung von antigenpräsentierenden Zellen wurde in vitro abgeschlossen und es wurde 
gezeigt, dass dendritische Zellen stimuliert werden. Dieser dendritische Zellstimulationsassay 
zeigte, dass sowohl MSP119-Biotin als auch MSP119-GPI in der Lage sind, die Dendritische-
Zellen zu aktivieren und die Freisetzung der Zytokine TNF-α und IL-12 einzuleiten. 
Allerdings wurden sehr hohe Konzentrationen beider Zytokine, TNF-α und IL-12, nur mit 
dem MSP119-GPI beobachtet. Diese Studie ist die erste immunologische und strukturelle 
Analyse eines homogenen synthetischen MSP119-GPI und zeigte, dass der GPI-Anker ein 
wichtiger und dominanter immunogener Faktor in der Immunantwort gegen GPI-verankerte 
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Proteine aus Plasmodium ist. Darüber hinaus zeigt diese Studie das MSP119-GPI als 
potenzielles Ziel für die Impfstoffentwicklung. 
Die auf GPIs vorhandenen Lipidketten sind sehr variabel und tragen zur Heterogenität von 
GPIs bei. Diese Ketten interagieren durch van der Waals Kräfte mit anderen Lipidketten der 
Doppelschicht, die an der Bildung von Membran-Mikrodomänen beteiligt sind. Der großen 
hydrophilen Oligosaccharid-Kopfgruppe in GPIs unterscheidet diese Glykolipide von anderen 
Phospholipiden, indem sie Flexibilität und zusätzliche Wasserstoffbindung bieten, die die 
Lipidwechselwirkungen dominieren können. Studien über die strukturelle Anordnung von 
GPIs in einer Modellmembran können Erkenntnisse über den Zusammenhang zwischen der 
Glykolipidzusammensetzung und ihrem Verhalten in Modellmembranen liefern.  
Um die Korrelation zwischen GPI-Lipidkomponenten und der strukturellen Anordnung von 
GPIs in Modellmembranen zu bewerten, die ihre biologische Funktion erklären könnten, stellt 
Kapitel 4 die Synthese von GPI-Fragmenten mit linearen, verzweigten und ungesättigten 
Lipidketten und die Ergebnisse ihrer Affinität zur Bildung von Substrukturen in 
Monoschichten an der Wasser-Luft-Grenzfläche vor. 
Vier GPI-Fragmente wurden synthetisiert, die das Pseudo-Disaccharid Glykan und ein 
Diacylglycerin mit gesättigten, ungesättigten oder verzweigten Fettsäureketten enthalten. 
Monoschichten der Glykolipide wurden erzeugt und ihre Strukturparameter wurden mit Hilfe 
von IR- und GIXD-Messungen bestimmt, um den Neigungswinkel der Alkylketten zu 
erhalten und die Änderung im Dichtungsmodus und im Gitter zu bestimmen. GIXD-Muster 
und Konturdiagramme der Monoschichten zeigten verschiedene Unterstrukturen, die von der 
Lipidzusammensetzung und von der polaren Kopfgruppe abhängen. Die Monoschichtstruktur 
zeigte eine Korrelation zwischen einer Erhöhung der zwitterionischen Eigenschaften des 
Glykolipids und einer Verringerung der Flexibilität in der Kopfgruppe des GPI-Fragments. 
GPI-Fragmente, die ein acetyliertes Glucosamin enthalten, waren flexibler und präsentierten 
eine reduzierte Packung im Vergleich zum nicht-acetylierten Glykolipid, was die Bedeutung 
dieses Amins in der Wasserstoffbindung und der elektrostatischen Interaktion für die Bildung 
geordneter Strukturen in der Membran bestätigt. Diese Ergebnisse können direkt mit der GPI-
Biosynthese korreliert werden, wobei die Deacetylierung des Glucosamins ein entscheidender 
Schritt ist. DIe Anwesenheit von Verzweigungen und Unsättigungen am Lipid führt zu einer 





deuten darauf hin, dass die Lipide eine entscheidende Rolle bei der Organisation der GPIs in 
der Membran spielen und für viele Zellfunktionen verantwortlich sind.  
Insgesamt konnte diese Arbeit die Anwendbarkeit der chemischen Synthese demonstrieren, 
um bessere Einblicke in die strukturellen und immunologischen Eigenschaften von GPIs und 
GPI verankertem Protein aus Plasmodium spp. zu erhalten. Darüber hinaus zeigen die 
Ergebnisse dieser Arbeit die Bedeutung von GPIs bei parasitären Infektionen und warum 
diese Glykolipide als wichtiger Bestandteil der Entwicklung von Anti-Malaria-Impfstoffen 
















1.1 Carbohydrates Occurrence and Importance  
 
Carbohydrates are the most abundant group of naturally occurring biomolecules and major 
constituents of plants, animals and microorganisms. They are the first product of 
photosynthesis, a main source of energy and play important role in the assembly of complex 
multicellular organs and organisms. Carbohydrates are naturally found as monosaccharides, 
oligosaccharides and polysaccharides with distinctive properties and complexity. They are 
involved in wide range of biological processes such as cell-cell recognition, proliferation of 
cells, fertilization, neuronal development, hormonal activities and activation of immune 
system.1  
The surface of all cells is covered with a dense layer of carbohydrates, the so-called 
glycocalyx.2 They are also found covalently linked to other bio-molecules, such as proteins 
(glycoprotein), peptides (glycopeptide) and lipids (glycolipid) in the form of glycoconjugates 
(figure 1.1).3  
Glycoproteins carry one or more glycans covalently attached to the amino acid side chain of 
the protein, mostly via N- or O- linkage.4-6 An N-glycoprotein carries a glycan chain 
covalently linked to an asparagine residue of a polypeptide chain (commonly involving 
GlcNAc residue).7 Whereas, an O-glycoprotein has glycan linked to the polypeptide via a 
hydroxyl group of a serine or threonine residue.8  
A glycolipid consists of a mono- or oligosaccharide attached to the terminal primary hydroxyl 
group of the lipid moiety. Glycolipids can be neutral or anionic and depending on the nature 
of lipid moiety it can be classified as glyceroglycolipids or sphingolipids. Glyceroglycolipid 
is the class of glycolipid characterized by glycerol with at least one fatty acid as the lipid 
moiety. Glycosphingolipids have sphingolipid as lipid moiety and can be sub classified as 
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gangliosides and cerebrosides. A ganglioside is an anionic glycolipid containing one or more 
residues of sialic acid.9, 10 Sialylation is characteristic of mammalian glycans and is important 
for immune response.4 A cereboside is a glycolipid with polysaccharide backbone and 
ceramide as lipid moiety. In protein–glycan interactions, particular glycans and branching is 




Figure 1.1: Different classes of glycans and glycocojugates found on the surface of cell.13 
 
1.1.1 Biosynthesis of Carbohydrates 
The structure and composition of carbohydrates present on any glycoconjugates is not 
genetically defined and depends on the differential expression and activity of the enzymes 
that are involved in their biosynthesis. The biosynthesis occurs mainly at the lumen of the 
endoplasmic reticulum (ER) and Golgi apparatus (figure 1.2). N-Glycans are initially 
synthesized in the ER as a dolichol diphosphate-linked high-mannose-type oligosaccharide 
containing three terminal glucose, eight mannose, and two internal GlcNAc residues. This 
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oligosaccharide is transferred to the Asn residues of Asn-X-Ser/Thr motifs of polypeptide 
chains.14-16 The processing of oligosaccharides starts in the ER but it is mostly carried out in 
the Golgi apparatus.17, 18 O-Glycans and glycosaminoglycans are synthesized in the Golgi by 
the sequential addition of sugars after the first unit is added to the Ser/Thr residues of 
proteins.19 The glycosyltransferases determines the type of glycosidic linkage formed and 
controls the formation of a particular glycan. The glycosyltransferases involved in N-and O-
glycan biosynthesis are membrane-bound enzymes and are specific for the assembly of a 
defined structure.20  
Proteoglycans are glycoconjugates of proteins covalently attached to the Glycoaminoglycans 
(GAGS) via O-glycosidic Xyl-β-Ser motif. GAGs are anionic polysaccharide consisting of 
GlcNAc or N-sulfated glucosamine along with uronic acid. Commonly found GAGs are 
hyaluronic acid, heparan sulfate, heparin, and keratan sulfate. The biosynthesis of GAGs 
starts with the release of the precursor protein into the rough endoplasmic reticulum 
frequently found with N-linked oligosaccharides. Major posttranslational modifications occur 
in the Golgi complex which includes addition of the either glycosaminoglycan chains or O-
linked oligosaccharides onto serine and threonine residues.21-24 
Glycophosphotidylinositols (GPI) are complex glycolipids found as posttranslational 
modification at the C-terminus of the protein. The biosynthesis of GPI anchor occurs 
exclusively in the ER but some modifications to the glycan and remodeling of the lipid takes 
place in the Golgi apparatus.25 The biosynthesis of GPI is discussed in detail in section 1.2.2. 
Glycosphingolipids (GSLs) are a class of glycolipids that are conjugates to glycans and bear 
ceramide containing lipids.26, 27 The ceramide is synthesized on the cytoplasmic side of the 
rough ER which is subsequently transferred to the luminal face and traffics to the Golgi 
apparatus.An important example of GSL is GlcCer that is synthesized on the cytoplasmic face 
of Golgi apparatus and flips into the Golgi lumen. GlcCer can be elongated by a series of 
glycosyltransferases in Golgi apparatus. Similar to N- and O-glycans, GSLs are involved in 
many physiological functions including cell–cell interactions, activation of immune responses 





Figure 1.2: Simplified representation of biosynthesis of different types of eukaryotic glycoconjugates present in a cell. Asterisks represent the addition of outer sugars to glycans in the Golgi apparatus.28 
 
1.2 Complexity to obtain Carbohydrates 
 
The chemical synthesis of linear oligomers from amino acids and nucleic acids require the 
formation of only one type of linkage (amide bond or phosphodiester bond), which can be 
obtained by standardized protocols. However, the synthesis of oligosaccharides is more 
challenging due to the presence of multiples functional groups and their possible assembly 
into both linear and branch structures (figure 1.3). To obtain oligosaccharides chemically a 
high level of stereo- and regio- selectivity is required during the process.  
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Figure 1.3: Linkages and combinational complexity found in the three major biopolymers. A) Nucleic acids, B) Proteins, C) Oligo and Polysaccharides 
 
The lack of genetic control leads to the biosynthesis of glycoconjugates as heterogeneous 
mixture of glycans. The difficulty in separateion of single glycoconjugate hinders the 
investigations to determine the role of a defined carbohydrate structure in the biological 
function of these molecules. Therefore, the most convenient strategies to obtain complex 
glycans in homogeneous form and good quantities are chemical,29 chemo-enzymatic30, 31 or 
enzymatic synthesis.32 These strategies provide substructures, regio-isomers or unnatural 
mimetics that can be aimed to get insights about role of carbohydrates in biological processes 
and for their application in biomedicine. Furthermore, these strategies facilitate  the 
development of high affinity ligands,33 mapping of immunogenic carbohydrate epitopes in 
polysaccharides,34  and to introduce labelling or incorporation of linkers to simplify their use 
in the preparation of glycoconjugates.35 
 
1.3 Organic Synthesis for Oligosaccharides 
 
Despite remarkable progress during last years, there are no standard protocols and conditions 
that can be used for the synthesis of homogeneous natural and unnatural oligosaccharides. 
Nucleic Acids 
Linear combination of toto 
different nucleotides: 2 
Peptides Linear combination of 
different am ifo acids: 2 
Oligosaccharides 
Linear combination of toto 
different monosaccharides: 20 
HO Ho o HO 
O 
/ (1-6) on-linkage o 
P O  *m Hoi HO OH I O I O 
R2 o H J N  
o §1 HO 
HO O 
\ 
Ö w» (1-3) a-linkage o 
DMTO B' 
R' 
OH FmocHN o TIPSO BnO OLev o ,weG 
o I NC ,p o `n |













There are two fundamental challenges in the chemical synthesis of oligosaccharides, the 
selective modification of specific hydroxyl groups in a carbohydrate unit and the control of 
the stereochemical outcome during glycosylation reactions. To overcome these problems, a 
large set of protecting groups, leaving groups, reaction conditions and glycosylation 
promoters have been established to obtain glycans having the desired structures and 
modifications.  
The control of regioselectivity has been carried out through the use of protecting groups that 
are installed during the preparation of protected monosaccharides building blocks. In addition 
to their masking role, these groups can also participate in the steric and electronic stabilization 
of intermediates during the glycosylation reactions and contribute in the stereoselectivity of 
the reactions and thereof in the configuration of the new connection between two 
carbohydrate units. The selection of a particular combination of protecting groups plays a 
significant role in obtaining complicated glycan structures in a simplified manner. 
 
1.3.1 Stereoselectivity in Glycosylation Reactions 
The main challenge in glycosylation reactions is the control of the stereoselectivity to obtain a 
defined product having a 1,2-trans- or a 1,2-cis-linkage. In uncontrolled glycosylations, both 
linkages are almost equally formed. Therefore, to favor the formation of one product, 
different parameters influencing the selectivity of glycosylation need to be established and 
optimized. The most common methods are changing the reaction temperature, solvent, 
promotor, type of leaving groups used and the size and type of protecting groups (figure 
1.4b).  
A control of the reaction temperature can be used to favor the formation of more stable 
products through a thermodynamically controlled process at high temperatures, or to favor the 
formation of kinetically controlled products at low temperature. However, depending of the 
reactivity of the glycosylation agents, the structural features and of the protecting groups 
installed in both, the glycosyl donor and the glycosyl acceptor, a mixture of stereoisomers can 








Figure 1.4: Strategies for controlling the outcome in glycosylation reactions. 
 
In a glycosylation reaction, the leaving group at the anomeric position of the glycosyl donor is 
activated by the promotor in the first step of the process. These promoters are generally salts, 
Lewis acids and salts or esters of trifluoromethansulfonic acid (Triflates).36 Some of the most 
common promoters include: AgCO3, AgClO4 and Ag2O, NIS/TfOH, Tf2O, BF3-Et2O, SnCl4, 
AgOTf, TfOH and its derivatives (TMSOTf, TBSOTf and MeOTf), and more recently the use 
of metal salts such as AgCl, AuCl3 and CuCl2.37 After the activation, the leaving group is 
released and an oxocarbenium ion is formed. This ion can be stabilized by adjacent protecting 
groups and can react with nucleophiles, i.e the hydroxyl group of the acceptor, that approach 
from either the top or the bottom face giving an α- or β-configured glycosylation product, or a 
mixture of them.  
 The selection of the protecting groups; especially of groups able to give neighboring 
participation is of exceptional importance to induce selectivity during glycosylations. An 
ß-face attack › o p ß ø ı  
ß-Glycoside O PGO PrQmQt ›=@o>a:i R-OH o › PGO LG Glycosyl donor Oxocarbenium Ion a-face attack OR a-Glycoside 
Q Nu PGO o o 
Promotor › PGo 0+ \ O ı ~. YO › 
o P G O , O R  _<0 
o 1,2-trans Glycoside Acyloxonium Ion 
PGO PGO O OPG O PGO HO R2sicı2› Promotor › HOQ PGO + LG OH 
O OPG LG o o ,o 









PGO* O Promoto peo- LG Hb 
o I* PGO \ HO-R o + 0*9( 




ester, amide or carbonate function at the C-2 position of the glycosyl donor can interact with 
the oxocarbenium ion forming an active intermediate through the formation of a cyclic 
acyloxonium ion that hinders the attack of the nucleophile from the face that this group is 
localized (figure 1.4b). As a consequence, the attack from the nucleophile (glycosyl acceptor) 
can take place only from the opposite face forming 1,2-trans-products dominantly.38 
The formation of 1,2-cis-linkages such as -mannopyranosides and -glucopyranosides is 
more challenging and require of additional considerations during the glycosylation 
reactions.39 Some strategies to increase the selectivity to 1,2-cis products are the 
intramolecular aglycon delivery (IAD),40 and the use of fluorides and bromides as leaving 
groups to favor the progress of the glycosylation via a SN2-type mechanism.41 Furthermore, 
the use of remote group participation involving a protecting group at the C-3, C-4 or C-6 
position of the glycosyl donor have also been developed over the past years and are nowadays 
efficiently applied to ensure the synthesis of complex saccharides having 1,2-cis linkages 
(figure 1.4c). 42 
Other reaction conditions such as temperature and the presence of certain solvents can favor 
the formation of an - or a -product. Whereas ethers and toluene can interact with the 
oxocarbenium anion favoring SN1-type conditions by a so-called inversion of the anomeric 
effect and support the formation of the thermodynamically stable -linkages, acetonitrile has 
been described to induce the formation of an -nitrilium-nitrile-conjugate with strong 
activated donors that favors the formation of equatorial -products.43  
 
1.4 Glycophosphatidylinositol (GPI) 
 
Glycophosphotidylinositols (GPI) are complex glycolipids which are attached to the C-
terminus of the protein as a posttranslational modification in eukaryotes. The surface of the 
cell contains many GPI and GPI like molecules such as lipophosphoglycans (LPG) or 
Glycoinositolphospholipids (GIPL).44-46 GPIs exist in free form or can be found anchored to 
proteins. GPIs have a conserved glycan core structure bearing a phosphoethanolamine unit 
connecting the C-terminus of the protein to the glycan and a lipid attached to the glycan core 
via phoshodiester bond at myo-inositol. The GPI anchoring a protein was first identified in 





was found to release alkaline phosphatase from tissues. Over the next several years, PI-PLCs 
purified from other types of bacteria contained similar enzymatic activity and various other 
proteins could be released from tissues when treated with PI-PLC. This evidence suggested 
that these proteins are covalently attached to the cell membrane via a site on the protein and a 




Figure 1.5: Structure and possible modifications found in Glycophosphatidylinositols anchored protein. 
 
The first full structure of a GPI was revealed in 1988 when the GPI anchor of the variant 
surface proteins (VSGs) of the protozoa Trypanosoma bruceiwas described.48, 49 Following 
this report, the GPI structure of the Thy-1 glycoprotein from rat brain49 and subsequently of 
various free GPIs and GPI anchored proteins have been isolated from eukaryotes. 
Approximately 150 proteins are modified with GPI and they play an important role in the 
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Table 1.1: Structural diversity found in some GPI-anchors 
Origin R1 R2 R3 R4 R5 R6 R7 R8 Lipid 
L. major PSP51 H H H H H H H H AAG 
P. falciparum52-54 ±Manα H H H H H H Acyl DAG 
T. cruzi NETNES55 Manα H H H H H AEP H AAG 
P. communis AGP56 H H ±Galβ H H H H H CER 
T. brucei VSG 11749 H H H Gal2-4α H H H H DAG 
T. brucei VSG 12157 H Galβ H Gal2-4α H H H H DAG 
T. gondii58 H H ±Glc-GalNAcβ H H H H H DAG 
T. congolense VSG59 H H Gal-GlcNAcβ H H H H H DAG 
Rat brain Thy-160 ±Manα H GalNAcβ H H PEtN H H n.d. 
Hamster brain PrPSc61 ±Manα H ±Sia-±Gal-GalNAcβ H H PEtN H H n.d. 
Human CD5262 ±Manα H H H H PEtN H ±pal. DAG 
Human sperm CD5263 H H H H H PEtN H pal. AG 
Human erythrocyte 
CD5964 
H H ±GalNAcβ H PEtN PEtN H pal. AAG 




 correspond to GPI modifications described in Figure1.5. AAG = 1-Alkyl-2-
acylglycerol; AEP = Aminoethyl phosphonate; AG = 1-Alkyl-2-lysoglycerol; DAG = Diacylglycerol; Gal = Galactose; 
GalNAc = N-Acetylgalactosamine; Glc = Glucose; Man = Mannose; n.d. = not determined; Sia = Sialic acid; PEtN: 
Phosphatidyl ethanolamine. 
 
The GPI glycan core consists of the pseudopentasaccharide  α-Man-(1→2)-α-Man-(1→6)- α-
Man-(1→4) -α-GlcN-(1→6)-myo-Inositol (figure 1.5)47 and is conserved across all species.  
Diverse site specific modifications and branched structures have been reported for the GPI 
core. The modifications can be in the form of additional acylations, phosphoethanolamine and 
additional saccharide units. The most common saccharide modifications include, α-
mannosylation of C2 position of ManIII (found in P. falciparum), a -galactose residue at the 
C3 of ManII and oligosaccharide branching at the C4 and C3 position of ManI. The presence 
of phospholipid at the C1 position of the inositol is common in all the GPIs (table 1.1). A late 
stage lipid remodeling during the GPI biosynthesis, provides GPIs with a diverse variety of 
lipids. This diversity includes a diacylglycerol, an alkylacylglycerol, lyso-alkylglycerols and 
ceramides with alkyl chains of different length and degree of unsaturation.65 Occasionally, a 
fatty acid ester is present at C2 position of inositol in addition to the phospholipid (palmitoyl 
at C2 position of inositol in Malaria GPI). The phosphoethanolamine at C6 position of the 
ManIII is present in all the GPIs and is involvedin the attachment of the GPIs to the C-
terminus of the protein. An additional phosphoethanolamine at the C2 position of ManI is 





An aminoethylphosphonate at C6 position of GlcN is found in GPI from Trypanosoma 
cruzi.66  
 
1.4.1 Function of GPI-Anchored Proteins 
GPI-anchored proteins have been identified in all major cell type and tissues. GPI-anchored 
proteins vary in size, from the 12 amino acid glycopeptide CD52 to the 175 kDa protein 
CDw109.67 GPI-anchored proteins display diverse biological functions. Many of these 
proteins have hydrolytic and other enzymatic activity, such as alkaline phosphatase, renal 
dipeptidase and erythrocyte acetylcholinesterase. Certain GPI-anchored proteins are involved 
in cell-cell interaction and adhesion, such as neural cell adhesion molecule (NCAM) and 
CD58. CD55 and CD59 are regulatory proteins of the complement system. Immunogenically 
important GPI-anchored proteins include CD24, CD52 and Thy-1. Folate-binding protein, 
CD14 and CD16b are the GPI anchored receptors.45, 68 There are some GPI-anchored proteins 
that do not yet have an assigned function like the Prion protein.69 Mutations in GPI-anchored 
proteins called glypicans can cause defects in cell division and tissue morphogenesis.70 
GPI-anchored proteins are also essential for the development of roots, pollen germination and 
synthesis of the cell wall in plants.71 Arabidopsis has about 250 GP1-anchored proteins that 
participate in cell wall deposition, defense responses, and cell signaling. Arabinogalactan 
proteins, a class of heavily glycosylated cell wall proteins are modified by the addition of a 
GPI anchor as well.72 The yeast Saccharomyces cerevisiae encodes around 50 GPI-anchored 
proteins out of 6000 proteins, which are essential for cell wall synthesis and growth.73, 74 
A large numbers of GPI-Anchored proteins are found on the cell surface of protozoa 
parasites.   Examples include the variant surface glycoprotein (VSG) of Trypanosoma brucei, 
gp63 of Leishmania spp., circumsporozoite protein (CSP) and merozoite surface protein 
(MSP) of Plasmodium spp., and Ssp-4 of Trypanosoma cruzi among others. Some studies 
have shown that the presence GPI anchors is critical for the survival of these protozoans.75, 76 
Malfunction in the GPI biosynthesis can lead to some disorder in humans. Paroxysmal 
nocturnal hemoglobinemia (PNH) is a rare hematopoietic stem cell disorder that arises from a 
somatic mutation of the phosphatidylinositol glycan-class A (PIG-A) gene.77-79 Erythrocytes 
generating from the mutation are particularly vulnerable to lysis mediated by complement 
system. The gene is essential for the biosynthesis of GPI that serves as an anchor for the 
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membrane proteins, CD55 (decay accelerating factor) and CD59 (membrane inhibitor of 
reactive lysis) which are involved in the regulation of the complement system.80, 81 The PNH 
cells are characterized by a total or partial lack of the GPI-anchored membrane proteins.82 
Complete deficiency of GPI-anchored proteins is embryonic lethal in mice due to 
malformation of brain.83  
 
1.5 Biosynthesis of GPI-Anchored Protein 
 
More than 150 different human proteins are GPI anchored and more than 40 enzymes are 
involved in the GPI biosynthesis. GPI-APs are involved in different biological processes and 
can contain protein- and cell-specific structure. GPI-APs on human erythrocytes have a 
different lipid structure having three lipid chains, which can be responsible for a more stable 
association of the plasma membrane and the long life of erythrocytes in the blood.64, 84 Figure 
1.6 depicts the biosynthetic pathway for GPI-anchored proteins from mammals, T. brucei, P. 
falciparum and T. gondii. 
 
1.5.1 Biosynthesis of GPI Anchor Precursor 
The GPI anchor precursor is synthesized in the endoplasmic reticulum (ER) from 
phosphatidylinositol (PI) involving at least nine sequential reaction and 18 gene products.85, 86 
The biosynthetic pathway of GPI begins on the cytoplasmic side of ER by the transfer of 
GlcNAc to PI from UDP-GlcNAc mediated by GPI-GlcNAc transferase to obtain GlcNAc-PI. 
GPI-GlcNAc is a complex transferase consisting of 6 different PIG proteins and DPM2. PIGA 
has a catalytic subunit; however the function of the other proteins is not yet clear. The next 
step is the de-acetylation of GlcNAc-PI to obtain GlcN-PI. This process is mediated by PIG-
L, an enzyme with deacetylase activity. Then, the GlcN-PI is flipped to the luminal side of ER 
by an unknown mechanism and it is probably mediated by a flippase, which has not been 
identified.87 In the next step, an acyl chain is added to the inositol from acyl-CoA to obtain 
GlcN-(acyl)PI mediated by PIG-W with acyltransferase activity.88, 89 It is followed by the 
sequential transfer of ManI and ManII from dolichol-phosphate-mannose (Dol-P-Man) to 
obtain Man-Man-GlcN-(acyl)PI  mediated by 1-4mannosyltransferase (PIG-M, PIG-X) and 1-








Figure 1.6: Biosynthesis of GPI-anchored protein on ER membrane from (A) mammals, (B) T. brucei, (C) P. falciparum and (D) T. gondii. Enzymes involved in different steps: a) GlcNAc transferase, b) deacetylase, c) acyltransferase, d) mannosyltransferase, e) ethanolamine phosphate transferase, f) transamidase, g) deacylase, h) phosphodiesterase and i) GalNAc transferase. 
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In next step, the phosphatidylethanolamine (EtNP) side branch is added to the second position 
of ManI from phosphatidylethanolamine (PE) to obtain Man-(EtNP)Man-GlcN-(acyl)PI  and 
is mediated by GPI-ethanolamine phosphate transferase I (GPI-ETI, PIG-N). This step is only 
present in mammalian GPI biosynthesis. Next step is the transfer of ManIII from Dol-P-Man 
to obtain Man-Man-(EtNP)Man-GlcN-(acyl)PI  via 1-2mannosyltransferase (PIG-B). Another 
EtNP is added to ManII via GPI-ETII, (consisting of PIG-G and PIG-F) as a side branch is 
found in mammalian GPI to obtain the GPI precursor. Finally, the EtPN responsible for 
making the amide bond between the GPI and the protein is added to ManIII is mediated by 
GPI-ethanolamine phosphate transferase III (GPI-ETIII, complex of PIG-O and PIG-
F)91(figure 1.6A). The addition of ManIV is found in Plasmodium GPI biosynthesis to 
generate GPI-anchor precursor (figure 1.6C). In case of T. gondii, N-acetylgalactosamine 
(GalNAc) is attached to the ManI via a β1-4 linkage mediated by GalNAc transferases (figure 
1.6D).92 
 
1.5.2 Posttranslational Attachment of GPI Anchor to Protein 
The GPI-anchor precursors are posttranslationally attached to the C-terminus of the protein by 
the action of GPI transmidase. Proteins to be glypiated N-terminal signal sequence for ER 
translocation and a C-terminal signal sequence for GPI attachment. Translocation of 
preproprotein to ER takes place via translocon and is followed by N-terminal signal peptide 
removal and attachment to GPI. The GPI attachment is catalyzed by transamidase consisting 
of five proteins (PIG-K, PIG-S, PIG-T, PIG-U and GPAA1).93 
 
1.5.3 Lipid Remodeling   
Lipid moieties of GPI are remodeled at the ER and Golgi apparatus. After the attachment of 
GPI to the protein and before the exit from ER, the inositol acyl chain is cleaved by deacylase 
PGAP1 in most of the cells except from erythrocytic cells and some parasites.94 The GPI-APs 
are then transported to the Golgi by secretory vesicles. In the Golgi, GPI-APs undergo lipid 
remodeling. The unsaturated fatty acid at sn-2 position is cleaved and replaced by the 
saturated fatty acid mediated by GPI specific phospholipase A2 (PGAP3) and reacylation by 





In yeast, the lipids of many GPI-anchored proteins are further changed from diacylglycerol to 
ceramide. It is possible that ceramide remodelase is required for recognizing the EtNP side 
chain on the GPI as a substrate. Very recently, it has been reported that CWH43 is the enzyme 
involved for the replacement of diacylglycerol with ceramide in GPI lipid moiety.96, 97 
  
1.6 Importance of GPI Anchor 
 
GPI anchoring is the only stable mechanism for the high affinity attachment of the protein to 
the cell membrane in eukaryotes. Attachment of the protein to the surface of the cell, using a 
single lipid chain would result in weak interactions and an easy loss of protein in extracellular 
matrix compared to the GPI anchor with its lipid moiety bearing a ceramide, diacyl or its 
alkyl, acyl moiety. Hydrophobic interactions between the lipid and the bilayer determine the 
binding affinity of the GPI anchor and are responsible for the lipid raft formation of the cell 
membrane. 
 
1.6.1 Lipid Raft Formation 
The cell membrane can organize into specialized microdomains, so-called lipid rafts.98 They 
are enriched in glycosphingolipids, cholesterol, and certain types of lipidated proteins and 
serve diverse cellular functions. Owing to the hydrophobic nature of the lipids present in GPI, 
GPI-anchored proteins have been associated with lipid raft formation. Lipid rafts are formed 
by the self-association of lipids present in GPI, favored by their long and mostly saturated 
hydrocarbons that allow them to pack tightly in a bilayer having cholesterol molecules fill 
the voids between the associating lipids. Due to the tight packing, lipid rafts are less fluid 
than the surrounding phospholipid bilayer which provides unique physical properties (for 
details refer to chapter 4).99, 100 
 
1.6.2 GPI-AP Degradation 
GPI specific phospholipases C and D are responsible for GPI degradation and cleavage. The 
removal of the GPI anchored protein from the cell surface is a useful immunological or 
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developmental process that requires adhesive cell contact and can provide terminating signal 
for GPI anchored protein. GPI-PLD might be responsible for the restriction and regulation of 
GPI-anchor and can degrade the excess GPI intracellularly which are not used for anchoring 
to proteins.101 
 
1.6.3 Signal Transduction 
The GPI anchor can act as mediator between the exterior of a cell and internal signaling 
molecules. Antibody cross-linking of some GPI-anchored proteins can affect the transduction 
of cellular activation or inhibition signals, resulting in Ca2+ fluxes, protein tyrosine 
phosphorylation, or cytokine secretion.102 These signaling are generally not observed with 
proteins where the GPI anchor has been replaced with a transmembrane domain, indicating 
that the GPI anchor is crucial for these signaling events. Although the GPI anchor does not 
completely cross the cell membrane, the transduction of cellular signals could occur through 
the physical association of the GPI anchor with other transmembrane proteins involved in 
intracellular signaling. 103, 104 
 
1.6.4 Prion Disease 
Prion disease is characterized by the formation of insoluble protein plaques (PrPSc) due to the 
posttranslational misfolding of the GPI anchored Prion protein (PrPC). Although the normal 
function of PrPC is still unknown, it has been suggested to be a signaling molecule.69 PrPC, 
like many GPI-anchored proteins, is able to migrate from one cell membrane to another. This 
transfer requires direct cell-cell contact, an intact GPI anchor and activation of the protein 
kinase C. This process permits PrPSc to infect healthy PrPC-containing cells. At the same time, 
intercellular transfer of PrPC may allow PrPSc infected cells to recruit PrPC from healthy cells, 











1.7 Chemical Synthesis of GPI 
 
Strategies for the chemical synthesis of GPIs focus in the assembly of glycan core although 
the core structure for the GPI remains conserved. Different modifications can be found 
attached to this core structure providing structural diversity to the GPI anchor. The syntheses 
of natural GPIs have faced several problems, such as the stereoselective construction of the 
glycan part and the regioselective introduction of different modifications. The chemical 
challenges, coupled with increasing biological importance of this class of glycoconjugates 
constituted the main driving force for developing new synthetic strategies toward efficient 
syntheses of GPI molecules. Various GPIs have been synthesized using different 
glycosylation and protecting group strategies in either linear or convergent means.106, 107 In a 
linear approach, the oligosaccharide is built from individual monosaccharides in a stepwise 
manner (figure 1.7A). The convergent approach constructs the oligosaccharide from smaller 
building blocks, which may result in a fewer number of protecting group manipulations 
within the oligosaccharide chain (figure 1.7B). Generally, all syntheses began with assembly 
of the glycan, followed by installation of the phosphate groups and a final deprotection. 
Nevertheless, a general unifying route that enable efficient access to a wide range of GPI 





Figure 1.7: Linear and a convergent synthetic strategy of the core from glycosylphosphatidylinositol anchors. a) linear assembly;106 b) convergent assembly.107  
 
1.8 Synthesis of Glycoconjugates 
 
In addition to oligosaccharides and polysaccharides, carbohydrates can also be found forming 
part of natural glycoconjugates such as glycoproteins, glycopeptides and glycolipids. 
Therefore, in addition to the synthesis of oligosaccharides, the synthesis of glycoconjugates 
plays an important role in the elucidation of the biological function of carbohydrates. 
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Extensive efforts have been made to establish protocols to obtain natural glycoconjugates 
such as glycoproteins.108  
Natural glycoproteins exist generally a mixture of molecules having the same peptide 
sequence displaying diverse oligosaccharide structures at the glycosylation positions. These 
so-called glycoforms can have different physical and biochemical properties.109, 110 The 
carbohydrates are often covalently linked to proteins via a nitrogen or an oxygen atom present 
in asparagine, serine or threonine residues forming N-linked and O-linked glycoproteins. 
S-linked, P-linked, or C-linked glycoproteins also exist but are less abundant.111 Efforts to 
develop an appropriate method for the preparation of homogeneous glycoproteins have 
included molecular biology, chemical synthesis or the combination of both methods.112  
A plethora of strategies have been investigated during the last years to obtain naturally 
glycosylated proteins as single glycoforms. However, there is still lack of a suitable and 
generalized method to obtain these molecules. Some protocols to synthesize natural O- and N-
glycoproteins are fully synthetic strategies that combine carbohydrate and peptide synthesis, 
or semi-synthetic strategies that required of synthetic peptides and glycopeptides, and of 
expressed proteins that are connected by chemoselective ligation reactions. But these 
strategies have been limited to the synthesis of small glycoproteins (generally below 20 
KDa).113-116  
Chemical glycosylation methods and chemoselective reactions are not restricted to the 
synthesis of natural glycoproteins, they can also be used for generating neoglycoproteins, 
which are glycoproteins containing unnatural linkages between protein and oligosaccharides. 
Neoglycoproteins are often selected as the best alternative to investigate the function of 
carbohydrates because their synthesis is easier to perform and only involve a conjugation 
reaction of an activated glycan with the lateral chains of amino acids present on a carrier 
protein.  
 
1.8.1 Synthesis of Neoglycoconjugates 
Huge efforts and developments have been made during the last decades to establish strategies 
for the incorporation of glycans into proteins. Depending on the functional groups present on 
the glycans and the amino acids involved in the process, in neoglycoprotein diverse types of 





Figure 1.8: Example of linkages used for the synthesis of neoglycoconjugates. a) some typical linkages obtained in neo-glycoconjugates, b examples of linkers using for conjugation of glycans to proteins. 
 
Carbohydrate-proteins linkages have been mostly synthesized by using the inherent reactivity 
of the amino group of lysine and the thiol of the cysteine side chains to achieve 
chemoselective reactions (figure 1.8).116, 117 The resulting linkages are usually very different 
from the linkage in natural glycoproteins and include a spacer, but they are generally stable to 
biological conditions allowing the biological evaluation of neoglycoconjugates. This strategy 
has been the favorite strategy applied to use glycoproteins as novel protein based therapeutics, 
carbohydrate antigen derivatives and immunogens.118  
Characteristic carbohydrates structures used for the preparation of neoglycoconjugates are 
glycans present on the surface on many pathogens. During infections, the immune system is 
activated by these structures inducing a response that can be detected in the form of anti-
glycan antibodies. Small, pure oligosaccharides are poor immunogens inducing a low immune 
response that can be enhanced via the conjugation of glycans to proteins. For the attachment 
of glycans to proteins, active groups present at the glycan, or introduced as part of a linker at 
the reducing end, can be used. Commonly, these active groups are used in conjugation 
processes involving a chemoselective reaction with the natural functional groups present on 
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the protein or with functional groups introduced by site-specific modifications and mutations 
of the protein.119 
For the application of neo-glycocojugates as immunogens, the presentation of multiple copies 
of the carbohydrate structure is also required to facilitate the interaction of the glycans with 
the immune system. In the development of carbohydrate vaccines, protein glycoconjugates 
are formed using immunogenic active carrier proteins such tetanus toxoid or to its nontoxic 
variant CRM197 to increase and facilitate the presentation of the glycans to the immune 
system inducing a specific response to the glycan (figure 1.9). Using these strategies diverse 




Figure 1.9: Synthetic glycoconjugates vaccine for S. pneumonia (ST8)120 
 
Similar to natural glycoproteins, the main limitation and in general of the protein neo-
glycoconjugates is the formation of heterogeneous mixtures of products, in this case having a 
protein modified with a variable number of glycans at different positions (amino acids) on the 
sequence. This heterogeneous modification of activated proteins results from the distinctive 
accessibility of the active groups on the protein surface for the reaction with the synthetic 
glycans.  The lack of homogeneity hinders the determination of thermodynamic and kinetic 
parameters of binding events between glycoconjugates and proteins by SPR, ITC or any other 
method.122 A requirement that certainly has to be fulfilled to conduct the aforementioned 
experiments is access to pure and defined glycoconjugates and their corresponding 
derivatives. 
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1.8.2 Synthesis of Natural Glycoconjugates 
The synthesis of glycoconjugates having natural bonds and site-specific modifications is 
demanding and has required the development of multiple strategies. These strategies are 
specific for the formation of the linkage between glycan and protein for delivering O- and N-
glycoproteins and to the lipids by forming glycolipids.  Whereas, in O-glycoproteins glycans 
are attached to serine or threonine residues, in N-glycoproteins the glycans are attached to 
asparagine residues in the consensus sequence Asn-Xxx-Ser/Thr, Xxx being any amino acid 
other than proline.  
 
Figure 1.10: Strategies for the semi-synthesis of homogeneous glycoproteins. CHO: mixtures of structures. 
 
N-glycoproteins are accessible via expression systems in cells lines such as Chinese Hamster 
Ovary cells (CHO), Human Embryonic Kidney (HEK) cells or other human cell lines. 
However, due the difficult control of the cell glycosylation machinery, which is out of genetic 
control, the expressed proteins are generally isolated as a mixture of glycoforms. Therefore, 
investigations aimed to investigate the role of single glycan structure on proteins, require of 
additional strategies.108 Proteins synthesis and semi-synthesis have emerged as suitable 
strategies to obtain well-defined glycoproteins.108 In these strategies, synthetic peptides or 
expressed protein fragments are ligated with synthetic glycopeptides having a defined glycan 
structure.123, 124  
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Chemical Synthesis of glycoproteins has been accomplished using active peptide and 
glycopeptide fragments, which are sequentially connected to a full sequence glycoprotein 
using ligation reactions.108 Among the different ligation reactions, the native chemical ligation 
has been the preferred method.125 In this strategy, the peptide are obtained as peptide 
thioester, or as peptide thioester precursors. These peptide thioesters can undergo a two-step 
chemoselective reaction with peptides having an N-terminal cysteine residue, which end with 
the formation of a native peptide bond between the C-terminal amino acid and the cysteine. If 
the synthesis of the glycoprotein requires more than two peptides, which is generally the case, 
peptides or glycopeptides can be obtained having a protected cysteine at the N-terminus that is 
deprotected after the first ligation is completed (figure 1.10a). Recently, a strategy involving 
the use of thioester precursors that are activated after a completed ligation has been 
established.126 
In addition to glycoprotein semi-synthesis, the use of enzymes for glycan remodeling and for 
transferring glycans to a protein having a monosaccharide precursor, trans-glycosylation, are 
becoming useful methods (figure 1.10b).127  The glycoproteins are generally expressed on 
cell lines and are treated with an endoglycosidase that cut the glycans leaving only a 
glucosamine unit attached to the protein. This glucosamine is used as an acceptor for the 
transfer of an oxazoline activated synthetic glycan having in the next step.128 Noteworthy here 
is the use of glycan endoglycosidase that has been mutated to act as a glycosyltransferase.129 
 
1.9 Aim of the Thesis 
 
Glycophosphatidylinositols (GPIs) are an important class of glycolipids present at the surface 
of all eukaryotic cells, especially of protozoa parasites. They play an important role in the 
activation of the immune system during parasitic infections and have been considered as 
potential vaccine candidates against malaria infection. There is still a need to understand the 
role of different components of the glycolipid glycan core and its modifications in the activity 
of these molecules and on the effect of glypiation to protein structure and function. 
 The main objective of this thesis is to apply chemical synthesis to obtain GPIs and GPI-
derivatives to investigate the role of GPIs, with and without attachment to a protein, on the 
activation of the immune system during malaria. To gain insight into the importance of GPIs 
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as an antimalarial vaccine candidate, a strategy will be designed to synthesize a library of GPI 
fragments to generate glycoconjugate vaccine candidates. This library may provide specific 
immunogenic epitopes present in the structure of GPI from Plasmodium. The synthesised 
glycans will be conjugated to the CRM197 carrier protein and tested for immunogenicity and 
efficacy as antimalarial vaccine candidates in an experimental cerebral malaria (ECM) model 
using C57BL/6JRj mice.  
To investigate the role of protein glypiation in malaria, chemical synthesis will be also used to 
synthesize a GPI anchored protein from P. falciparum in a homogenous form. Two fragments 
are necessary to complete this semi-synthesis, an expressed active proteins and a GPI anchor 
containing a cysteine residue. The synthesis of the glycolipid will be completed using an 
established strategy involving a phosphorylation with cysteine-containing unit. After the 
ligation of the protein and the GPI, this glypiated protein will be use to obtain information 
about the biological functions and structure-activity relationship of the GPI-anchored proteins 
and the GPI structure. In vitro assays will be used to obtain information about the role of the 
glycolipid in the activity of the GPI-anchored protein and thereby improve the understanding 
of GPI anchor on the activity of proteins from Plasmodium. 
Since GPIs are also involved in the formation of microdomains on the cell membrane which 
are responsible for cell signaling. Lipidated, synthetic GPI derivatives are also good tools to 
investigate the correlation between GPI composition and structural arrangement of GPI in 
model membranes. In this work, a set of structures having different glycans and lipids 
composition will be synthesized and used in biophysical studies towards the formation of 
substructures in monolayers at the water/air interface using GIXD. The monolayer structure 
parameters will be determined by using GIXD measurements using the tilt angle of the alkyl 
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Malaria is a serious and often a fatal disease caused by a protozoan parasite of the genus 
Plasmodium. It is a vector borne disease that affects humans and is a major health threat to 
developing countries. According to a 2016 WHO report, nearly half of the world's population 
is at risk of malaria infection, especially children and pregnant women in sub-Saharan 
Africa.130 In 2016, 216 million cases of malaria and 445 000 deaths were reported and is thus 
becoming a major contributor to the global burden of infectious diseases.131 The disease is 
transmitted to humans by the bite of an anopheles mosquito infected with one or more of the 
four species of Plasmodium: P. falciparum, P. vivax, P. ovale or P. malariae. 
Malarial infections can be classified as either complicated or uncomplicated and are generally 
accompanied by symptoms that include fever, headache, weakness, muscle ache, vomiting 
cough and abdominal pain. While, uncomplicated malaria can be treated with the anti-
malarial drugs such as artemether, dihydroartemisinin and quinine, humans affected by 
complicated malaria require strong drug cocktails for the treatment which usually consist of a 
combination of antimalarial drugs, but the patients are at a higher risk of renal failure, 
respiratory disease, pulmonary edema and siezures.132 Furthermore, young children, the 
elderly and immunosuppressed people are at higher risk of severe malaria. The most severe 
form of malaria, cerebral malaria, is caused by P. falciparum which can lead to death.  
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The treatment of P. falciparum is becoming more complicated due the emergence of drug 
resistant parasite strains. Thus, there is an urgent need for new therapeutics and the 
development of a vaccine.133 
 
2.1.1 Life Cycle of Plasmodium  
The Plasmodium parasites develop in both, human and mosquito. The life cycle of the 
parasite comprises of two stages: a sexual stage that takes place in the mosquito and an 
asexual stage that takes place in the host (figure 2.1). The life cycle starts with the bite of an 
infected mosquito, injecting Plasmodium parasites in the form of sporozoites into the host 
bloodstream. These sporozoites move to the liver and invade hepatocytes. This is called the 
pre-erythrocytic stage and lasts about two weeks. During this time sporozoites multiply 
asexually in the liver without inducing any symptoms of malaria. 
 
 






The erythrocytic stage begins with the release of parasites from the liver into the bloodstream 
in the form of merozoites. These merozoites invade red blood cells, multiply exponentially, 
and then burst from cells to invade other erythrocytes thus causing the symptoms of malaria. 
Some of the infected red blood cells leave the cycle of asexual multiplication and these 
merozoites are either already setup or develop into male and female gametocytes that circulate 
in the blood stream. These gametocytes are taken up by mosquitoes during the bite. After a 
female Anopheles mosquito has ingested the blood from an infected person, the gametocytes 
develop into mature gametes. The fertilized female gametes develop into mobile ookinetes 
and burrow through the midgut to form oocyts in the lining of the gut. The oocysts eventually 
burst and release sporozoites that enter the salivary glands, which can be transferred to the 
host starting the cycle of infection again.135  
The parasite is exposed to the immune system for a short time and only in the blood stage of 
infection. The symptoms of infection also begin during this stage of the parasite’s life cycle. 
Therefore, efforts have been focused on developing a vaccine against this stage of the 
infection. This would limit the parasite growth and hence minimize the disease.136 
 
2.1.2 Current Vaccine Candidates 
A lot of protective measures have been taken to control malaria by reducing the number of 
yearly infections, but readication may only be achieved by a vaccine. Thus, a global interest 
in developing a vaccine for malaria has drastically increased over the past decade. Most of the 
tested vaccine candidates contain attenuated microbes, killed microbes or protein subunits 
which target either the pre-erythrocytic stage, blood stage or the transmission stage of 
infection.137  The progress towards different malaria vaccines is shown in table 2.1. 
The most effective and advanced vaccine against malaria is the RTS,S, a pre-erythrocytic 
vaccine that targets the circumsporozoite protein (CSP) of P. falciparum. This vaccine was 
developed by GlaxoSmithKline Biologicals and the Walter Reed Army Institute of 
Research.138 The RTS,S vaccine is composed of the repeated (R) and carboxy-terminal (T) 
segments of the P. falciparum circumsporozoite (CS) protein fused to the hepatitis B surface 
(S) antigen. By expression of the CS fragments and the hepatitis B surface (S) antigen in 
yeast, these two proteins assemble into particulate structures RTS,S.138 The RTS,S antigen 
was first formulated in combination with adjuvant AS02A, which is composed of an oil-in-
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water emulsion and the immunostimulants, mono-phosphoryl lipid A and QS21.139 During a 
series of trials, RTS,S/AS02A showed efficacy of up to 66% protection against infection.140 
 
Table 2.1: Current malaria vaccine candidates in clinical or preclinical trials classified on the basis of infection stage.141 
Parasite stage Vaccine Classification Status 
Pre-erythrocytic PfSPZ 




Whole organism  
(genetic attenuation) 
Phase I 
Pre-erythrocytic RTS,S Subunit Phase IV 
Pre-erythrocytic CVac 
Whole organism  
(chemical attenuation) 
Phase I 
Erythrocytic AMA1-RON2 Subunit Preclinical 
Erythrocytic PfRH5 Subunit Phase I 
Transmission Pfs25 Subunit Phase I 
Transmission Pfs230 Subunit Phase I 
Transmission Pfs47 Subunit Preclinical 
    
 
In 2009, Sacarlal et al. reported a follow up study on the immunization of African children 
between 14 years of ages with RTS,S/AS02A. In the first six months after immunization, the 
vaccine showed efficacy of 30% against clinical malaria, 45% against infection and 58% 
against severe malaria. After 45 months of immunization, the people that received the vaccine 
showed a lower level of parasitemia compared to control groups indicating significant vaccine 
efficacy.142 
In order to improve the efficacy of the adjuvant, a new formulation was carried out having 
AS01B adjuvant with liposomes instead of the AS02A. Kester et al. compared the vaccine 
with both the adjuvants (RTS,S/AS02A and RTS,S/AS01B) in terms of immunogenicity and 
short- and long-term efficacy in healthy and malaria-naïve adults. Using these adjuvants the 
RTS,S/AS01B vaccine showed an increase in efficacy of up to 50%, however, this is not 
significantly different from 32% efficacy obtained with RTS,S/AS02A.  
The RTS,S/AS01B vaccine also showed greater antibody response against circumsporozoite 
protein (CSP) as compared to the other adjuvant, providing better understanding of the 





been used in combination with other drugs to fight infection. Thus, a vaccine with higher 
efficacy that can be used alone is still required to control malaria and to combat infection.  
 
2.1.3 Malaria and GPI 
An antitoxin vaccine represents an alternative approach to target malarial pathogenesis in the 
host.143 Glycophosphatidylinositol (GPI), a glycolipid present on the surface of the parasite, 
has been identified as a prominent toxin in malaria that is highly conserved across the 
different species of Plasmodium. These GPIs are found both in free form as well as anchored 
to the C-terminus of proteins and constitute up to 90% of the protein glycosylation on the 
membrane of the parasites.144, 145 P. falciparum synthesizes GPIs in all stages of its life cycle 
and this GPI biosynthesis is important for the development and survival of the parasite.146 
The structure of the GPI of P. falciparum consists of a conserved pseudo-pentasaccharide 
core structure and an additional mannose attached to the terminal mannose at the non-
reducing end. Additionally, wide heterogeneity is present on the lipid component attached to 
the inositol. P. falciparum GPIs are additionally acylated with palmitate (90% of the time) in 
most cases but occasionally with myristate (10% of the time) at the C-2 position of the 









Figure 2.2: Structure and possible modifications of the GPI from P. falciparum. The heterogeneity in the lipid moeity is expressed in percentage. 
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The phospholipid attached to the inositol is a diacylglycerol having alkyl chains of different 
length and degree of unsaturation depicted in figure 2.2. The GPI structure is highly 
conserved across the different Plasmodium species.54  
GPIs have been shown to activate and induce the production of inflammatory cytokines in 
macrophages during malarial infection. Schofield et al. used parasite fractions enriched with 
GPIs to induce the production of TNF-α and IL-1 in macrophages from mice.147 Furthermore, 
diverse studies have shown the presence of anti-GPI antibodies in the sera of patients from 
malaria endemic regions148, 149and the toxic activity of GPIs that are released into the blood 
stream during infection. The toxicity of these GPIs can be blocked by using GPI mediated 
signaling and monoclonal antibodies.150 Thus, there is a growing interest in understanding the 
role of the immune response against GPIs in protection against malaria. 
 
2.2 Synthetic GPI as Potential Anti-malarial Vaccine 
 
Earlier studies showed that isolated GPI can induce an immune response in both rodents and 
humans suggesting the use of GPIs as a candidate for the development of anti-malarial 
vaccines. 
 
2.2.1 Evaluation of GPI Conjugates as a Malaria Vaccine Candidate 
In an initial report, Schofield et al. described the generation of a non-toxic P. falciparum GPI 
glycan derived from chemical and enzymatic hydrolysis of native GPI.151, 152 The chemical 
structure of this molecule was characterized by the protein of a cyclic phosphate at the 
inositol residue as a product of phospholipase C action (figure 2.3A).153 This semi-synthetic 
GPI was treated with 2-aminothiolane to obtain a thiol modification that was conjugated to a 
maleimide-activated carrier protein, keyhole limpet hemocyanin (KLH). This glycoconjugate 
was directly used to immunize mice (figure 2.3B).  
This glycoconjugate was immunogenic and the mice were substantially protected against 
severe malaria with a survival rate of around 75 %, after two weeks of the parasitic challenge. 
Interestingly, the parasitemia did not change during the infection, indicating that the generated 





This vaccine is still under development for clinical use,154 however, these results provided 




Figure 2.3: Immunization with the synthetic GPI protects against murine cerebral malaria. (A) Synthetic P. falciparum GPI glycan used as immunogen; (B) synthesis of P. falciparum GPI glycan-KLH conjugate; (C) Kaplan-Meier survival plot and (D) mice parasitemias post infection of KLH-glycan immunized (closed circles) and sham-immunized (open squares) mice.153 
 
2.2.2 Study of the Anti-GPI Antibody Response using Microarrays 
Several studies have used isolated GPIs to study the anti-GPI antibody response in malaria.149, 
155-157 The results obtained from this research were contradictory, some studies showed 
significant association of anti-GPI IgG response with infection158, 159 and others did not show 
any relationship.148 On the other hand some reports described the GPI glycan as the dominant 
epitope of the glycolipid; whereas others described the lipid part as the dominant epitope in 
GPI activity. The discrepancies in these results can be attributed to the difference in the 
composition and purity of the isolated GPIs.  
In order to address this problem, a library of GPI glycan fragments of different lengths was 
synthesized and printed on glass slides (figure 2.4).160 The obtained glycan array was used to 
evaluate the presence of anti-GPI antibodies by recognizing the synthesized glycans. This 
experiment helped to determine the epitope that was responsible for inducing the immune 
response and the production of specific anti-GPI antibodies in malaria. The results showed the 
pentasaccharide as the minimum epitope recognized by anti-GPI antibodies in sera. A 
comparison between the fragments with and without Man4 identified the fourth mannose as a 
key recognition element for the binding of anti-GPI antibodies. The phosphoethanolamine 
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unit at Man3 did not show any significant effect on the binding. Although this study did not 
provide any information about the role of the lipid part, it was able to provide better insight 




Figure 2.4: Synthetic P. falciparum GPI glycan fragments used for studying anti-GPI antibody response on microarrays.160  
 
2.3 Design of Epitopes 
 
Based on the structural information of the P. falciparum GPI and results from previous 
studies on the microarray, a new library of GPI-fragments was designed to expand the 
investigations on the role of the GPI glycan in malaria. This new library was designed to 
study other fragments of GPI and to understand the importance of the myo-inositol and 
phosphoethanol amine unit on the immunogenicity of GPIs and in the anti-GPI antibody 
response observed during the parasite infection. This library would also provide better insight 
into the role of the GPI modification as immunogenic epitopes. 
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Six synthetic GPI fragments with different frameshifts were designed having a terminal thiol 
group for conjugation with a carrier protein for immunization experiments. The fragments 
GPI 14 were designed without the myo-inositol moiety whereas GPI 1 and GPI 3 were 
designed without the phosphoethanolamine unit. GPI 6, containing the core structure and the 
terminal thiol at the phosphodiester linker at the inositol part of the structure was used as a 
reference. The thiol linker was used to retain the amine intact during the conjugation and was 
installed at the reducing end of the glycans to keep the natural orientation and presentation of 




Figure 2.5: Designed P. falciparum GPI fragments for the conjugation to CRM197 carrier protein and for immunization studies.† 
 
GPI conjugates in previous studies used KLH as carrier protein and Freund’s adjuvant to 
enhance the immunogenicity of the glycoconjugates. However, Freund’s adjuvant is not 
feasible for use in humans due to its high toxicity; however, the combination of CRM197 and 
alum adjuvant is approved and widely used in the development of vaccines. CRM197, a non-
toxic variant of the tetanus toxoid, was selected as the carrier protein for the synthesis of the 
                                                          
†
 Fragment GPI 5 and GPI 6 were synthesized by Dr. Ivan Vilotijevic and Dr. Daniel Varon Silva. 
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glycoconjugates with all GPI fragments. Alum was selected as adjuvant for the immunization 
experiments in the murine model against cerebral malaria.  
 
2.4 Retrosynthetic Analysis 
 
The synthesis of GPI 14 was designed using a strategy that required common building 
blocks (2-6, 2-7 and 2-8) for the assembly of the glycans and installation of 
phosphoethanolamine at the last stage of the synthesis. The phosphorylation step would be 
omitted in the synthesis of GPI 1 and GPI 3 so they would not contain phosphoethanolamine 
residue. A common synthetic approach can be used to synthesize all the fragments. Figure 
2.6 shows the synthetic pathway designed for all the fragments using GPI 4 as example. 
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The assembly of fragment GPI 4 was considered with a terminal stage phosphorylation using 
H-phosphonate 2-3. The TIPS group was considered as an orthogonal protecting group to 
introduce the phosphate; acetyl and phthalimide were employed at C-2 to obtain 
stereoselectivity during the glycosylation reactions. To obtain GPI 5, a [3+2] glycosylation 
strategy with building blocks 2-4 and 2-5 was considered. All the fragments could be obtained 
by using two mannose building blocks (2-6 and 2-7) and a glucosamine building block (2-8). 
 
2.5 Results and Discussion 
 
The mannose building blocks (2-6 and 2-7) were synthesized according to established 
protocols previously reported by our group.161 The synthesis of the other fragments was 
divided into the synthesis of disaccharide and trisaccharide fragments, which were then used 
for glycosylation to obtain the desired GPI fragment for the immunological study. The use of 
the more traditional amine-functionalized linker for conjugation was avoided because of the 
presence of amine functionality on the GPI fragments, hence requiring additional protection 
steps prior to conjugation of the fragments. A thiol group can be chemoselectively coupled to 
carrier proteins in the presence of an amine.162-164 Thus, the fragments were synthesized 
having a thiol linker at the reducing end of the glycans. 
2.5.1 Synthesis of Glucosamine Building Block 
The synthesis of fragments GPI 1 to GPI 4 started with the production of the protected 
glucosamine building block from commercially available glucosamine hydrochloride 2-9 as 
shown in scheme 2.1. Glucosamine 2-9 was treated with sodium methoxide and phthalic 
anhydride to protect the amine as a phthalimide and at the same time introduce a participating 
group at the C-2 position to facilitate high stereoselectivity at the anomeric position during 
glycosylation. The following acetylation with acetic anhydride and pyridine provided the 
peracetylated intermediate that was converted into thioglycoside 2-10, stereoselectively as 
solely the  isomer, using 2-methyl-5-tert-butyl-thiophenol and BF3-Et2O as the Lewis acid 
activator. The obtained thioglycoside was deacetylated using freshly prepared sodium 
methoxide and the 4-O and 6-O positions of the resulting triol were blocked by the formation 
of 4,6-O-benzylidene acetal 2-11 using benzaldehyde dimethyl acetal and CSA. The free 3-O 
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position of 2-11 was benzylated using NaH and BnBr to obtain 2-12 in 63% yield. Due to the 
presence of thiol ether in the linker, the thioglycoside could not be used directly for 
glycosylation as it could interfere in the glycosylation reaction. Therefore, the thioglycoside 
was converted into imidate donor 2-13 by hydrolysis with NIS and H2O followed by 
conversion of the hemiacetal into imidate 2-13 using trichloroacetonitrile and DBU. The 
obtained imidate donor 2-13 was used to glycosylate the thiol linker (6-(benzylthio)hexan-1-
ol) using TMSOTf as activator to obtain the -isomer of glucosamine building block 2-8 in 




Scheme 2.1: Synthesis of glucosamine building block 2-8. a) i. NaOMe, phthalic anhydride, MeOH, 
rt, 16 h; Ac2O, pyridine, rt, 12 h, 64%; b) 2-Methyl-5-tert-butyl-thiophenol, BF3Et2O, CH2Cl2, rt, 12 h, 77%; c) NaOMe, MeOH, rt, 1 h, quant.; d) PhCH(OMe)2, CSA, CH3CN, rt, 3 h, 59%; e) NaH, BnBr, DMF, rt, 12 h, 63%; f) NIS, acetone-H2O (9:1), rt, 2 h, 93%; g) CCl3CN, DBU, CH2Cl2, 0 °C, 1 h, 65%; h) 6-(benzylthio)hexan-1-ol , TMSOTf, CH2Cl2, -40 °C to -20 °C, 1 h, 87%.  
 
2.5.2 Synthesis of Disaccharides 
The mannose (1→4) glucosamine disaccharide 2-15, present in all the fragments, was used 
as a common building block to obtain all the fragments via a convergent approach involving a 
[2+2] or a [2+3] glycosylation. Hence, the benzylidene acetal 2-8 was selectively opened in 
80% yield to the 6-O benzyl analog to obtain glucosamine acceptor 2-14 having a free 
hydroxyl at the 4-O position.165 The glucosamine acceptor 2-14 was glycosylated with the 
mannose imidate donor 2-6 using TMSOTf in DCM to obtain the disaccharide 2-4 in 88% 
OAc 
HO- 
OH a. b › 
AcO' ACO O 
_$_  
c .d  › 
O s ¬ =o 
HCLNH2 'OH 
2-9 2-10 2-11 
e 
f, g 
O BnO o BnO o (\/*3 SBn < h 
ph \ o O 
BnO o o ccı3 < 
O S 3 
=o 
ph \ o  o 
o 
2-8 2-13 






yield. Then, the TIPS protecting group at the 6-O position of mannose was removed using 




Scheme 2.2: Synthesis of disaccharide 2-15. a) TFAA, TFA, TES, CH2Cl2, 0 °C, 5 h, 80%; b) 2-6, TMSOTf, CH2Cl2, -40 °C to -20 °C, 1 h, 88%; c) HFpy, THF, rt, 48 h, 83%. 
 
The second building block corresponding to the (1→2)-dimannose 2-17 was obtained by 
deactylation of mannose building block 2-7b using freshly prepared sodium methoxide. The 
following glycosylation of obtained acceptor 2-16 with the imidate donor 2-6 using TMSOTf 




Scheme 2.3: Synthesis of disaccharide 2-17. a) NaOMe, MeOH/CH2Cl2, rt, 1 h, quant; b) 2-6, TMSOTf, CH2Cl2, -40 °C to -20 °C, 1 h, 80%. 
 
2.5.3 Assembly of the Fragments GPI 1 and 2 
With the disaccharide fragments in hand, GPI 1 and GPI 2 were synthesized using a [2+2] 
glycosylation strategy. The mannose disaccharide 2-17 was deallylated using a two-step 
process involving Ir-catalyzed isomerization of the double bond followed by hydrolysis of the 
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vinyl ether with mercuric oxide, mercuric chloride and water to provide the desired 
hemiacetal. The obtained hemiacetal was transformed into the corresponding imidate donor 2-
18 using trichloroacetonitrile and DBU. The glycosylation of disaccharide acceptor 2-15 with 
the disaccharide imidate donor 2-18 using TBSOTf as an acid activator gave the desired 
terasaccharide 2-19 as  mixture of 5/1 in 70% yield. The reaction was performed with 
diethyl ether as solvent to favor the formation of the  stereoisomer, which was isolated using 
flash column chromatography with silica gel as the stationary phase. The TIPS group was 
removed using scandium triflate in CH3CN and water to obtain the desired tetrasaccharide 
alcohol 2-20, which was used to obtain the two GPI fragments (GPI 1 and GPI 2). To obtain 
GPI 1, the tetrasaccharide 2-20 was fully deprotected using a two-step protocol involving the 
removal of the phthalimide using ethylenediamine in butanol at 90 °C,166, 167 and followed by 
Birch reduction using sodium and liquid ammonia. The fully deprotected tetrasachharide 
fragment GPI 1 was obtained as a mixture of the reduced and oxidized forms of the thiol. The 
product GPI 1 was purified using size exclusion column chromatography on sephadex G-15 
to remove the excess salts (scheme 2.4).   
 
 
Scheme 2.4: Synthesis of fragment GPI 1. a) i. H2, [Ir(COD)(PMePh2)2]PF6, THF, rt, 12 h; ii. HgO, HgCl2, acetoneH2O (5:1), rt, 2 h, 81% ; b) CCl3CN, DBU, CH2Cl2, 0 °C, 2 h, 86%; c) 2-15, TBSOTf, Et2O, 0 °C, 2 h, 55% (-isomer); d) Sc(OTf)3, H2O, CH3CN, 50 °C, 12 h, 71%; e) (CH2NH2)2, H2O, n-BuOH, 90°C, 4 h; f) i. Na, liq. NH3, THF, -78 °C, 1 h; ii. MeOH, rt, 1 h, 57% (over two steps).  
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Tetrasaccharide alcohol 2-20 was phosphitylated with H-phosphonate 2-3 using pivolyl 
chloride as activator and oxidized using iodine and water to obtain the tetrasaccharide 
phosphate 2-21 in 66% yield. The tetrasaccharide 2-21 was fully deprotected using a two-step 
protocol which involved deprotection of the phthalimide using ethylenediamine in butanol at 
90 C and Birch reduction using sodium and liquid ammonia. The fully deprotected 
tetrasaccharide fragment GPI 2 was obtained as a mixture of thiol and disulfide in 75% yield. 
The final product GPI 2 was purified using size exclusion column chromatography on 
sephadex G-15 to remove the excess salts (Scheme 2.5).  
  
 
Scheme 2.5: Synthesis of fragment GPI 2. a) i. 2-3, PivCl, py, rt, 16 h; ii. I2, H2O, py, rt, 1 h, 66% ; b) (CH2NH2)2, H2O, n-BuOH, 90 °C, 4 h; c) i. Na, liq. NH3, THF, -78 °C, 1 h; ii. MeOH, rt, 1 h, 75% (over two steps). 
 
2.5.4 Synthesis of the Fragments GPI 3 and 4 
For the synthesis of fragments GPI 3 and GPI 4, mannose disaccharide 2-17 was deacylated 
using freshly prepared sodium methoxide to obtain the disaccharide acceptor 2-22. Due to the 
steric hindrance caused by the TIPS group on the disaccharide acceptor, the synthesis of 
trimannose using TMSOTf in CH2Cl2 as the reagent for the key glycosyation step failed. 
Thus, the glycosylation of disaccharide acceptor 2-22 and imidate donor 2-7a was achieved 
by using TBSOTf as activator in diethyl ether to obtain the desired trimannose 2-23. The 
trisaccharide 2-23 was subsequently deallylated using an iridium complex for the 
isomerization of the double bond followed by hydrolysis with mercuric oxide and mercuric 
chloride. The obtained hemiacetal was transformed into the corresponding imidate donor 2-5 
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using trichloroacetonitrile and DBU. The obtained trisaccharide imidate donor 2-5 was used 
to glycosylate the disaccharide acceptor 2-15 using TBSOTf as activator in diethyl ether to 
favor the formation of the  isomer of pentasaccharide 2-2. The TIPS group of 
pentasaccharide 2-2 was cleaved using scandium triflate in CH3CN and water to obtain the 
pentasaccharide alcohol 2-24. Pentasaccharide 2-24 was fully deprotected using a two-step 
protocol, involving the removal of the phthalimide using ethylenediamine in butanol at 90 °C 
followed by the Birch reduction. The fully deprotected pentasaccharide fragment GPI 3 was 
obtained as a mixture of thiol and disulfide. The final product GPI 3 was purified using size 
exclusion column chromatography on sephadex G-15 to remove the excess salts (scheme 
2.6). 
 
Scheme 2.6: Synthesis of fragment GPI 3. a) NaOMe, MeOH/CH2Cl2, rt, 12 h, quant; b) TBSOTf, Et2O, 0 °C, 2 h, 68%; c) i. H2, [Ir(COD)(PMePh2)2]PF6, THF, rt, 12 h; ii. HgO, HgCl2, acetone-H2O (5:1), rt, 2 h, 64% ; d) CCl3CN, DBU, CH2Cl2, 0 °C, 2 h, 80%; e) TBSOTf, Et2O, 0 °C, 2 h, 65% (isomer); f) Sc(OTf)3, H2O, CH3CN, 50 °C, 12 h, 72%; g) (CH2NH2)2, H2O, n-BuOH, 90 °C, 4 h; h) i. Na, liq. NH3, THF, -78 °C, 1 h; ii. MeOH, rt, 1 h, 74% (over two steps). 
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Pentasaccharide 2-24 was phosphitylated with H-phosphonate 2-3 using pivolyl chloride as 
activator and oxidized using iodine and water to obtain tetrasaccharide phosphate 2-1 in 86% 
yield. Pentasaccharide 2-1 was fully deprotected using a two-step protocol, involving 
deprotection of the phthalamide using ethylenediamine in butanol at 90 °C followed by the 
Birch reduction using sodium and liquid ammonia to cleave the benzyl ethers. The fully 
deprotected tetrasachharide fragment GPI 4 was obtained as a mixture of thiol and disulfide. 
The final product GPI 4 was purified using size exclusion column chromatography on 




Scheme 2.7: Synthesis of fragment GPI 4. a) i. 2-3, PivCl, py, rt, 16 h; ii. I2, H2O, pyr, rt, 1 h, 86%  b) (CH2NH2)2, H2O, n-BuOH, 90 °C, 4 h; c) i. Na, liq. NH3, THF, -78 °C, 1 h; ii. MeOH, rt, 1 h, 60% (over two steps). 
 
The fractions containing the glycans were lyophilized and directly conjugated to the non-toxic 
variant of the diphtheria toxin carrier protein, CRM197, which can enable a T-cell dependent 
immune response.168 
2.5.5 Synthesis of Glycoconjugates 
In order to obtain the glycoconjugates for immunological studies, the disulfide of GPI 16 
was first reduced to a thiol using polymer supported tris(2-carboxyethyl)phosphine (TCEP) 
resin and immediately used for the conjugation to the immunogenic carrier protein CRM197. It 
is important to reduce the disulfide glycans before the conjugation reaction. Thiol can exist as 
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a free thiol as well as a disulfide, but only free thiols are nucleophilic enough to react with the 
activated protein during the conjugation reaction.162-164 
The carrier protein CRM197 was activated by the modification of the lysine residue with 2-
bromoacetates using bifunctional spacer N-succinimidyl-3-(bromoacetamido)propionate 
(SBAP). This reaction converts the free -amine groups into the reactive bromide. Following, 
a reaction of the bromide with the freshly reduced thiol of the glycan gave the desired glyco-
conjugates with loading of between 58 glycans per molecule of carrier protein. Loading is 
expressed as number of glycan residues per CRM197 molecule. The unreacted bromides were 
quenched with cysteine. Figure 2.7 depicts the conjugation process for GPI 6 as an example. 
All the other conjugations followed the same protocol unless specified to generate 6 mg of the 




Figure 2.7: Schematic representation of a CRM197GPI 6 glycoconjugate. a) SBAP,0.1 M NaPi pH 7.4, rt; b) GPI 6, 0.1 M NaPi pH 8, 1mM EDTA, rt; c) L-cysteine, 0.1 M NaPi pH 8, 1mM EDTA, rt. 
The conjugates were characterized using different methods (figure 2.8). MALDI-TOF mass 
spectrometry analysis of the activated CRM197 shows that approximately sixteen bromides 
were introduced on average per molecule of CRM197 protein. The activated CRM197 protein 
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reacted with GPI 6 in the second step to give the glycoconjugate with an average loading of 
6.4 glycans per molecule of CRM197, corresponding to about 12% of glycan by weight on 
average. 
The other five glycoconjugates were synthesized in a similar manner and were characterized 
using MALDI-TOF mass spectroscopy and SDS-PAGE. Since a small variation was observed 
in the two different batches of the conjugates, an averaged loading was used for the 
calculation of the conjugates for the mice immunization study (figure 2.9). All the 
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A CRM197 conjugate of galactose (CRM197Gal) was also synthesized as a negative control 
for the immunization experiment to account for possible conformational changes of the 
glycan loaded carrier protein. Apart from CRM197Gal, only CRM197 and PBS buffer were 




Figure 2.9: Glycan loading of the CRM197 glycoconjugates determined by MALDI-TOF mass spectrometry.  Glycan loading was determined by MALDI and expressed as GPI molecules per CRM 
and as a percentage of weight for each CRM197GPI glycoconjugate, Δ m/z represents the difference in mass of the CRM-glycan and the activated CRM197.  
 
GPI CRVI Batch A m/z GPI molecular weight Loading: GPUCRW (% of nass) GPI1 1 3835 781.82 4.92 (6.500 glycan) 
2 4778 6.12 ( 7.20 o glycan) 
GPI2 1 6972 904.87 7.4 (10.2°o glycan) 
2 4329 5 (70 o glycan) 
GPI3 1 5668 943.96 5.7 (8.1°o glycan) 
2 9299 9.8 (1300 glycan) 
GPI4 1 9865 1067.01 9.3 (1400 glycan) 
2 9792 9.2 (l3.7% glycan) 
GPI5 1 5889 1146.99 5.2 (8.900 glycan) 
2 10240 8.9 (l4.30<› glycan) 
GPI6 1 9322 1309.13 7. 12 (1300 glycan) 





2.6 Immunological Results 
 
All the immunization studies and results were obtained from Dr. Fridolin Steinbeis. The 
immunogenicity and the activity as anti-malarial toxin vaccine of the glycoconjugates were 
studied using a murine model for cerebral malaria. Five-week old female mice were divided 
into seven groups each consisting of 15 animals. The mice were vaccinated three times on 
days 0, 14 and 28 with the glycoconjugate formulated with alum adjuvant (1:2). The study 
groups were immunized with CRM197GPI 16 glycoconjugates and control mice were 
immunized with CRM197Gal. Serum was taken at 14-day intervals on day 0, 14 and 28 for 
anti-GPI antibody analysis before infection and after infection on day 42. All mice were 
challenged on day 42 with P. berghei ANKA-infected erythrocytes. On day 6 post infection, 
five mice per group were sacrificed for immunological characterization (spleen cell 
composition, brain T-cell sequestration, vaccine-specific T-cell re-stimulation). The 
remaining ten mice per group were used for survival studies to test vaccine efficacy (figure 
2.10). 
The role of lymphoid cells (CD8+ and CD4+ T-cells, NK and NKT-cells) and myeloid cells 
(monocytes, dendritic cells, neutrophils) as well as proinflammatory cytokines (IL-1β, IL6, 
IL-8, IL-10, IL-4, IL-12p70, TNF-α, INF-γ) were also studied during this experiment. 
 
 
Figure 2.10: Study design for testing immunogenicity of CRM197GPI 16 against CRM197Gal in the murine model of cerebral malaria. All the immunization studies and results were obtained from Dr. Fridolin Steinbeis. 
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2.6.1 Efficacy, Parasitemia and Clinical Score 
Mice were immunized with glycoconjugates CRM197-GPI 1-6, CRM197-Gal, CRM197 and 
PBS as control. Control mice succumbed to experimental cerebral malaria in 100% of the 
cases by day 9, whereas all CRM197-GPI immunized mice displayed improved survival 
compared to the control groups (1040%). Mice that recieved CRM197-GPI 5 showed the 
highest survival of 40% compared to PBS, CRM197-Gal, CRM197 control groups. However, 
mice immunized with CRM197-GPI 14 and CRM197-GPI 6 glycoconjugates showed a 
survival rate between 11% and 30% compared to the control group which was not significant 
(figure 2.11). 
The parasitemia was determined on days 5, 7, 9 post-infection. As shown in figure 2.12, the 
level of parasitemia was not affected by CRM197-GPI immunization compared to the control 
group. The high level of errors displayed on day 12 for the individual groups were the result 
of low numbers of surviving mice in each group. 
The appearance of experimental cerebral malaria symptoms were monitored daily from day 7 
post-infection. Clinical scoring of challenged mice was found to be the highest for CRM197-
Gal control mice and lowest for CRM197-GPI 5 immunized mice at day 12 post-infection, 
suggesting the protective potential of the glycoconjugate used in this group of mice. Survival 
data are based on 910 mice per group and the mice that did not develop parasitemia were 
excluded from the study (one mouse each in CRM197-GPI 3 and CRM197-GPI 4 immunized 
groups) (figure 2.13). 
As the survival study was only based on five mice, the survival rates ranging between 
1040% were unlikely to yield significant results. Thus, higher number of mice would 
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Figure 2.12: Parasitemia post infection on days 5, 7, 9 and 12 for mice infected with P. berghei ANKA infected erythrocytes.  (A) Percentage of infected RBC for the conjugates. (B-G) Parasitemia 
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Figure 2.13: Clinical score post infection on day 5, 7, 9 and 12 for mice infected with P. berghei ANKA infected erythrocytes.  (A) All mice were monitored for clinical symptoms. Successive points for respective symptoms of infected mice: healthy (0), ruffled fur (1), hunching (2), wobbly gait (3), 
limb paralysis (4), convulsions (5) and coma (6). Mice scoring ≥ 3 were euthanized, and dead mice 
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2.6.2 Anti-GPI Antibody Response and Cross-reactivity 
The level of antibodies in mice against the GPI structures was determined by glycan array 
analysis. After the first immunization boost (day 28), all GPI fragments with a 
phosphoethanolamine group (GPI 2, and 46) developed a significantly higher level of anti-
GPI antibodies (figure 2.14). Mice immunized with CRM197-GPI 1 and CRM197-GPI 3 did 
not develop a significant level of antibody compared to control mice. CRM197-GPI 2 and 
CRM197-GPI 5 showed a drastic increase in anti-GPI antibodies immediately after day 1, 
whereas mice immunized with CRM197-GPI 4 and CRM197-GPI 6 showed anti-GPI antibody 
levels only after day 28. The highest level of anti-GPI antibodies was observed in mice from 
the CRM197-GPI 5 group. The antibody levels dropped for all the conjugates after infection 
except for CRM197-GPI 6 immunized mice. 
 
 
Figure 2.14: Anti-GPI antibody responses for mice immunized with CRM197-GPI 16. Statistical significance was determined using two-way ANOVA to compare anti-GPI antibody levels between groups. Significance shown by asterisks *(p <0.05) and ****(p <0.0001). MFI = mean fluorescence intensity; PI = post infection.  
 
IgG antibodies from mice immunized with CRM197-GPI 2 and CRM197-GPI 4-6 showed a 
high level of cross reactivity between these fragments(figure 2.15 and 2.16). As expected, 
control mice immunized with CRM197-Gal did not develop cross-reacting antibodies against 
GPI epitopes, but generated antibodies against itself. The antibodies against the CRM197-GPI 
1 and CRM197-GPI 3 glycoconjugates, without inositol and phosphoethanolamine, showed 
cross-reactivity to GPI 2-4, whereas no reactivity was detected against inositol containing 
GPI 5 and GPI 6 (figure 2.16 A). Mice immunized with CRM197-GPI 2 and CRM197-GPI 4 
glycoconjugates bearing a phosphoethanolamine moiety but lacking an inositol showed high 
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level of cross-reacting antibodies against phosphoethanolamine containing GPIs, but almost 
insignificant reactivity against the inositol-containing GPI 5 and GPI 6 (figure 2.16 B). 
CRM197-GPI 5 and CRM197-GPI 6 induced cross-reacting antibodies with high binding 
affinity to GPI 5 and GPI 6 itself and, moderate binding to phosphoethanolamine containing 
GPI 2 and GPI 4 and undetectable binding to GPI 1 and GPI 3  (figure 2.16 C). From these 
results, it can be concluded that inositol and phosphoethanolamine play a very important role 
in the immunogenicity of glycoconjugate vaccine candidates. 
 
Figure 2.15: Glycan microarray for glycoconjugates at two concentrations for anti-GPI antibody level at days 0, 14, 28 and 42. (A) Representative microarray wells results from serum of mice 
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2.6.3 T-Cell Response 
ELIspot analysis was used to determine the production of IFN- by the CRM197-GPI 
glycoconjugates and CRM197 specific T-cells response upon re-stimulation of spleen cells. 
Increased T-cell activation was observed for CRM197-GPI compared to CRM197 alone. (figure 
2.17A). No significant difference was observed in the number of glycoconjugate-specific 
IFN-γ producing T-cells between PBS-control and GPI immunized mice for GPI 1, 3 and 5. 
The decreased level of INF- production can explain the high survival rate in those groups. 
Also, higher INF- response for glycoconjugates can be attributed to their better uptake by 
the cells compared to CRM197 alone, making them better vaccine candidates. 
 
 
Figure 2.17: T-cell response in immunized mice. (A) IFN-γ production by T-cells upon re-stimulation of spleen cells by their immunized CRM197-GPI conjugate or CRM197 alone. (B) Comparison between T-cell response for re-stimulation with glycoconjugates treated animals to non-treated animals. Statistical significance was determined using the unpaired Student’s t-test, significance shown by asterisks *(p <0.05), **(p <0.01) , ***(p <0.001); not significant results labeled ns (p >0.05). SFU = spot forming unit. 
 
Regulatory T-cells play an important role in experimental cerebral malaria.169 The proportion 
of regulatory T-cells was measured by intracellular staining of the transcription factor 
Forkhead-Box-Protein P3 (FoxP3) of spleen cells. An increase in regulatory T-cells was 
observed for all the immunized mice compared to control mice. No difference was observed 
in the T-cell frequency for CRM197-Gal and CRM197-GPI suggesting that GPI toxin does not 
affect regulatory T-cells (figure 2.18). 
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Downstream pro-inflammatory effects of macrophages and dendritic cells have been 
associated with experimental cerebral pathology and human cerebral malaria pathogenesis 
(figure 2.19). To test the impact of CRM197-GPI conjugates on macrophage and dendritic 
cell composition of the spleen, flow cytometry was used. No significant changes in population 
size were detected regarding myeloid cell populations in spleens of immunized versus control 
mice. Cellular activation (measured by activation marker CD80) was significantly increased 
in both macrophages and dendritic cells compared to non-infected controls upon P. berghei 
ANKA challenge. Only marginal differences in cellular activation were observed between 
mice immunized with glycoconjugate vaccine candidates CRM197-GPI and control CRM197-





Figure 2.18: Regulatory T cell activation. On day 6 post infection, regulatory T-cells in all challenged groups were compared to the non-infected control group. Statistical significance was 
determined using the unpaired Student’s t-test, significance shown by asterisks **(p<0.01); not significant results labeled ns (p >0.05) 
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Figure 2.19: Proportion of activated (A) macrophages and (B) dendritic cells measured per 1x104 spleen cells of CRM197-GPI immunized and control mice on day 6 post infection. Significance is shown by asterisks *(p <0.05); not significant results labeled ns (p >0.05) 
 
In order to understand the specificity of the immune response, serum levels of pro- and anti-
inflammatory cytokines (IL-6, TNF-, IFN-) were measured by cytometric bead array before 
and after infection (days 42 and 48) of five mice per group. Low levels of IFN-, TNF-, IL-6 
were observed for CRM197-GPI 1-6 immunized and as well as control mice (Figure 2.20 A, 
C, E) after a second boost-vaccination, indicating that CRM197-GPI-glycoconjugates did not 
induce an unspecific immune response. To investigate whether CRM197-GPI immunization 
modified the humoral immune responses towards infection, serum cytokines of mice were 
further measured on day 48. Infected groups showed significantly increased levels of IFN-, 
TNF- and IL-6 compared to the non-infected mice (Figure 2.20 A, C, E). TNF- was not 
significantly increased in CRM197-GPI 1 and CRM197-GPI 5 immunized mice, and was at a 
comparable level to CRM197-GPI 3 and CRM197-GPI 4 (figure 2.20 C). The level of pro-
inflammatory cytokines post infection varied between CRM197-GPI vaccinated mice (Figure 
2.20, B, D, F). The mice immunized with CRM197-GPI 6 showed increased levels of IFN-, 
TNF- and IL-6, whereas levels of IFN-, TNF- and IL-6 were considerably reduced for 
mice immunized with CRM197-GPI 5. No significant difference in cytokine levels was 
observed in CRM197-GPI glycoconjugate vaccinated versus CRM197-Gal control mice 
(figure 2.20, B, D, F).  
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Figure 2.20: Pro-inflammatory cytokine levels of infected mice. (A, C, E) comparison in the level 
of IFN-, TNF- and IL-6 for CRM197-GPI 16 immunized and control mice before and after infection. (B, D, F) Comparison in the serum levels of pro-inflammatory cytokines between non-infected mice and CRM197-GPI vaccinated mice. Statistical significance was determined using the 
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2.7 Conclusion and Outlook 
 
A new library of GPI fragments was designed and synthesized to improve understanding of 
the structureactivity relationship in regard to the immunogenicity of CRM197-GPI 
glycoconjugates. The molecules were designed to cover different components of P. 
falciparum GPI structure. The structures were designed in order to understand the importance 
of phosphoethanolamine, inositol and the terminal mannose (ManIV) in immunological 
response and to deepen understanding about the structureactivity relationship. Six different 
structures were designed and synthesized using a convergent approach. An aminocontaining 
linker, which is commonly used to conjugate the oligosaccharides to carrier proteins, could 
not be used due to the presence of the amine group at the phosphoethanolamine moiety and 
glucosamine residue of the GPI structure. Thus, the GPI fragments were synthesized bearing a 
thiol linker that can be orthogonally conjugated to the carrier protein in presence of free 
amines. Benzyl ethers were used as the permanent protecting group and acetyl, TIPS and allyl 
were used as orthogonal temporary protecting groups. Birch reduction was used for global 
deprotection and products were obtained as a mixture of thiol and disulfide oligosaccharide.  
GPI fragments were synthesized with the thiol linker either at the reducing end or at the 
inositol to maintain the natural presentation of the GPI on the cell membrane. 
Unlike the previous study, where KLH was used as carrier protein, CRM197 was chosen as a 
carrier protein for the synthesis of glycoconjugates and alum as adjuvant to improve the 
immunogenicity of the vaccine candidate. They are both clinically approved and already used 
in many glycoconjugate vaccines. A mouse model was used for the challenge study of 
cerebral malaria. Mice were immunized with CRM197-GPI 1-6 glycoconjugate vaccine 
candidates or CRM197-Gal as control. Ten mice from each group were used to study the 
efficacy of the glycoconjugates and five mice per group were used for the immunological 
characterization. 
As expected, the conjugates varied in the induction of protection against experimental 
cerebral malaria. All the CRM197-GPI immunized mice showed an increased survival 
compared to the control group. CRM197-GPI 5 showed the highest protection against cerebral 
malaria with a survival rate of 40%. Mice immunized with CRM197-GPI 2 and CRM197-GPI 
4-6 displayed increased levels of anti-GPI antibodies compared to the control group. CRM197-
GPI 5immunized mice displayed a lower level of serum IFN- and did not develop a 
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significant increase in TNF- post infection which was not seen in the mice immunized with 
other GPI glycoconjugates. This can explain the increased survival of the mice immunized 
with CRM197-GPI 5. 
Cross-reactivity revealed that the length of the mannose backbone is important for immune 
recognition. CRM197-GPI 1 was slightly immunogenic and was not detected by antibodies; 
CRM197-GPI 3 was more immunogenic compared to CRM197-GPI 1 and also detected by 
cross-reacting antibodies from CRM197-GPI 1immunized mice. This is consistent with 
previous findings on human anti-GPI antibody binding that did not recognize glycan 
fragments containing less than five carbohydrate units (section 2.2.2). Phosphoethanolamine 
was detected as an important immunogenic epitope in mice, unlike in human anti-GPI 
antibody binding, where only a slight difference in antibody response was observed.160 As 
described in the literature, inositol was the immunodominant epitope present in GPI 5 and 
6.54  
Despite the initial evidence that GPIattached lipid moieties are important for GPI antibody 
recognition, synthetic GPIs lacking lipid moieties are also recognized by human antibodies. 
Naik et al., showed that anti-GPI antibodies are mainly directed towards the conserved glycan 
structure of purified Plasmodium GPIs in humans.155, 160 This study was able to establish a 
structureactivity relationship profile between the GPI compositions in a murine model. 
Plasmodium expresses both ManIV-GPI and ManIII-GPIs on the surface of the parasite. 
Naturally, ManIV-GPI exists as GPI anchored to the protein (MSP-1 and MSP-2) whereas 
ManIII-GPI exists as free GPI and ManIII-GPI is five times more abundant than GPI 
anchored to the protein.144, 152 All the conjugates were synthesized with protein either at the 
reducing end of the oligosaccharide or at the inositol residue. The higher survival and efficacy 
of the glycoconjugate ManIII GPI (GPI 5) over ManIV GPI (GPI 6) can be explained by the 
higher abundance and natural presentation of ManIII-GPIs on the surface of the parasite 
which is similar to the CRM197-GPI 5. 
 In the previous study, GPI-KLH glycoconjugate was synthesized with a KHL carrier protein 
at the phosphoethanolamine residue of the GPI where the natural presentation is similar to 
ManIV-GPI anchored to the protein.54, 153 The immunized mice in this case were protected 
from cerebral pathology in ~80% of cases. However, a structurally related GPI conjugated to 





cerebral malaria. This provides the evidence that the site of conjugation and the structural 
representation of GPI in a vaccine plays an important role in vaccine efficacy. 
It can be concluded that GPI is a toxin and hence an anti-toxin GPI vaccine can decrease the 
severity of the disease. The protection is dependent on both the antibody and cellular immune 
response. GPI composition and presentation on the carrier protein plays an important role in 
inducing an immune response. 
It was difficult to compare the survival rate for different glycoconjugates because of the small 
number of mice used for the challenge study. Thus, a detailed study with a larger set of mice 
is necessary to improve the understanding of GPI-based glycoconjugate vaccines. 
Immunization in a different animal model could further provide a better understanding of the 
mechanism of a GPI anti-toxin vaccine. Further optimization to improve the vaccine efficacy 
should include dose dependent responses, different carrier proteins and adjuvant systems.  
A detailed immunological characterization with optimized vaccine formulation is necessary to 




2.8.1 Methods of Synthetic Chemistry 
All purchased chemicals were of reagent grade and all anhydrous solvents were of high-purity 
grade and used as supplied except where noted otherwise. Reactions were performed in oven-
dried glassware under an inert argon atmosphere unless noted otherwise. Reagent grade 
thiophene was dried over activated molecular sieves prior to use. Pyridine was distilled over 
CaH2 prior to use. Sodium hydride suspension was washed with hexane and THF and stored 
in an anhydrous environment. Benzyl bromide was passed through activated basic aluminum 
oxide prior to use. Metal sodium was washed with hexane and stored in hexane. Analytical 
thin layer chromatography (TLC) was performed on Merck silica gel 60 F254 plates (0.25mm). 
Compounds were visualized by UV irradiation or heating the plate after dipping in staining 
solution. The staining solutions were cerium sulfate-ammonium molybdate (CAM) solution, 
basic potassium permanganate solution, acidic ninhydrin-acetone solution, or a 3-
methoxyphenol-sulfuric acid solution (Sugar Stain). Flash column chromatography was 
carried out using a forced flow of the indicated solvent on Sigma Aldrich silica gel high purity 
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grade 60 Å (230-400 mesh particle size, for preparative column chromatography). Solvents 
were removed under reduced pressure using rotary evaporator and high vacuum (<1 mbar). 
Freeze drying of the aqueous solutions was performed using Alpha 2-4 LD Lyophilizer 
(Christ, Osterode am Harz, Germany) 
1H, 13C and 31P-NMR as well as all 2D-spectra (1H-1H COSY, 1H-1H TOCSY, 1H-13C HSQC, 
1H-13C HMBC) were recorded on a Varian 400 (400 MHz), a Varian 600 (600 MHz), a 
Bruker 400 (400 MHz) and a Bruker Ascend 400 (400 MHz)  spectrometer in CDCl3 (7.26 
ppm 1H, 77.1 ppm 13C), D2O (4.79 ppm 1H), MeOD (4.87 ppm and 3.31 ppm 1H, 49.00 ppm 
13C), Acetone-d6 (2.05 ppm and 2.84 ppm 1H, 206.26 ppm and 29.84 ppm 13C)  unless 
otherwise stated. The coupling constants (J) are reported in Hertz (Hz). Splitting patterns are 
indicated as s, singlet; d, doublet; t, triplet; q, quartet; br, broad singlet; dd, doublet of 
doublets; m, multiplet; dt, doublet of triplets; h, hextet for 1H NMR data. Signals were 
assigned by means of 1H-1H COSY, 1H-1H TOCSY, 1H-13C HSQC, 1H-13C HMBC spectra 
and version thereof. ESI mass analyses were performed by Waters Xevo G2-XS Q-TOF with 






A solution of glucosamine 2-9 (10 g, 46.4 mmol) in 1 M NaOMe (60 mL) was stirred 
vigorously for 1 h at room temperature to obtain a milky liquid. After 1 h, the reaction 
mixture was filtered and washed with MeOH (50 mL). To the obtained solution, was added 
phthalic anhydride (10.3 g, 69.6 mmol) and Et3N (7.12 mL, 51mmol) and reaction mixture 
was stirred overnight at room temperature. The reaction mixture was concentrated and crude 
product was dissolved in pyridine (50 mL). Then, Ac2O (26.2 mL, 278 mmol) was added to 
the solution and the resulting solution was stirred overnight. The reaction mixture was diluted 
with aq. NaHCO3, extracted with CH2Cl2, washed with brine, dried over Na2SO4 and 
concentrated to obtain desired peracetylated intermediate (14.06 g, 29.5mmol, 64%).  
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To the stirred solution of peracetylated intermediate and 2-methyl-5-tertbutyl- thiophenol 
(13.55 mL, 73.6 mmol) in anhydrous CH2Cl2 (50mL) was added borontrifluoride etherate 
(7.27 mL, 58.9 mmol) dropwise and was stirred overnight at room temperature. The reaction 
mixture was quenched with aq. NaHCO3, extracted with CH2Cl2, washed with brine and dried 
over Na2SO4. The solvents were removed under reduced pressure and the crude product was 
purified by flash column chromatography to obtain thioglycoside 2-10 (13.5 g, 22.59 mmol, 
77%) as yellow oil. R f = 0.35 (EtOAc/hexane = 1:1) 1H NMR (400 MHz, CDCl3) δ 7.86 (d, J 
= 7.2 Hz, 2H), 7.80 – 7.71 (m, 2H), 7.46 (d, J = 2.1 Hz, 1H), 7.21 (dd, J = 8.0, 2.1 Hz, 1H), 
7.06 (d, J = 8.0 Hz, 1H), 5.81 (dd, J = 10.2, 9.2 Hz, 1H), 5.63 (d, J = 10.6 Hz, 1H), 5.19 (dd, J 
= 10.0, 9.3 Hz, 1H), 4.42 (t, J = 10.4 Hz, 1H), 4.33 (dd, J = 12.4, 4.7 Hz, 1H), 4.16 (dd, J = 
12.3, 2.2 Hz, 1H), 3.86 (ddd, J = 10.2, 4.7, 2.2 Hz, 1H), 2.16 (s, 3H), 2.10 (s, 3H), 2.02 (s, 
3H), 1.85 (s, 3H), 1.27 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 170.74, 170.13, 169.43, 
149.57(2C), 137.65, 134.44, 134.32, 131.07(2C), 130.50, 130.02(2C), 125.77(2C), 123.71, 






To a stirred solution of thioglycoside 2-10 (5.86 g, 9.8 mmol) in MeOH (20mL) was added 
freshly prepared 1 M solution of NaOMe. After 1 h, the reaction was neutralized with 
Amberlite IR 120 H+ resin, filtered and concentrated. To the solution of crude product in 
CH3CN (35 mL) were added benzaldehyde dimethyl acetal (2.94 mL, 19.56 mmol) and CSA 
(0.682 g, 2.93 mmol). The reaction mixture was stirred for 3 h at room temperature. The 
reaction was quenched with aq.NaHCO3, extracted with CH2Cl2, washed with brine and dried 
over Na2SO4. The solvents were removed under reduced pressure and the crude product was 
purified by flash column chromatography to obtain compound 2-11 (3.23 g, 5.77 mmol, 59% 
over two steps). R f = 0.4 (EtOAc/hexane = 1:1) 1H NMR (400 MHz, CDCl3) δ 7.91 (d, J = 
4.8 Hz, 1H), 7.84 (d, J = 4.6 Hz, 1H), 7.78 – 7.71 (m, 2H), 7.53 – 7.44 (m, 4H), 7.37 (dd, J = 
5.0, 1.7 Hz, 4H), 7.19 (dd, J = 8.0, 2.0 Hz, 1H), 7.05 (d, J = 8.0 Hz, 1H), 5.64 – 5.56 (m, 2H), 




4.72 – 4.62 (m, 1H), 4.45 – 4.33 (m, 2H), 3.91 – 3.81 (m, 1H), 3.74 – 3.61 (m, 3H), 2.15 (s, 
3H), 1.27 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 149.53(2C), 136.92, 136.85, 134.24, 
131.28, 130.22, 129.97, 129.39, 128.40(2C), 126.28(2C), 125.37, 123.88, 123.29, 101.99, 






To a stirred solution of 2-11 (3 g, 5.36 mmol) in anhydrous DMF (20 mL) was added NaH 
(0.25 g, 10.72 mmol) at 0 °C. After 20 min, BnBr (0.96 mL, 8.04 mmol) was added and the 
reaction was stirred overnight at room temperature. The reaction was quenched with MeOH 
and concentrated. The crude product was purified by flash chromatography to obtain 2-12 
(2.2 g, 3.39 mmol, 63%). R f = 0.4 (EtOAc/hexane = 2:3)  1H NMR (400 MHz, CDCl3) δ 7.88 
(d, J = 7.0 Hz, 1H), 7.73 (dt, J = 15.4, 6.8 Hz, 3H), 7.63 (d, J = 7.0 Hz, 1H), 7.53 (dd, J = 7.7, 
1.7 Hz, 3H), 7.46 – 7.35 (m, 5H), 7.17 (dd, J = 8.0, 2.0 Hz, 1H), 7.06 – 6.96 (m, 3H), 6.94 – 
6.82 (m, 3H), 5.65 (s, 1H), 5.54 (d, J = 10.6 Hz, 1H), 4.80 (d, J = 12.3 Hz, 1H), 4.55 – 4.42 
(m, 2H), 4.44 – 4.31 (m, 2H), 3.88 (q, J = 9.5, 8.9 Hz, 2H), 3.70 (td, J = 9.8, 5.0 Hz, 1H), 2.11 
(s, 3H), 1.25 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 149.47(2C), 137.72, 137.24, 136.75, 
134.02, 133.84, 131.54, 131.32, 129.96, 129.92, 129.04, 128.30(2C), 128.15(2C), 128.03(2C), 
127.42, 126.03(2C), 125.21, 123.27, 101.33, 84.80, 82.88, 75.44, 74.20, 70.26, 68.71, 54.84, 
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To a solution of thioglycoside 2-12 (1 g, 1.54 mmol) in a acetone-water (9:1) mixture was 
added NBS (0.82 g, 4.62 mmol). After 30 min., the reaction mixture was concentrated, 
extracted with EtOAc and washed with aq. NaHCO3, water and brine. The organic layer was 
dried over Na2SO4and concentrated. The residue was purified by flash chromatography to 
obtain hemiacetal intermediate (0.7 g, 1.436 mmol, 93%). R f = 0.3 (EtOAc/hexane = 1:1) 1H 
NMR (400 MHz, CDCl3) δ 7.73 – 7.64 (m, 4H), 7.52 – 7.45 (m, 3H), 7.41 – 7.30 (m, 2H), 
7.26 (s, 0H), 7.01 – 6.80 (m, 5H), 5.60 (d, J = 6.6 Hz, 1H), 5.35 (d, J = 8.5 Hz, 1H), 4.75 (d, J 
= 12.3 Hz, 1H), 4.51 – 4.31 (m, 3H), 4.08 (dd, J = 10.4, 8.5 Hz, 1H), 3.79 (dt, J = 11.7, 9.7 
Hz, 3H), 3.64 (td, J = 9.8, 4.9 Hz, 1H). 13C NMR (101 MHz. CDCl3) δ 137.74, 137.22, 
133.94, 131.48, 129.01, 128.25, 128.03, 128.01, 127.42, 126.00, 123.32, 101.28, 93.22, 83.09, 
74.47, 74.07, 68.73, 66.11, 57.45, 49.51, 49.30, 49.08. 
To a stirred solution of hemiacetal (0.6 g, 1.23 mmol) in CH2Cl2 (10 mL) at 0 °C were added 
CCl3CN (0.62 mL, 6.15 mmol) and DBU (0.019 mL, 0.123 mmol). The reaction mixture was 
stirred for 1 h at 0 °C. The resulting mixture was concentrated and purified by flash column 
chromatography to obtain imidate donor 2-13 (0.5 g, 0.79 mmol, 65%) as clear oil. R f = 0.45 
(EtOAc/hexane = 2:3) 1H NMR (400 MHz, CDCl3) δ 8.57 (s, 1H), 7.71 (s, 3H), 7.54 (dd, J = 
7.6, 1.8 Hz, 3H), 7.46 – 7.34 (m, 3H), 7.02 (d, J = 6.6 Hz, 2H), 6.98 – 6.84 (m, 3H), 6.49 (d, J 
= 8.4 Hz, 1H), 5.65 (s, 1H), 5.30 (s, 2H), 4.82 (d, J = 12.4 Hz, 1H), 4.57 – 4.50 (m, 3H), 3.94 
– 3.87 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 160.79, 137.73, 137.11, 133.98, 131.36, 
129.11, 128.32, 128.06, 127.47, 126.07, 123.41, 101.46, 94.31, 82.61, 74.31, 74.21, 68.53, 






The imidate donor 2-13 (0.43 g, 0.68 mmol) and 6-(benzylthio)hexan-1-ol (0.117 g, 0.523 
mmol) were co-evaporated with anhydrous toluene (3x5 mL) and dried under high vacuum 
for 1 h. The mixture was dissolved in anhydrous CH2Cl2 and activated molecular sieves were 
added. The solution was stirred for 10 min at room temperature and cooled to -40 °C. The 
ph \ o o o BnO o O (`/*3 SBn 
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mixture was treated with TMSOTf (19 µL, 0.105 mmol) and slowly warmed to -20 °C over a 
period of 1 h. The reaction was diluted with CH2Cl2, quenched with Et3N and concentrated. 
The crude product was purified by flash column chromatography to obtain 2-8 (0.32 g, 0.454 
mmol, 87%). R f = 0.4 (EtOAc/hexane = 2:3) 1H NMR (400 MHz, CDCl3) δ 7.68 (s, 2H), 7.57 
– 7.50 (m, 3H), 7.45 – 7.19 (m, 9H), 7.04 – 6.93 (m, 3H), 6.93 – 6.84 (m, 4H), 5.63 (s, 1H), 
5.19 (dd, J = 8.5, 3.3 Hz, 1H), 4.80 (d, J = 12.3 Hz, 1H), 4.51 (d, J = 12.4 Hz, 1H), 4.46 – 
4.36 (m, 3H), 4.20 (dd, J = 10.4, 8.5 Hz, 1H), 3.91 – 3.71 (m, 3H), 3.63 (d, J = 7.5 Hz, 3H), 
3.43 – 3.24 (m, 2H), 2.18 (t, J = 7.3 Hz, 2H), 1.38 (ddd, J = 23.9, 12.1, 5.5 Hz, 2H), 1.19 (dd, 
J = 10.2, 7.4 Hz, 2H), 1.13 – 0.98 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 137.92, 137.32, 
133.89, 131.53, 129.01, 128.77, 128.42, 128.29, 128.04, 127.36, 126.86, 126.04, 101.30, 







To a stirred solution of 2-8 (0.5 g, 0.72 mmol) in CH2Cl2 (8 mL) were added trifluoroacetic 
anhydride (0.31 mL, 2.16 mmol) and triethylsilane (0.58 mL, 3.6 mmol) were added at 0 °C 
followed by trifluoroacetic acid (0.28 mL, 3.6 mmol) drop wise. The reaction mixture was 
stirred at 0 °C. After 5 h, the reaction mixture was quenched with Et3N and concentrated to 
give yellow oil that was purified by flash column chromatography to obtain glucoasamine 
acceptor 2-14 (0.4 g, 0.57 mmol, 80 %) as a colorless oil. Rf = 0.33 (Hexanes/EtOAc = 3:1) 
1H NMR (400 MHz, CDCl3) δ 7.83 – 7.62 (m, 3H), 7.40 – 7.16 (m, 9H), 7.04 (dd, J = 7.3, 2.0 
Hz, 2H), 6.99 – 6.87 (m, 4H), 5.28 (s, 2H), 5.10 (dd, J = 8.3, 3.0 Hz, 1H), 4.73 (d, J = 12.2 
Hz, 1H), 4.63 (d, J = 11.9 Hz, 1H), 4.54 (dd, J = 20.4, 12.1 Hz, 2H), 4.26 – 4.16 (m, 1H), 4.12 
(ddd, J = 10.7, 8.3, 1.8 Hz, 1H), 3.86 – 3.68 (m, 4H), 3.68 – 3.57 (m, 2H), 3.39 – 3.22 (m, 
2H), 2.16 (t, J = 7.3 Hz, 1H), 1.40 – 1.30 (m, 2H), 1.20 – 1.11 (m, 2H), 1.09 – 0.94 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ 138.17, 137.55, 133.88, 128.77, 128.51, 128.42, 128.14, 
127.91, 127.88, 127.81, 127.40, 126.85, 98.30, 78.64, 77.33, 77.01, 76.69, 74.61, 74.28, 
73.78, 73.37, 70.82, 69.48, 55.37, 36.20, 31.08, 29.08, 28.91, 28.36, 25.37. 








The imidate donor 2-6 (0.36 g, 0.52 mmol) and glucosamine acceptor 2-14 (0.3 g, 0.43 mmol) 
were co-evaporated with anhydrous toluene (3x7 mL) and dried under high vacuum for 2 h. 
The mixture was dissolved in anhydrous CH2Cl2 (8 mL) and activated molecular sieves were 
added. The solution was stirred for 10 min at room temperature and cooled to -40 °C. The 
mixture was treated with TMSOTf (19 µL, 0.086 mmol) and slowly warmed to -20 °C over a 
period of 1 h. The reaction was diluted with CH2Cl2, quenched with Et3N and concentrated. 
The crude product was purified by flash column chromatography to obtain disaccharide 2-4 
(0.47 g, 0.38 mmol, 88%) as white solid. Rf = 0.5 (Hexanes/EtOAc = 3:1) 1H NMR (400 
MHz, CDCl3) δ 7.63 (d, J = 16.0 Hz, 5H), 7.39 – 7.17 (m, 28H), 7.00 (d, J = 7.4 Hz, 2H), 
6.88 (t, J = 7.6 Hz, 2H), 6.77 (t, J = 7.3 Hz, 1H), 5.42 (s, 1H), 5.27 (s, 1H), 5.05 (dd, J = 8.4, 
2.7 Hz, 1H), 4.85 (dd, J = 15.8, 11.5 Hz, 3H), 4.76 – 4.47 (m, 7H), 4.37 (dd, J = 10.7, 8.7 Hz, 
1H), 4.28 (d, J = 12.2 Hz, 1H), 4.20 – 3.98 (m, 3H), 3.95 – 3.85 (m, 4H), 3.79 – 3.70 (m, 5H), 
3.63 (d, J = 25.1 Hz, 4H), 3.32 (dt, J = 9.7, 6.8 Hz, 1H), 2.15 (t, J = 7.2 Hz, 2H), 1.97 (s, 3H), 
1.42 – 1.25 (m, 3H), 1.17 (dt, J = 15.0, 6.9 Hz, 3H), 1.13 – 1.03 (m, 7H), 1.04 (s, 22H). 13C 
NMR (101 MHz, CDCl3) δ 170.05, 138.73, 138.29, 138.00, 137.82, 133.73, 128.75, 128.40, 
128.34, 128.32, 128.26, 128.07, 128.01, 127.99, 127.95, 127.91, 127.66, 127.61, 127.37, 
127.29, 127.07, 126.83, 99.16, 98.07, 81.00, 77.93, 76.81, 75.27, 74.63, 74.54, 73.79, 73.59, 
73.29, 71.83, 69.37, 69.27, 68.97, 62.12, 55.64, 36.18, 31.07, 29.09, 28.90, 28.36, 26.89, 
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To a stirred solution of disaccharide 2-4 (0.16 g, 0.13 mmol) in THF (4 mL) was added 70% 
HF in pyridine (0.08 mL, 0.65 mmol). The reaction mixture was stirred for 48 h at room 
temperature. The reaction was quenched with aq. NaHCO3, extracted with CH2Cl2, washed 
with brine and dried over Na2SO4. The solvents were removed under reduced pressure and the 
crude product was purified by flash column chromatography to obtain the disaccharide 
acceptor 2-15 (0.12 g, 0.11 mmol, 83%). Rf = 0.4 (Hexanes/EtOAc = 2:1) 1H NMR (400 
MHz, CDCl3) δ 7.71 – 7.63 (m, 6H), 7.51 – 7.21 (m, 20H), 7.07 – 6.91 (m, 4H), 6.88 – 6.79 
(m, 1H), 5.55 – 5.47 (m, 1H), 5.35 (d, J = 1.4 Hz, 1H), 5.07 (d, J = 8.5 Hz, 1H), 4.88 (dd, J = 
24.8, 11.5 Hz, 1H), 4.78 – 4.60 (m, 3H), 4.63 – 4.51 (m, 1H), 4.44 (ddd, J = 11.4, 8.7, 2.9 Hz, 
1H), 4.32 (d, J = 12.2 Hz, 1H), 4.24 – 4.11 (m, 1H), 4.10 – 3.89 (m, 2H), 3.90 – 3.58 (m, 
10H), 3.36 (dt, J = 9.8, 6.6 Hz, 1H), 2.19 (t, J = 7.3 Hz, 1H), 2.05 (s, 3H), 1.38 (ddt, J = 30.1, 
13.0, 6.8 Hz, 3H), 1.30 – 0.84 (m, 7H). 13C NMR (101 MHz, CDCl3) δ 169.95, 138.59, 
138.19, 138.07, 137.84, 137.76, 133.87, 130.05, 129.05, 128.80, 128.46, 128.43, 128.38, 
128.11, 128.05, 128.03, 127.89, 127.80, 127.76, 127.65, 127.26, 127.19, 126.90, 99.27, 98.09, 
81.25, 77.90, 76.90, 75.32, 74.94, 74.70, 74.02, 73.67, 73.11, 71.85, 69.43, 68.85, 68.60, 
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The mannosyl imidate 2-6 (1.65 g, 2.35 mmol) and allyl mannosyl acceptor 2-16 (1.1 g, 2.24 
mmol) were co-evaporated with toluene (3 x 12 mL) and dried under high vacuum for 2 h. 
The mixture was dissolved in anhydrous CH2Cl2 (30 mL) and activated molecular sieves were 
added. The solution was stirred for 10 min at room temperature and cooled to -40 °C. The 
mixture was treated with TMSOTf (41 µL, 0.22 mmol) and slowly warmed to -20 °C over a 
period of 1 h. The reaction was diluted with CH2Cl2, quenched with Et3N and concentrated. 
The crude product was purified by flash column chromatography to obtain disaccharide 2-17 
(1.8 g, 1.75 mmol, 80%) as a colorless oil. Rf  = 0.33 (EtOAc/Hexanes 1:9) 1H NMR (400 
MHz, CDCl3) δ 7.37 – 7.22 (m, 28H), 7.18 (t, J = 7.1 Hz, 3H), 5.85 (ddt, J = 16.4, 10.8, 5.6 
Hz, 1H), 5.52 – 5.46 (m, 1H), 5.22 (dd, J = 17.2, 1.5 Hz, 1H), 5.15 (t, J = 5.1 Hz, 2H), 4.85 (t, 
J = 10.9 Hz, 3H), 4.74 – 4.58 (m, 6H), 4.56 – 4.48 (m, 2H), 4.41 (d, J = 11.0 Hz, 1H), 4.18 – 
4.07 (m, 3H), 4.03 – 3.80 (m, 9H), 3.72 (dd, J = 24.0, 8.5 Hz, 4H), 2.07 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ 170.14, 138.68, 138.34, 138.27, 138.12, 133.71, 128.33, 128.31, 128.29, 
128.16, 128.05, 127.90, 127.58, 127.52, 127.42, 117.23, 98.77, 98.08, 80.10, 78.08, 
75.20(2C), 74.56, 73.98, 73.45, 73.28, 72.77, 71.93, 71.90, 71.88, 69.18, 68.77, 67.76, 62.65, 
21.02, 18.03(3C), 17.97(3C), 12.03(3C).  
 
2-O-Acetyl-3,4-di-O-benzyl-6-O-triisopropylsilyl--D-mannopyranosyl-(1→2)-3,4,6-tri- 
O-benzyl-D-mannopyranosyl trichloroacetimidate (2-18) 
 
A solution of [IrCOD(PPh2Me)2]PF6 (5.0 mg, 5.8 μmol) in THF (3 mL) was stirred under 
hydrogen atmosphere until the color turned from red to colorless to pale yellow. The 
hydrogen atmosphere was exchanged with Argon. The activated catalyst solution was added 
to a solution of disaccharide 2-17 (0.30 g, 0.29 mmol) in THF (10 mL) and stirred at room 
temperature. After 16 h, the solvent was removed and the residue was dissolved in a mixture 
of acetone (5.2 mL) and water (0.6 mL). Mercury (II) chloride (0.39 g, 1.45 mmol) and 
mercury (II) oxide (0.01 mg, 0.044 mmol) were added. After 1 h, saturated aq.NaHCO3 was 
added to reaction mixture and was extracted three times with CH2Cl2. The combined organic 
layers were dried over Na2SO4 and concentrated. The crude product was purified by flash 
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column chromatography to obtain disaccharide hemiacetal intermediate (0.24 g, 0.24 mmol, 
81%) as colorless oil. 
To a stirred solution of hemiacetal (0.285 g, 0.28 mmol) in CH2Cl2 (13 mL) at 0 °C were 
added CCl3CN (0.29 mL, 2.88 mmol) and DBU (0.009 mL, 0.06 mmol). The reaction mixture 
was stirred for 1 h at 0 °C. The resulting mixture was concentrated and purified by flash 
column chromatography to obtain imidate donor 2-18 (0.28 g, 0.25 mmol, 86%) as clear oil. 
Rf = 0.4 (EtOAc/hexane = 2:3) 1H NMR (400 MHz, CDCl3) δ 8.53 (s, 1H), 7.39 – 7.31 (m, 
5H), 7.31 – 7.13 (m, 17H), 6.29 (s, 1H), 5.51 (s, 1H), 5.15 (s, 1H), 4.93 – 4.85 (m, 2H), 4.79 – 
4.68 (m, 3H), 4.67 – 4.56 (m, 2H), 4.47 (dd, J = 28.1, 11.5 Hz, 2H), 4.12 (s, 1H), 4.08 – 3.91 










The disaccharide imidate 2-18 (0.18 g, 0.16 mmol) and disaccharide acceptor 2-15 (0.14 g, 
0.13 mmol) were co-evaporated with toluene (3 x 5 mL) and dried under high vacuum for 2 h. 
The mixture was dissolved in a mixture of anhydrous diethylether and anhydrous CH2Cl2 
(1:1, 6 mL) and activated molecular sieves were added. The solution was stirred for 10 min at 
room temperature and cooled to 0 °C. The mixture was treated with TBSOTf (9 µL, 0.04 
mmol) and stirred at 0 °C for a period of 1 h. The reaction was diluted with CH2Cl2, quenched 
with Et3N and concentrated. The crude product was purified by flash column chromatography 
to obtain tetrasaccharide 2-19 (0.15 g, 0.07 mmol, 55 % isomer). R f = 0.3 (EtOAc/hexane 
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= 2:3) 1H NMR (400 MHz, CDCl3) δ 7.68 – 7.59 (m, 6H), 7.31 (dd, J = 17.9, 11.8 Hz, 30H), 
7.21 (dd, J = 14.7, 7.7 Hz, 36H), 7.17 – 7.08 (m, 7H), 7.01 (d, J = 7.4 Hz, 3H), 6.90 (t, J = 7.5 
Hz, 3H), 6.79 (t, J = 7.2 Hz, 1H), 5.49 (d, J = 13.5 Hz, 3H), 5.34 (s, 1H), 5.15 (s, 1H), 5.08 – 
5.01 (m, 2H), 4.93 – 4.79 (m, 8H), 4.72 – 4.27 (m, 23H), 4.23 – 3.99 (m, 7H), 4.02 – 3.79 (m, 
16H), 3.77 (t, J = 10.2 Hz, 7H), 3.75 – 3.58 (m, 7H), 3.55 – 3.38 (m, 5H), 3.39 – 3.21 (m, 
3H), 2.41 – 2.28 (m, 2H), 2.15 (t, J = 7.2 Hz, 1H), 2.07 (s, 3H), 1.98 (s, 3H), 1.08 (d, J = 4.1 
Hz, 30H), 0.96 (d, J = 36.0 Hz, 2H), 0.92 – 0.81 (m, 23H). 13C NMR (101 MHz, CDCl3) δ 
170.17, 169.87, 138.83, 138.54, 138.42, 138.16, 138.09, 138.02, 137.78, 137.63, 133.79, 
129.99, 128.98, 128.76, 128.42, 128.38, 128.32, 128.30, 128.27, 128.23, 128.17, 128.14, 
127.98, 127.93, 127.90, 127.75, 127.55, 127.49, 127.46, 127.32, 127.29, 127.22, 127.11, 
126.85, 99.36, 99.01, 98.88, 98.09, 80.96, 79.65, 78.45, 77.93, 75.23, 75.02, 74.78, 74.54, 
74.23, 73.77, 73.37, 73.12, 71.88, 71.81, 71.75, 71.55, 69.33, 68.85, 68.59, 66.18, 62.50, 
55.77, 36.20, 32.36, 31.93, 31.07, 29.70(2C), 29.37, 29.08, 28.90, 28.37, 26.35, 25.39, 22.70, 








To a stirred solution of tetrasaccharide 2-19 (0.13 g, 0.190 mmol) in CH3CN (7 mL) were 
added water (50 μL) and Sc(OTf)3 (0.093 g, 0.19 mmol). The reaction mixture was heated up 
to 50 °C ans stirred for 6 h. The reaction was quenched with Et3N and concentrated. The 
crude product was purified by flash column chromatography to obtain 2-20 (0.09 g, 0.05 
mmol, 71%). R f = 0.35 (EtOAc/hexane = 1:1) 1H NMR (400 MHz, CDCl3) δ 7.63 (d, J = 16.4 
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Hz, 4H), 7.30 (dd, J = 9.4, 6.1 Hz, 17H), 7.23 (d, J = 7.3 Hz, 22H), 7.16 (dd, J = 14.8, 5.9 Hz, 
9H), 7.00 (d, J = 7.5 Hz, 2H), 6.89 (t, J = 7.5 Hz, 2H), 6.77 (t, J = 7.3 Hz, 1H), 5.48 (s, 2H), 
5.32 (s, 1H), 5.07 – 4.97 (m, 2H), 4.95 – 4.83 (m, 3H), 4.82 (d, J = 11.5 Hz, 3H), 4.69 – 4.54 
(m, 8H), 4.50 (dd, J = 20.1, 9.3 Hz, 3H), 4.47 – 4.33 (m, 5H), 4.29 (d, J = 12.2 Hz, 1H), 4.22 
– 4.13 (m, 1H), 4.07 (s, 1H), 4.01 – 3.68 (m, 24H), 3.65 – 3.53 (m, 5H), 3.53 – 3.44 (m, 3H), 
3.37 – 3.21 (m, 2H), 2.14 (t, J = 6.7 Hz, 2H), 2.08 (s, 3H), 1.98 (s, 3H), 1.37 (dd, J = 15.8, 8.1 
Hz, 3H), 1.35 – 1.22 (m, 3H), 1.15 (dd, J = 15.2, 7.9 Hz, 3H), 1.12 – 0.91 (m, 6H), 0.86 (d, J 
= 10.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.04, 170.04, 169.91, 138.41, 138.32, 
138.13, 138.01, 137.78, 137.69, 128.77, 128.43, 128.38, 128.34, 128.30, 128.26, 128.21, 
128.12, 128.10, 128.01, 127.96, 127.94, 127.79, 127.61, 127.54, 127.50, 127.37, 127.26, 
127.12, 126.86, 99.46, 99.20, 99.03, 98.08, 79.23, 79.14, 78.82, 78.78, 77.98, 77.34, 77.20, 
77.02, 76.70, 76.48, 76.17, 75.15, 75.03, 74.96, 74.76, 74.58, 74.49, 74.31, 74.11, 73.41, 
73.26, 73.19, 72.39, 72.31, 71.83, 69.38, 69.30, 69.07, 68.80, 68.67, 66.19, 66.19, 55.74, 
31.93, 31.06, 29.70, 29.08, 28.91, 28.37, 25.39, 21.09. 
 
1-O-(6-thio)hexyl--D-mannopyranosyl-(1→2)--D-mannopyranosyl-(1→6)--D-
mannopyranosyl-(1→4)-2-amino-2-deoxy--D-glucopyranoside (GPI 1) 
 
 
Tetrasaccharide 2-20 (0.03 g, 0.02 mmol) was dissolved in a mixture of ethylenediamine (2 
mL) and butanol (2 mL) and stirred at 90 °C for 3 h. After 3 h, the reaction mixture was 
concentrated to obtain partially deprotected crude intermediate. The crude intermediate was 
dissolved in anhydrous THF and MeOH. This solution was added dropwise to blue solution of 
20 mL liquefied ammonia with sodium -78 °C. The reaction was stirred at -78 °C. After 1 h, 
the reaction was quenched with MeOH and stirred for additional 1h at rt. Sodium methoxide 
generated in the reaction was quenched by dropwise addition of glacial acetic acid. The 
reaction mixture was concentrated and the crude product was purified by size exclusion 
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column chromatography using a Sephadex® super fine G-15 (GE Healthcare) column and 5% 
ethanol in water as eluent to obtain GPI 1 (7 mg, 0.009 mmol, 57%) as white solid. 1H NMR 
(600 MHz, Deuterium Oxide) δ 5.08 (s, 1H), 5.02 (s, 1H), 4.91 (s, 1H), 4.53 – 4.37 (m, 0H), 
3.94 (ddd, J = 5.6, 3.1, 1.9 Hz, 3H), 3.91 – 3.88 (m, 2H), 3.85 – 3.74 (m, 9H), 3.75 – 3.52 (m, 
22H), 3.53 – 3.42 (m, 4H), 3.23 – 3.08 (m, 1H), 2.97 – 2.91 (m, 1H), 2.86 – 2.72 (m, 1H), 
2.64 (t, J = 7.2 Hz, 1H), 1.55 (ddd, J = 25.0, 14.1, 7.0 Hz, 6H), 1.30 – 1.25 (m, 6H). 13C NMR 
(151 MHz, D2O) δ 104.93, 104.55, 102.58, 100.95, 81.28, 79.80, 77.57, 75.85, 75.34, 74.88, 
73.29, 73.00, 72.92, 72.82, 72.78, 72.56, 69.54, 69.48, 69.03, 68.89, 63.75, 63.54, 63.38, 
58.69, 40.75, 31.13, 30.78, 29.82, 27.22, 25.82. HRMS (m/z) of the oxidized compound: 







Tetrasaccharide 2-20 (0.02 g, 10.5 μmol) and Hphosphonate 2-3 (0.01 g, 0.03 mmol) were 
co-evaporated with pyridine for three times and dried under high vacuum for 2 h. The mixture 
was dissolved in anhydrous pyridine (5 mL) and a solution of pivolyl chloride (4 μL, 0.03 
mmol) in pyridine (1 mL) was added. The solution was stirred for 6 h at room temperature. 
After 6 h, iodine (8 mg, 0.03 mmol) and water (0.05 mL) were added and reaction was stirred 
for additional 2 h at room temperature. The reaction mixture was quenched with Na2S2O3 and 
extracted with CH2Cl2. The organic layer were concentrated and purified by Et3N deactivated 
silica gel flash column chromatography to obtain phosphorylated tetrasaccharide 2-21 (15 mg, 
7 μmol, 66%). R f = 0.5 (MeOH/ CH2Cl2 = 1:10)  1H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 
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16.6 Hz, 4H), 7.21 (dd, J = 11.7, 8.2 Hz, 27H), 7.15 (dd, J = 10.7, 5.4 Hz, 15H), 7.14 – 7.01 
(m, 4H), 5.48 (d, J = 8.0 Hz, 2H), 5.37 (s, 1H), 5.25 (s, 0H), 5.09 (s, 1H), 5.03 – 4.93 (m, 1H), 
4.87 – 4.67 (m, 5H), 4.64 – 4.34 (m, 9H), 3.96 – 3.85 (m, 5H), 3.76 (td, J = 23.3, 21.0, 9.8 Hz, 
7H), 3.65 – 3.52 (m, 4H), 3.37 – 3.17 (m, 7H), 2.11 (t, J = 7.2 Hz, 1H), 2.00 – 1.90 (m, 6H), 
1.53 (t, J = 7.3 Hz, 0H), 1.25 – 1.16 (m, 4H), 1.14 – 0.94 (m, 3H). 13C NMR (151 MHz, D2O) 
δ 105.02, 104.44, 104.44, 100.81, 81.53, 79.88, 77.48, 75.35, 74.85, 74.59, 73.17, 72.96, 
72.81, 72.78(2C), 72.48, 69.49, 69.16, 68.90, 64.53, 64.50, 63.50, 58.94, 53.53, 42.64, 30.99, 




glucopyranoside (GPI 2) 
 
Tetrasaccharide 2-21 (16 mg, 7.5 μmol) was dissolved in a mixture of ethylenediamine (2 
mL) and butanol (2 mL) and stirred at 90 °C for 3 h. After 3 h, the reaction mixture was 
concentrated to obtain partially deprotected crude intermediate. The crude intermediate was 
dissolved in anhydrous THF and MeOH. This solution was added dropwise to blue solution of 
20 mL liquefied ammonia with sodium -78 °C. The reaction was stirred at -78 °C. After 1 h, 
the reaction was quenched with MeOH and stirred for additional 1h at rt. Sodium methoxide 
generated in the reaction was quenched by dropwise addition of glacial acetic acid. The 
reaction mixture was concentrated and the crude product was purified by size exclusion 
column chromatography using a Sephadex® super fine G-15 (GE Healthcare) column and 5% 
ethanol in water as eluent to obtain GPI 2 (5 mg, 5.6 μmol, 75%) as white solid. 1H NMR 
(600 MHz, D2O) δ 5.14 – 5.06 (m, 1H), 5.04 – 4.96 (m, 1H), 4.93 – 4.87 (m, 1H), 4.37 (d, J = 
8.2 Hz, 1H), 4.06 – 3.39 (m, 26H), 3.21 – 3.13 (m, 2H), 2.83 – 2.74 (m, 1H), 2.67 (s, 1H), 
1.62 (dt, J = 15.6, 7.5 Hz, 2H), 1.54 – 1.47 (m, 2H), 1.30 (ddd, J = 23.9, 13.9, 6.8 Hz, 4H). 
13C NMR (151 MHz, D2O) δ 105.01, 104.42, 100.80, 81.52, 79.87, 77.47, 75.34, 74.84, 
Ho- 
I I I  1 o 
\ 
HO HO HO 
HO\ 0 o"Plo NH2 
O HO 
HO 





72.78, 72.47, 69.49, 68.89, 64.52, 63.49, 53.53, 42.64, 30.99, 29.94, 27.22, 26.47, 25.86. 31P 





To a stirred solution of dimannoside 2-17 (1.1 g, 1.07 mmol) in MeOH (12 mL) was added 
freshly prepared 1 M solution of NaOMe. After 1 h, the reaction was neutralized with 
Amberlite IR 120 H+ resin, filtered and concentrated to obtain crude product 2-22 (0.96 g, 
0.97 mmol, 91%). Rf  = 0.35 (EtOAc/Hexanes 1:3) 1H NMR (400 MHz, CDCl3) δ 7.38 – 7.23 
(m, 28H), 7.27 – 7.15 (m, 5H), 5.85 (ddt, J = 16.3, 10.9, 5.5 Hz, 1H), 5.25 (dd, J = 3.5, 1.5 
Hz, 2H), 5.20 (d, J = 1.5 Hz, 1H), 5.17 – 5.12 (m, 2H), 4.91 – 4.80 (m, 4H), 4.76 – 4.58 (m, 
5H), 4.60 – 4.49 (m, 4H), 4.14 (dd, J = 13.5, 4.5 Hz, 4H), 4.00 – 3.66 (m, 15H), 1.06 (d, J = 
4.3 Hz, 21H). 13C NMR (101 MHz, CDCl3) δ 138.54, 138.50, 138.39, 138.19, 138.05, 133.76, 
128.43, 128.41, 128.35, 128.33, 128.27, 127.97, 127.95, 127.89, 127.80, 127.77, 127.65, 
127.63, 127.47, 127.40, 117.10, 100.16, 98.28, 80.25, 80.03, 75.18, 75.08, 74.71, 74.15, 
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The mannosyl imidate 10a (0.19 g, 0.30 mmol) and disaccharide acceptor 2-22 (0.20 g, 0.20 
mmol) were co-evaporated with toluene (5 mL x 3) and dried under high vacuum for 2 h. The 
mixture was dissolved in anhydrous diethylether (8 mL) and activated molecular sieves were 
added. The solution was stirred for 10 min at room temperature and cooled to 0 °C. The 
mixture was treated with TBSOTf (14 µL, 0.06 mmol) and stirred at 0 °C for a period of 1 h. 
The reaction was diluted with CH2Cl2, quenched with Et3N and concentrated. The crude 
product was purified by flash column chromatography to obtain mannosyl trisaccharide 2-23 
(0.2 g, 0.14 mmol, 68%) as colorless oil. Rf  = 0.4 (EtOAc/Hexanes 1:4) 1H NMR (400 MHz, 
CDCl3) δ 7.40 – 7.27 (m, 36H), 7.30 – 7.16 (m, 39H), 7.15 (dd, J = 16.8, 5.4 Hz, 6H), 5.86 
(ddt, J = 16.3, 10.8, 5.5 Hz, 1H), 5.55 (s, 1H), 5.30 (s, 1H), 5.27 – 5.11 (m, 3H), 5.03 (s, 1H), 
4.88 (t, J = 8.2 Hz, 3H), 4.85 – 4.71 (m, 3H), 4.67 (dd, J = 11.5, 6.3 Hz, 3H), 4.67 – 4.50 (m, 
9H), 4.53 – 4.46 (m, 3H), 4.50 – 4.35 (m, 3H), 4.27 (dd, J = 12.1, 5.4 Hz, 1H), 4.14 (dd, J = 
12.9, 5.0 Hz, 2H), 4.06 (s, 3H), 4.02 – 3.86 (m, 13H), 3.89 – 3.83 (m, 3H), 3.77 (dt, J = 14.1, 
10.9 Hz, 7H), 3.69 (d, J = 9.1 Hz, 3H), 3.64 – 3.54 (m, 2H), 3.46 (d, J = 10.0 Hz, 1H), 2.13 (s, 
3H), 1.09 – 1.01 (m, 22H).13C NMR (101 MHz, CDCl3) δ 170.12, 138.69, 138.68, 138.52, 
138.49, 138.35, 138.26, 138.14, 138.11, 133.78, 128.38, 128.33, 128.31, 128.29, 128.25, 
128.14, 128.05, 128.00, 127.97, 127.79, 127.77, 127.73, 127.63, 127.55, 127.51, 127.42, 
117.14, 100.02, 99.87, 98.16, 80.03, 78.49, 75.18, 75.08, 74.78, 74.23, 73.57, 73.36, 73.30, 






A solution of [IrCOD(PPh2Me)2]PF6 (5.0 mg) in THF (3 mL) was stirred under hydrogen 
atmosphere until the color turned from red to colorless to pale yellow. The hydrogen 
atmosphere was exchanged with Argon. This solution was added to a solution of trisaccharide 
2-23 (0.18 g, 0.13 mmol) in THF (10 mL). After 16 h, the solvent was removed and the 
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residue was dissolved in a mixture of acetone (2.7 mL) and water (0.3 mL). Mercury (II) 
chloride (0.17 g, 0.63 mmol) and mercury (II) oxide (5.5 mg, 0.03 mmol) were added. After 1 
h, saturated NaHCO3 (aq) was added and the reaction mixture was extracted three times with 
CH2Cl2. The combined organic layers were dried over Na2SO4 and concentrated. The crude 
product was purified by flash column chromatography to give trisaccharide hemiacetal 
intermediate (0.12 g, 0.08 mmol, 64%) as colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.30 – 
7.21 (m, 25H), 7.23 – 7.12 (m, 33H), 7.16 – 7.02 (m, 13H), 5.47 (dd, J = 2.9, 1.7 Hz, 2H), 
5.23 (d, J = 7.7 Hz, 2H), 4.93 (s, 1H), 4.86 – 4.66 (m, 7H), 4.68 – 4.32 (m, 20H), 4.29 – 4.14 
(m, 2H), 4.06 (dd, J = 5.6, 2.3 Hz, 1H), 3.97 (s, 1H), 3.94 – 3.67 (m, 18H), 3.67 – 3.59 (m, 
6H), 3.56 (ddd, J = 19.2, 9.9, 3.5 Hz, 7H), 3.42 (dd, J = 10.3, 6.3 Hz, 2H), 2.06 (s, 3H), 1.00 
(d, J = 2.1 Hz, 22H). 13C NMR (101 MHz, CDCl3) δ 170.21, 138.65, 138.54, 138.47, 138.22, 
138.11, 128.47, 128.43, 128.38, 128.30, 128.20, 128.16, 128.14, 128.08, 128.01, 127.86, 
127.74, 127.69, 127.65, 127.61, 127.55, 127.48, 100.07, 99.80, 99.66, 79.73, 79.27, 78.48, 
75.58, 75.14, 74.78, 74.21, 73.75, 73.43, 73.33, 72.15, 72.01, 71.76, 69.39, 69.18, 68.76, 
68.68, 62.94, 62.88, 34.80, 31.97, 29.74, 26.11, 22.75, 21.24, 18.21, 14.20, 11.99(3C). 
To a stirred solution of hemiacetal (0.11 g, 0.08 mmol) in CH2Cl2 (10 mL) at 0 °C were added 
CCl3CN (0.08 mL, 0.77 mmol) and DBU (4 μL, 0.02 mmol). The reaction mixture was stirred 
for 1 h at 0 °C. The resulting mixture was concentrated and purified by flash column 
chromatography to obtain imidate donor 2-5 (0.1 g, 0.06 mmol, 80%) as clear oil. Rf = 0.4 
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The trisaccharide imidate 2-5 (0.19 g, 0.12 mmol) and disaccharide acceptor 2-15 (0.11 g, 
0.10 mmol) were co-evaporated with toluene (3 x 5 mL) and dried under high vacuum for 2 h. 
The mixture was dissolved in anhydrous diethylether (10 mL) and activated molecular sieves 
were added. The solution was stirred for 10 min at room temperature and cooled to 0 °C. The 
mixture was treated with TBSOTf (7 µL, 0.03 mmol) and stirred at 0 °C for a period of 1 h. 
The reaction was diluted with CH2Cl2, quenched with Et3N and concentrated. The crude 
product was purified by flash column chromatography to obtain pentasaccharide 2-2 (0.17 g, 
0.07 mmol, 65 % -isomer). R f = 0.4 (EtOAc/hexane = 1:3) 1H NMR (400 MHz, CDCl3) δ 
7.63 (d, J = 16.2 Hz, 3H), 7.34 – 7.17 (m, 57H), 7.20 – 7.07 (m, 12H), 7.10 – 7.04 (m, 4H), 
7.03 – 6.84 (m, 6H), 6.77 (t, J = 7.4 Hz, 1H), 5.52 (d, J = 19.8 Hz, 1H), 5.30 (s, 2H), 5.06 – 
4.99 (m, 2H), 4.92 – 4.20 (m, 32H), 4.15 (dd, J = 17.7, 7.1 Hz, 2H), 4.07 – 3.92 (m, 6H), 3.96 
– 3.80 (m, 11H), 3.75 (ddd, J = 19.1, 15.0, 10.8 Hz, 11H), 3.60 (s, 2H), 3.50 – 3.22 (m, 6H), 
2.13 (d, J = 14.8 Hz, 5H), 1.93 (d, J = 3.4 Hz, 3H), 1.44 – 1.17 (m, 5H), 1.21 – 1.00 (m, 27H), 
1.01 – 0.80 (m, 5H). 13C NMR (101 MHz, CDCl3) δ 170.13, 169.83, 138.83, 138.75, 138.56, 
138.53, 138.45, 138.07, 137.79, 128.75, 128.47, 128.41, 128.35, 128.31, 128.26, 128.25, 
128.23, 128.17, 128.15, 128.12, 128.08, 128.02, 127.96, 127.92, 127.77, 127.74, 127.65, 
127.53, 127.48, 127.43, 127.31, 127.16, 127.08, 126.84, 100.00, 99.91, 99.39, 99.06, 98.06, 
80.99, 79.42, 78.62, 78.54, 77.67, 75.02, 74.87, 74.65, 74.54, 74.42, 74.04, 73.37, 73.14, 
72.71, 72.13, 72.01, 71.73, 71.47, 71.39, 69.36, 68.92, 68.77, 68.58, 55.79, 36.20, 31.07, 
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To a stirred solution of pentasaccharide 2-2 (0.07 g, 0.03 mmol) in CH3CN (7 mL) were 
added water (50 μL) and Sc(OTf)3 (0.04 g, 0.08 mmol). The reaction mixture was warmed to 
50 °C and stirred for 6 h. The reaction was quenched with Et3N and concentrated. The crude 
product was purified by flash column chromatography to obtain 2-24 (50 mg, 0.02 mmol, 
72%). R f = 0.25 (EtOAc/hexane = 2:3) 1H NMR (400 MHz, CDCl3) δ 7.63 (d, J = 15.8 Hz, 
4H), 7.35 – 7.13 (m, 86H), 7.16 – 7.08 (m, 11H), 7.02 (dd, J = 16.1, 7.6 Hz, 4H), 6.88 (t, J = 
7.5 Hz, 3H), 6.77 (t, J = 7.2 Hz, 1H), 5.50 (d, J = 18.3 Hz, 3H), 5.29 (s, 1H), 5.15 (s, 1H), 
5.02 (d, J = 9.0 Hz, 3H), 4.92 – 4.75 (m, 8H), 4.76 – 4.60 (m, 4H), 4.62 – 4.49 (m, 11H), 4.51 
– 4.39 (m, 7H), 4.42 – 4.24 (m, 7H), 4.22 – 4.13 (m, 1H), 4.07 (s, 2H), 3.99 – 3.57 (m, 33H), 
3.58 – 3.39 (m, 4H), 3.35 – 3.18 (m, 1H), 2.16 (d, J = 7.1 Hz, 1H), 2.11 (s, 4H), 1.93 (s, 3H), 
1.42 – 1.22 (m, 2H), 1.21 – 1.08 (m, 1H), 1.04 – 0.79 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 
170.07, 169.88, 138.49, 138.45, 138.32, 138.12, 137.99, 137.93, 137.87, 137.81, 137.69, 
128.76, 128.48, 128.41, 128.36, 128.32, 128.28, 128.26, 128.24, 128.17, 128.13, 128.08, 
127.98, 127.92, 127.85, 127.78, 127.72, 127.66, 127.61, 127.53, 127.48, 127.44, 127.36, 
127.33, 127.19, 127.09, 126.84, 100.18, 99.31, 99.19, 98.96, 98.05, 81.01, 78.99, 78.32, 
77.89, 75.17, 75.00, 74.84, 74.78, 74.58, 74.42, 74.25, 74.05, 73.61, 73.40, 73.37, 73.20, 
72.64, 72.04, 71.95, 71.77, 71.64, 69.34, 69.26, 68.84, 68.62, 68.54, 68.47, 65.97, 62.01, 




glucopyranoside (GPI 3) 
 
Tetrasaccharide 2-24 (0.02 g, 8.6 μmol) was dissolved in a mixture of ethylenediamine (2 
mL) and butanol (2 mL) and stirred at 90 °C for 3 h. After 3 h, the reaction mixture was 
concentrated to obtain partially deprotected crude intermediate. The crude intermediate was 
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dissolved in anhydrous THF and MeOH. This solution was added dropwise to blue solution of 
20 mL liquefied ammonia with sodium -78 °C. The reaction was stirred at -78 °C. After 1 h, 
the reaction was quenched with MeOH and stirred for additional 1h at rt. Sodium methoxide 
generated in the reaction was quenched by dropwise addition of glacial acetic acid. The 
reaction mixture was concentrated and the crude product was purified by size exclusion 
column chromatography using a Sephadex® super fine G-15 (GE Healthcare) column and 5% 
ethanol in water as eluent to obtain GPI 3 (6 mg, 6.36 μmol, 74%) as white solid. 1H NMR 
(600 MHz, D2O) δ 5.19 – 5.15 (m, 1H), 5.10 – 5.06 (m, 1H), 5.00 (s, 1H), 4.92 (d, J = 1.5 Hz, 
1H), 4.61 – 4.52 (m, 1H), 4.01 – 3.96 (m, 1H), 3.94 (s, 2H), 3.90 – 3.80 (m, 9H), 3.80 – 3.41 
(m, 28H), 2.96 – 2.88 (m, 1H), 2.84 – 2.72 (m, 1H), 2.27 – 2.21 (m, 1H), 1.55 – 1.50 (m, 2H), 
1.46 (p, J = 7.4 Hz, 1H), 1.30 (ddd, J = 28.5, 14.3, 7.2 Hz, 4H). 13C NMR (151 MHz, d2o) δ 
104.82, 104.59, 103.27, 101.21, 100.95, 81.41, 81.12, 79.75, 77.59, 75.83, 75.33, 74.90, 
73.22, 72.93, 72.76, 72.56, 69.66, 69.53, 69.43, 68.93, 63.70, 63.52, 63.28, 63.20, 58.44, 









Pentasaccharide 2-24 (0.03 g, 0.01 mmol) and H-phosphonate 2-3 (0.02 g, 0.04 mmol) were 
co-evaporated with pyridine for three times and dried under high vacuum for 2 h. The mixture 
was dissolved in anhydrous pyridine (4 mL) and a solution of pivolyl chloride (5 μL, 0.04 
BnO BnO' BnO 
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mmol) in pyridine (1 mL) was added. The solution was stirred for 6 h at room temperature. 
After 6 h, iodine (0.01 g, 0.04 mmol) and water (0.05 mL) were added and reaction was 
stirred for 2 h. The reaction mixture was quenched with Na2S2O3 and extracted with CH2Cl2. 
The organic layer were concentrated and purified by Et3N deactivated silica gel flash column 
chromatography to obtain phosphorylated pentasaccharide 2-1 (0.03 g, 0.01 mmol, 86%). R f 
= 0.5 (MeOH/CH2Cl2 = 1:10) 1H NMR (400 MHz, CDCl3) δ 7.63 (d, J = 16.2 Hz, 6H), 7.33 
(d, J = 7.7 Hz, 5H), 7.32 – 7.24 (m, 15H), 7.25 – 7.14 (m, 57H), 7.14 (d, J = 3.2 Hz, 5H), 7.11 
(d, J = 7.1 Hz, 6H), 7.08 – 7.02 (m, 4H), 6.97 (d, J = 7.3 Hz, 4H), 6.87 (t, J = 7.6 Hz, 2H), 
6.78 (d, J = 5.7 Hz, 2H), 5.53 (d, J = 25.7 Hz, 3H), 5.29 (s, 1H), 5.20 (s, 1H), 5.00 (td, J = 
23.2, 22.0, 14.0 Hz, 4H), 4.79 (dt, J = 21.0, 11.9 Hz, 11H), 4.68 – 4.22 (m, 28H), 4.21 – 4.06 
(m, 4H), 4.02 – 3.68 (m, 27H), 3.60 (d, J = 7.8 Hz, 4H), 3.51 – 3.36 (m, 5H), 3.29 (s, 3H), 
2.14 (t, J = 7.3 Hz, 2H), 1.95 (s, 3H), 1.40 – 1.21 (m, 5H), 1.07 – 0.83 (m, 3H). 13C NMR 
(101 MHz, CDCl3) δ 170.07, 169.98, 156.49, 138.70, 138.49, 138.13, 138.04, 137.76, 137.68, 
137.02, 133.82, 128.75, 128.49, 128.42, 128.32, 128.22, 128.15, 127.98, 127.89, 127.80, 
127.71, 127.55, 127.47, 127.41, 127.32, 127.20, 126.86, 100.29, 99.44, 99.30, 98.89, 98.01, 
80.99, 78.48, 75.15, 74.97, 74.89, 74.68, 74.55, 74.40, 74.01, 73.50, 73.35, 73.12, 72.12, 
72.03, 71.91, 71.73, 71.52, 71.34, 69.37, 68.58, 66.17, 55.86, 45.58, 36.19, 31.06, 29.69, 




deoxy-2-amino--D-glucopyranoside (GPI 4) 
 
Pentasaccharide 2-20 (0.04 g, 0.02 mmol) was dissolved in a mixture of ethylenediamine (2 
mL) and butanol (2 mL) and stirred at 90 °C for 3 h. After 3 h, the reaction mixture was 
concentrated to obtain partially deprotected crude intermediate. The crude intermediate was 
Hb- Q H0\ 0 NH2 '°\o 
ı\..ı 1 Ho o Ho o HO 
OH 
o SH H2N 
94 
 
dissolved in anhydrous THF and MeOH. This solution was added dropwise to blue solution of 
20 mL liquefied ammonia with sodium -78 °C. The reaction was stirred at -78 °C. After 1 h, 
the reaction was quenched with MeOH and stirred for additional 1h at rt. Sodium methoxide 
generated in the reaction was quenched by dropwise addition of glacial acetic acid. The 
reaction mixture was concentrated and the crude product was purified by size exclusion 
column chromatography using a Sephadex® super fine G-15 (GE Healthcare) column and 5% 
ethanol in water as eluent to obtain GPI 4 (11 mg, 10.2 μmol, 60%) as white solid.  1H NMR 
(600 MHz, D2O) δ 5.18 – 5.15 (m, 1H), 5.08 (s, 1H), 4.97 (s, 1H), 4.94 – 4.90 (m, 1H), 4.32 
(ddd, J = 19.6, 7.9, 3.7 Hz, 1H), 4.03 – 3.95 (m, 5H), 3.94 (dt, J = 5.6, 2.7 Hz, 2H), 3.88 – 
3.77 (m, 6H), 3.76 (d, J = 10.7 Hz, 2H), 3.74 – 3.51 (m, 14H), 3.48 (q, J = 8.8, 7.7 Hz, 2H), 
3.47 – 3.41 (m, 2H), 3.21 – 3.14 (m, 2H), 3.01 (dt, J = 17.5, 6.4 Hz, 1H), 2.87 (dd, J = 10.2, 
5.3 Hz, 0H), 2.65 (t, J = 7.2 Hz, 1H), 2.42 (t, J = 7.1 Hz, 0H), 1.62 – 1.45 (m, 3H), 1.32 – 
1.23 (m, 2H). 13C NMR (151 MHz, D2O) δ 184.07, 104.80, 104.45, 103.35, 100.90, 81.59, 
81.01, 79.87, 77.44, 75.89, 75.36, 74.92, 74.78, 74.72, 73.20, 72.96, 72.78, 72.62, 72.42, 
69.49, 69.14, 68.98, 67.28, 64.44, 63.69, 63.48, 58.99, 42.70, 42.65, 40.78, 31.13, 30.78, 
29.81, 27.27, 27.13, 25.86. 31P NMR (243 MHz, D2O) δ -2.75. HRMS (m/z): [M]+ cald 
1066.3652 obsd 1066.3646 
 
2.8.2 Methods of Biochemistry 
 
CRM197 was purchased from Pfēnex Inc., 1M solution of resin bound TCEP was purchased 
from thermo scientific and autoclaved sterile water was used for the conjugation. 
Conjugation of GPI 16 to CRM197  
250 µl of TCEP resin solution was centrifuged for 3 mins and excess of water was removed. 
TCEP resin was redissolve in 0.1 M sodium phosphate buffer (pH 8) (150 µL) and centrifuged 
for 3 mins. Again excess buffer was removed and autoclaved water was added. GPI fragment 
(in 120µL water) was transferred to the TCEP solution and incubated for 1h at rt. After 1 h, 
TCEP resin is filtered off using syringe and washed with autoclaved water (5x50 µL). All the 
water fractions are combined lypholized. The reduction of disulfide to thiol is followed by 
LC-MS. To a stirred solution of CRM197 (3 mg) in 0.1 M sodium phosphate buffer (pH 7.4) was 





mixture was stirred for 1 h. After 1 h, the solution was concentrated to 250 μL volume using 
an Amicon® Ultra-4 Centrifugal Filter Unit (10 kDa cut off, Millipore) and washed with 
water (4x 1 mL) and once with 0.1 M sodium phosphate buffer (pH 8.0). Finally, the activated 
CRM197 is concentrated to obtain around 100 μL of solution. To the stirred solution of 
activated CRM197 solution was added the reduced glycan. The solution was stirred overnight 
at room temperature. The solution was concentrated to 250 μL of volume using an Amicon® 
Ultra-4 Centrifugal Filter Unit (10 kDa cut off, Millipore) and washed with water (4x 1 mL) 
and once with 0.1 M sodium phosphate buffer (pH 8.0) to obtain the CRM-GPI conjugate. 
cysteine (0.94 mg) was added directly to that solution in the Centricon and incubated for 1 h 
at r.t. After 1 h, the mixture was washed with water (4x 1 mL) re-buffered with PBS to obtain 
the desired CRM-GPI conjugate. MALDI-TOF mass spectroscopy and SDS-PAGE was done 
for all the intermediates and final samples. 
 
Characterization of conjugates 
CRM197-GPI conjugates were characterized by MALDI-TOF spectrometry and by gel 
electrophoresis and directly stained against carrier protein with Coomassie Brilliant Blue 
R250 (CBB) (Sigma-Aldrich, Munich, Germany, 6104-59-2) or used for western blotting. For 
gel electrophoresis, glycoconjugates were diluted 1:10 in sterile water; loading buffer was 
added, boiled for 5 minutes and loaded onto a 12% polyacrylamide gel. Gel electrophoresis 
was performed at 150 V, 150 mA for 60 minutes. Western blot transfer was accomplished at 
100 V and 35 mA. The membrane was routinely tested for positive transfer with Ponceau S 
(Sigma-Aldrich, Munich, Germany, 6226-79-5), subsequently blocked for 2 h at RT with 5% 
BSA in PBS-T. Biotinylated Concavalin-A (Vector Laboratories, Burlingame, California, B-
1005) was diluted 1:500 in 1x PBS 5% BSA 0.01mM Mn2+ 0.1mM Ca2+ and incubated 2 h 
shaking at rt. The membrane was subsequently washed and streptavidin HRP (BD 
Pharmingen, Heidelberg, Germany, 557630) was added 1:500 in 1x PBS 5% BSA 0.01mM 
Mn2+ 0.1mM Ca2+ and incubated 1 h shaking at RT. Finally, the membrane was washed again 
in 1x PBS 0.01mM Mn2+ 0.1mM Ca2+ and developed by enhanced luminol-based 
chemiluminescent according to manufacturer’s instructions (Thermo Fisher Scientific, 
Darmstadt, Germany, 32109). Dual color precision protein standard (Bio-Rad Laboratories, 
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Figure 2.21: MALDI-TOF analysis of the activated CRM197 (CRM-AcBr) and CRM197-GPI (CRM-Glycan) during glycoconjugate synthesis. Δ (observed) represents the difference in m/z for activated CRM197 and CRM-GPI and was used to calculate the glycan loading of the glycoconjugates. (A-F) represent the MALDI-TOF spectra for CRM197-GPI 16 respectively. 
 
Animal Experiments 
Animals were treated strictly according to German (Tierschutz-Versuchstierverordnung) and 
European Law (Directive 2010/63/EU). Recommendations of the Society for Laboratory 
Animal 43 Science (GV-SOLAS) and of the Federation of European Laboratory Animal 
Science Associations (FELASA) were followed. The Office for Health and Social Affairs 
Berlin (LAGeSo) approved the experiment conclusively (Permit Number: G0239/14). All 
efforts were made to minimize suffering. All C57BL/6JRj mice used in this study were 
obtained from Janvier Labs (Saint-Berthevin, France). Mice were housed in individually-
ventilated cages (IVCs) under specific pathogen free (SPF) conditions in the animal facility of 
the Federal Institute for Risk Assessment (BfR, Berlin, Germany). Mice were provided food 
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and water ad libitum. Upon delivery (day -7), mice were allowed to rest for one week before 
experimental setting was started. 
Statistical analysis  
Statistical analysis was performed using the GraphPad Prism software (GraphPad Software 
Inc., La Jolla, CA, US). Unpaired Student’s t test was used to compare different sets of data, 
whereas two-way ANOVA was used to compare anti-GPI antibody levels over time between 
immunized and non-immunized groups. Log rank test was employed for analysis of survival 
between different groups. Statistical significance within figures is shown by asterisks: * 
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One very important component of the cell membrane is different proteins that perform 
specific functions for the cell. Membrane proteins can be classified as peripheral or integral 
depending on the nature of their interactions with the membrane. Peripheral membrane 
proteins do not interact with the hydrophobic part of the cell membrane. They are found 
bound to the membrane through electrostatic interactions with the polar head of the 
membrane lipids or by interactions with integral membrane proteins. Most of the membrane 
proteins found in red blood cells such as spectrin and glycoforin are peripheral membrane 
proteins.  
Integral membrane proteins are embedded in the membrane bilayer and contain hydrophobic 
residues that interact with the alkyl chains of the membrane bilayer. These proteins can also 
span the entire cell membrane one or more times generating a transmembrane protein such as 
a porins, an integral protein found in outer membrane of E. coli. Some integral proteins are 
anchored to the plasma membrane through fatty acid chains attached to the side chain of 
cysteine residues to keep the protein outside the membrane.2 Other proteins have post 
translational modifications at the C-terminus involving fatty acid chains,170 diacylglycerols,171 
isoprenoids172 or glycosylphosphatidylinositol anchors (GPIs)173. 
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GPI is a complex glycolipid added as a post-translational modification at the C-terminus of 
eukaryotic proteins. This glycolipid has a unique and conserved core structure attached to an 
inositol phospholipid. Many membrane proteins, enzymes and receptors are bound to the 
plasma membrane by a GPI anchor.174 
 
3.1.1 GPI-Anchored Proteins in Plasmodium 
GPI-anchored proteins are present in all eukaryotic cells and are involved in various cellular 
functions like signal transduction and cell adhesion. Apart from their cellular functions, GPI-
anchored proteins have been associated with many diseases like malaria and toxoplasmosis. 
Large amount of GPI-anchored proteins are found on the surface of protozoa such as 
Trypanosoma spp., Leishmania spp., Toxoplasma and Plasmodium spp. GPI-anchored 
proteins participate in the modulation of the immune system during infections and are 
believed to be essential for the these pathogens. 
GPI-anchored proteins are found in all developmental stages of Plasmodium parasites. During 
different stages of the life cycle of the parasite, such as sporozoite, merozoite, gamete and 
ookinete, the surface of the parasite is covered with GPI anchored proteins. These proteins 
include the circumsporozite protein (CSP) on sporozoites and the merozoite surface proteins 
(MSP) family and the rhoptry-associated membrane antigen (RAMA), some of the most 
important proteins expressed on merozoites. Additional examples are the Pfs48/45 protein 
expressed on gametes, Pfs28 and Pfs25 expressed on ookinete, and the Pf34 and apical sushi 
protein (ASP), which are GPI anchored proteins expressed during the erythrocyte stage.175-181 
Circumsporozoite Protein (CSP) is a preerythrocytic GPI-anchored protein found on the 
surface of sporozoites. It is composed of five regions, an N-terminal region that binds to 
proteoglycans, a central repeating unit with multiple copies of a strain specific sequence, two 
conserved regions (one responsible for the invasion of sporozoites and the other responsible 
for the binding to hepatocytes) and the C-terminus containing a thrombospondin-like domain 
that carries the GPI.  CSP is responsible for the invasion and development of sporozoites. Due 
to its high abundance on the surface of sporozoites, it is commonly used in the development 
of malaria vaccine candidates.182 
Merozoite Surface Protein (MSP) is a family of GPI-anchored proteins displayed on the 





invasion of red blood cells. MSP are divided into integral, peripheral and membrane bound 
proteins. Two-thirds of all GPI-anchored proteins in Plasmodium during the blood stage are a 
member of the MSP family. The MSP structure and properties will be explained in detail in 
section 3.1.2.  
Rhoptry-Associated Membrane Antigen (RAMA) is expressed as a 170 kDa protein that 
undergoes proteolytic cleavage to yield three N-terminal repeat regions and a 60 kDa GPI-
anchored protein. RAMA is the first protein expressed on the parasite surface after red blood 
cell invasion. It consists of an N-terminal hydrophobic sequence corresponding to the signal 
sequence, three acidic repeat regions at the N-terminal region. The other fragment at the C-
terminus is anchored to a GPI.183 
Ookinete surface proteins Pfs25 and Pfs28. These are the predominant proteins on the 
surface of ookinetes. They are characterized by an N-terminal signal sequence, three 
epidermal growth factors and a GPI-anchor at the C-terminus. They are involved in the 
interaction between the ookinete with the midgut environment of the vector.181  
Pfs48/45 is a protein expressed by gametocytes present on the surface of the sporogonic 
stages of plasmodium parasites. It plays an important role in parasite fertilization. This protein 
contains three domains and ten cysteine residues forming a complex structure defined by 
disulfide bridges.184 
 
3.1.2 Merozoite Surface Proteins 
The merozoite surface proteins are important for the primary attachment of merozoites to the 
red blood cell surface and for the subsequent invasion. Therefore, the MSPs have been 
considered for the development of an antimalaria vaccine and have been included in various 
potential vaccine candidates. Many of these proteins are attached to the membrane of the 
parasite using a GPI anchor, such as MSP1, MSP2, MSP4, MSP5 and MSP10.185, 186  
Merozoite surface protein 1 (MSP1) is the most abundant and well characterized protein in 
the MSP family. It has been described as an essential protein for the invasion process and 
survival of the parasite.187 MSP1 is a cysteine-rich protein stabilized by multiple disulfide 
bonds that is expressed as a ~200 kDa protein precursor. MSP1 undergoes proteolytic 
cleavage catalyzed by the Subtilisin-like protease 1 (SUB1) that modifies the secondary 
structure of the protein. After the processing, the protein remains on the surface of the 
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merozoite as a complex of four polypeptide fragments of MSP1. Three non-covalently bound 
fragments make up the N-terminal fragment MSP183 (83 kDa) and two internal fragments 
MSP130 (30 kDa) and MSP138 (38 kDa). The N-terminal fragment MSP183 interacts with 
glycophorin A as a mediator for the invasion process. The processed protein can bind and 
rupture the red blood cells. The GPI-anchored C-terminal fragment MSP142 (42 kDa) remains 
covalently bound to the merozoite.188-193  
During the invasion, the C-terminal bound fragment MSP142 undergoes further proteolytic 
processing mediated by Subtilisin-like protease 2 (SUB2) to shed MSP133 (33kDa) from the 
merozoite surface. A C-terminal fragment MSP119 (19 kDa) fragment anchored to GPI 
remains bound to the merozoite surface and is carried to the red blood cells, where it localizes 
at the food vacuole. MSP1 is regarded as a dimorphic protein but the MSP119 region remains 




Figure 3.1: Schematic processing of MSP1 showing primary processing mediated by SUB1 and secondary processing mediated by SUB2 during the invasion of red blood cells. 
 
Merozoite surface protein 2 (MSP2) is the second most abundant surface protein found on 
merozoites of P. falciparum. Unlike MSP1, it does not undergo proteolytic cleavage and it 
possesses only one disulfide bond. Studies have shown that the N-terminus of MSP2 interacts 
with the lipids on the membrane of the merozoite and is believed to be important during the 
invasion process. It is retained on the parasite surface during invasion and it degrades soon 
after the invasion, however, the precise role of MSP2 is still unknown.188, 200-202 
GPI __ 
Proteolitically cleaved by SUB1 
merozoite QM w N Mspl.. Mspl:. MSP14z 
hiàont f l 4 o «Ü J Proteolitically cleaved by SUB2 







Merozoite Surface Protein 4, 5 and 10 (MSP4, 5 and 10) are not well known surface 
proteins. MSP4 and MSP10 are very similar to MSP1 and are highly immunogenic. MSP4 is 
expressed as a 40 kDa protein and is an important protein for the development of the parasite 
post-invasion. MSP5 encodes 272 amino acids and contains an EGF-like domain. Although it 
is conserved across P. falciparum, its function is not known. MSP10 is expressed as an 80 
kDa protein and then processed to 36 kDa. It is found on the apical end of the merozoite. 
Though it is highly immunogenic, no red blood cell receptors have been identified.203-207 
 
3.2 Synthesis of GPI-Anchored Proteins  
 
It has been shown that GPIs influence the structure and function of anchored proteins. 
However, studies evaluating the structure and function of GPI-anchored proteins are limited 
due to the difficult in isolating of GPI-anchored proteins in homogeneous form. Therefore, 
semi-synthesis of proteins has emerged as an alternative approach to obtain GPI anchored 
proteins.208, 209 
The first attempt to synthesize a GPI-anchored protein was undertaken by Guo and coworkers 
with the synthesis of GPI-anchored CD52. CD52 is a GPI anchored glycopeptide consisting 
of 12 amino acids and one N-glycosylated site. In this work, the linkage between the synthetic 
glycopeptide and the glycolipid was obtained by reaction with an active ester of the peptide 
and the amine group on the phosphoethanolamine unit of the GPI. This method showed great 
potential, however, it is limited to the size of the peptide and it can only be used for short 
sequences.210 
To accommodate larger proteins, the groups of Bertozzi and Becker applied a semi-synthetic 
approach to obtain mimetics of GPI-anchored proteins using expressed protein ligation.211, 212 
Using the same approach, Seeberger and coworkers reported the synthesis of a GPI-anchored 
Prion protein (PrP) containing a synthetic monolipidated GPI anchor. To obtain the GPI-PrP 
molecule, a cysteine residue was attached to the phosphoethanolamine moiety of the GPI to 
carry out a native chemical ligation between the GPI and an expressed PrP thioester.209, 212 
There are still limitations to evaluate the biological significance of GPIs and to study the 
effect of the GPI anchor on the structure and activity of proteins. Therefore, it is necessary to 
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establish new methodologies for the synthesis of GPI-anchored proteins having a natural 
glycolipid structure. In this work, the synthesis of a homogeneous GPI-anchored protein was 
planned to investigate the role of the GPI on proteins during infection by Plasmodium 
parasites. To carry out this study, the synthesis of the 19 kDa fragment of the merozoite 
surface protein 1 (MSP119) from P. bergei was designed to compare the structural and 




To synthesize a GPI-anchored protein from Plasmodium falciparum bearing a natural linkage 
between the protein (MSP119) and the GPI (structure PfGPI 1 in figure 3.2), a synthetic GPI 
containing a cysteine residue attached to the phosphoethanolamine unit was designed for 
chemoselective introduction of the activated protein. This cysteine residue can undergo a 
chemoselective reaction with a C-terminal protein thioester via a trans-thioesterification and 
rearrangement process to provide GPI-MSP119. To incorporate the cysteine residue for 
ligation, the cysteine will be coupled to the phosphoethanolamine unit prior to 
phosphorylation of the GPI anchor. The amine and thiol functionalities of the cysteine will be 
protected using acid labile groups, which can be removed by acid treatment of the GPIs after 
deprotection of the glycan by hydrogenolysis.209 The core glycan part of the GPI anchor can 
be obtained using a general synthetic approach previously established in our group, which 
involves the orthogonally protected building block 3-5, 3-6 and 3-7 and a [3+1+2] 
glycosylation strategy (figure 3.2).107  
After the assembly of the orthogonally protected pseudo-hexasaccharide, two-step 
phosphorylations would provide the desired biphosphorylated glycan. Finally, a three step 
global deprotection would provide access to the GPI anchor bearing a cysteine residue primed 
for ligation with MSP119. As discussed in chapter 2 (figure 2.2), the GPIs from Plasmodium 
are highly heterogeneous on the lipid component and it also carries an additional acyl group 
on the myo-inositol which is not present in GPIs from other protozoa. Thus, using the general 
synthetic strategy, two GPI anchors from plasmodium falciparum will be synthesized: PfGPI 
1 carrying a glycerolipid and PfGPI 2 carrying a glycerolipid plus an additional acyl moiety 








Figure 3.2: (A) Retrosynthesis of GPI-Anchored protein (GPI-MSP119); (B) Retrosynthetic analysis of cysteine-containing GPIs from P. falciparum for the synthesis of GPI-anchored proteins. 
A) 
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3.4 Chemical Synthesis of GPIs from P. Falciparum 
 
PfGPI 1 and PfGPI 2 (figure 3.2) from P. falciparum were synthesized from three 
fragments: mannose trisaccharide 3-5, mannose building block 3-6 and pseudo-disaccharide 
3-7. Mannose trisaccharide 3-5 was synthesized using the protocol described in chapter 2 
(section 2.5). Mannose building block 3-6 was synthesized using a protocol previously 
established in our laboratory.213   
The core glycan structure (3-1) for PfGPI 1 was assembled using a [3+1+2] glycosylation 
strategy following the protocols previously established in our lab. However, in order to 
incorporate a palmitic ester at the 2-O position of the myo-inositol in PfGPI 2, the 
pseudodisaccharide building block 3-7b was initially synthesized bearing the acid labile PMB 
moiety as an orthogonal protecting group at the 2-O position of myo-inositol (scheme 
3.1a).214 The acidic conditions during required for the glycosylation of the myo-inositol 
cleaved the PMB group during the reaction and hence, the PMB group was replaced with the 
more stable 2-(napthyl)methyl group. The synthesis of the pseudo-disaccharide was 
performed using myo-inositol containing a 2-(napthyl)methyl at the 2-O position of 3-10. 
Glycosylation of myo-inositol 3-10 with trichloroacetimidate donor 3-11 using TMSOTf in 
Et2O/DCM at 0 C afforded the pseudo-disaccharide 3-12 as an anomeric mixture of products  
(/ = 5:1) in 80% yield. The / mixture of 3-12 could not be separated using silica gel 
chromatography, therefore, the obtained anomeric mixture of the pseudo-disaccharide 3-12 
was deacetylated using freshly prepared sodium methoxide. The 4-O and 6-O positions of the 
resulting triol 3-13 were blocked by formation of the 4,6-O-benzylidene acetal using 
benzaldehyde dimethyl acetal and CSA. Then, the free 3-O position was benzylated using 
NaH and BnBr to obtain 3-14 in 54% yield. The benzylidene acetal of 3-14 was selectively 
opened towards the 6-O position in 80 % yield to obtain the pseudo-disaccharide acceptor 3-













Scheme 3.1b: Synthesis of pseudodisaccharide. a) TMSOTf, CH2Cl2-Et2O, 0 °C; b) NaOMe, MeOH, rt, quant.; c) PhCH(OCH3)2, CSA, CH3CN, rt, 3 h, 59%; d) BnBr, NaH, DMF, rt, 54%; e) TFAA, TFA, TES, CH2Cl2, 0 °C, 5 h, 80%. 
 
For the synthesis of PfGPI 2, the mannose building block 3-6a was glycosylated with the 
trimannosyl trichloroacetimidate donor 3-5a using TBSOTf as activator in a mixture of 
thiophene and CH2Cl2 as solvent to promote α-selectivity during the reaction (Scheme 3.2). 
The [3+1] glycosylation under these reaction conditions furnished tetramannose 3-15a in 50% 
yield of -isomer. Subsequently, the allyl group of the obtained tetramannoside was 
isomerized using an activated Ir-catalyst and the formed vinyl ether was hydrolyzed with 
mercury salts to obtain the lactol. This lactol was treated with trichloroacetonitrile and DBU 
to provide trichloroacetimidate donor 3-16a in 65% yield over two steps. To complete the 
synthesis of the GPI core glycan, the trichloroacetimidate 3-16a was used to glycosylate the 
pseudo-disaccharide 3-7c using TMSOTf as acid activator at 40 °C giving the pseudo-
hexasaccharide 3-17 in 51% yield. This glycan has tree orthogonal groups and can be used to 
generate the trilipidated PfGPI 2.  
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The glycan pseudo-hexasaccharide 3-3 required for the synthesis of PfGPI 1, was synthesized 
by Dr. Ivan Vilotijevic using the same synthetic strategy as described above using a myo-
inositol with the benzyl ether instead of the NAP protecting group. In order to optimize and 
evaluate the production of GPI anchored proteins, bilipidated PfGPI 1 was synthesized by 
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To complete the synthesis of PfGPI 1, pseudo-hexasaccharide 3-3 was phosphorylated using 
two-step phosphorylation reactions. First, the allyl group from the 1-O position of myo-
inositol was removed under optimized conditions using PdCl2 and sodium acetate to obtain 3-
18 in 80% yield (scheme 3.3). Unfortunately, removal of the allyl ether using the iridium 
catalyst for isomerization followed by hydrolysis gave only low yields, especially in the 
hydrolysis step. The resulted alcohol 3-18 was phosphitylated with H-phosphonate 3-8 using 
pivaloyl chloride in pyridine. After completion of the reaction, oxidation with iodine in wet 
pyridine delivered the phospholipidated compound 3-19. The triethylammonium salt from the 
product was exchanged to sodium using Amberlite IR120 (Na+ form) and the 6-O TIPS group 
of Man-III was removed under acidic conditions using scandium triflate and water. The 
resultant alcohol was phosphitylated with the cysteine containing H-phosphonate 3-9 and 
oxidized using iodine to deliver the fully protected and bilipidated GPI 3-1 (scheme 3.3). 
Finally, GPI 3-1 was deprotected using a three-step global deprotection strategy involving 
treatment with hydrazine acetate to cleave the Lev group present at the 2-O position of ManI, 
followed by hydrogenolysis using palladium hydroxide on charcoal as catalyst, and finally 
removal of N-Boc and St-Bu protecting groups from cysteine using Hg(TFA)2 in 
trifluoroacetic acid (scheme 3.2). PfGPI 1 was obtained in 35% yield after purification. The 
synthesis of PfGPI 2 was not completed in this work. However, the protocols established for 
the synthesis of PfGPI 1 can easily be applied to the synthesis of PfGPI 2 by adding two 
steps before the removal of the allyl group: an oxidative removal of the Nap group and 
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3.5 Protein-GPI Ligation 
The ligation strategy developed by Dr. Renee Roller in our group was utilized to obtain GPI-
anchored MSP119. This semi-synthetic strategy is carried out by combining a protein 
activation with ligation to the GPI molecule in a one-pot process.  A modified C-terminal 
intein fragment from the DNAE split intein from Nostoc punctiforme was designed having 
two essential residues (Asn35 and Cys36) mutated to Ala residues to obtain NpuC(AA). 
These mutations defunctionalize the intein for the protein trans-splicing process but allowed 
the capture of a thioester using thiols. Identical to the wildtype NpuC, this modified intein 
fragment can associate with the N-terminal fragment of the protein to bring the C-terminus of 
the protein in close proximity to that of NpuC(AA). To replace the intramolecular trans-
thioesterification from Cys1 of NpuN to Cys36 of NpuC, a thiol reagent was added to form a 
protein thioester in situ. This protein activation is followed by a ligation reaction of the 
formed protein thioester with the cysteine-containing GPI already present in the reaction 
mixture. The rearrangement in the process leads to formation of the desired GPI-anchored 
product and the fragment NpuN as a by-product of the reaction. Figure 3.3 shows a schematic 
representation of the one-pot ligation rearrangement during the process. 
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3.5.1 Synthesis of MSP119-GPI and MSP119-Biotin 
In order to compare the effect of glypiation on the structure and immunological properties of 
the MSP119 protein, the protein was ligated to PfGPI 1 and Cys-Biotin (Figure 3.4). MSP119-
Biotin was used for the optimization of the process and as a control in the biological studies.  
Purified fusion protein MSP119NpuN, provided by Dr. Maria A. Carillo, synthetic 
NpuC(AA) and 4-(mercaptomethyl)benzoic acid (MMBA) were used to generate a MSP119 
protein thioester in situ. The ligations to PfGPI 1 and Cys-Biotin  with the protein were carried 
out under optimized conditions using the 10 μM MSP119NpuN, 30 μM NpuC(AA),  20 mM 
TCEP solution and 70 mM MMBA in Tris buffer at pH 7.2. The reactions were incubated at 
37 ˚C for five days to obtain the ligated products, MSP119-Biotin and MSP119-GPI. The 
ligation was run in small batches with maximum 200 μg of protein to avoid precipitation of 
protein during the reaction. 
 
     
                                                                
Figure 3.4: Protein ligation with MSP119-NpuN, NpuC* and PfGPI.‡
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The ligation reactions were monitored by analytical SEC and SDS-PAGE (Figure 3.5 A, B, 
C). MSP119-Biotin and MSP119-GPI were purified using His-Trap affinity chromatography. 
MSP119-NpuN and cleaved NpuN bearing an N-terminal His-Tag were retained on the column 
and eluted using a gradient of imidazole. This purification step separates the cleaved intein 
fragments from the product leaving a mixture of the hydrolyzed protein and the NpuC(AA) 
peptide that co-elutes with the product in the flow through fractions. To separate this mixture, 
FPLC purification on a Superdex 30 column was used. The fractions from FPLC were 
analyzed using SDS-PAGE with silver staining (Figure 3.5 D).  
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The pure fractions were collected and dialyzed to partially remove the salts from the ligated 
samples. The pure ligated product was obtained in 45% yield and analyzed using LC-ESI-MS 
(figure 3.6). The products MSP119-Biotin and MSP119-GPI were detected in the LC-ESI-MS 
spectra. However, the detection of MSP119-GPI was very difficult due to the loss of labile 
fatty acid chains during the MS analysis, which were also observed in the MS spectra. Figure 
3.6 shows the deconvoluted spectrum for MSP119-GPI with an observed mass of 





Figure 3.6: LC-ESI-MS analysis of ligation of MSP119 and GPI after five days. Deconvoluted mass spectrum for MSP119-GPI. 
 
3.6 Structural Analysis 
 
Circular dichroism (CD) was used to analyze the global conformation of the protein and to 
evaluate the effect of the C-terminal modification on the structure of MSP119. The native 
conformation of MSP119 has two epidermal growth factor (EGF) like domains with three 
disulfide bonds each. In its native state, each EGF domain contains a random coil segment 
followed by four antiparallel -strands. Thus, the overall structure of MSP119 is described as  
a random coil structure (figure 3.7).215  
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The purified ligated products were structurally analyzed using CD. The CD spectra for both 
MSP119-GPI and MSP119-Biotin showed an identical profile that corresponds to a random coil 
structure, which are also in agreement with previously reported CD spectra for an expressed 
MSP119 protein.216 These results confirm that any of the added C-terminal modification does 
not induce any structural changes in MSP119 or affect the general profile of the CD spectra 
(figure 3.8). However, a more detailed analysis is required to determine the local effects of 
these modifications and cannot be detected by this method.  
 
                
 




Figure 3.8: Circular dichroism analysis. Circular dichroism spectra of MSP119-Biotin (red) and MSP119-GPI (blue).  
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3.7 Dendritic Cell Stimulation Assay 
 
Dendritic cells are important for initiating cellular immune response.217 They act as antigen 
presenting cells (APC) and can activate a T-cell response. Upon activation, dendritic cells 
produce pro-inflammatory cytokines such as IL-12, TNF-α and IFN-γ, among others, that 
activate T-cells and can be used to monitor the immunogenicity of antigen for vaccine 
development.218 Several studies have shown enhanced levels of IL-6, TNF-α and IL-10 in 
patients with severe malaria and a correlation of the level of these cytokines with parasitemia. 
Therefore, a proinflammatory response is considered important for malaria clearance.219, 220 
To determine the activity of the synthesized proteins, a quantitative enzyme-linked 
immunosorbent assay (ELISA) was performed to determine the levels of TNF-α and IL-12 
cytokines in MSP119-GPI and MSP119-Biotin in in vitro-stimulated dendritic cells. The cells 
were cultured in the presence of the proteins at three different concentrations, 0.01, 0.1 and 1 
μM. LPS (lipopolysaccharide), a strong immunostimulator, was used as a positive control for 
this study (Figure 3.9). This in vitro assay showed that the production of cytokines was 
directly proportional to the concentration of MSP119-Biotin and MSP119-GPI. At 0.01 μM, 
almost no activation was observed for TNF-α and IL-12 and higher level of cytokines were 
observed at 0.1 μM. The activation was similar for both MSP119-Biotin and MSP119-GPI. 
However, at 1 μM very high concentration of TNF-α and IL-12 were observed for MSP119-
GPI compared to MSP119-Biotin. This confirms that GPI can improve the immunogenicity of 













Figure 3.9: T-cell activation. Comparison of the levels of pro inflammatory cytokines of (A) TNF-α and (B) IL-12, for MSP119-Biotin and MSP119-GPI. Statistical significance was determined using the 
unpaired Student’s t-test, significance shown by asterisks **(p <0.01) , ****(p <0.0001). 
 
3.8 Conclusion and Outlook 
 
To investigate the role of protein glypiation in the proteins from parasites, two GPIs, PfGPI 1 
and PfGPI 2 from P. falciparum, containing two lipids and three lipids respectively, were 
designed synthesize the glypiated fragment MSP119 of the MSP1 protein of Plasmodium. The 
MSP119 fragment of the MSP-1 was selected as a protein model. This fragment stays intact 
during the merozoite invasion and plays an important role for the survival of the parasite. 
The PfGPI 1 glycolipid and the core structure of the trilipidated PfGPI 2 were successfully 
synthesized by applying a convergent strategy. The synthesis of the PfGPI 1 glycolipid was 
only possible using a [3+1+2] glycosylation strategy to obtain the glycan part and then using 
two-step phosphorylation reactions. The synthesis process was limited by multiple challenges 
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which drastically reduced the yield of the process. The main limitations were the formation of 
an α(1→6)-linkage between the ManI and ManII, the purification of phosphorylated 
intermediates and the removal of protecting groups in the global deprotection. Furthermore, 
the characterization of the GPI was challenging due to the poor solubility in aqueous and 
organic solvents and the amphiphilic nature of the final product PfGPI 1.   
The PfGPI 1 glycolipid was used to obtain a homogeneous GPI-anchored protein. An 
expressed MSP119-NpuN fusion protein and a synthetic peptide were used for the ligation with 
GPI to obtain MSP119-GPI. MSP119-Biotin was synthesized as a control to evaluate the 
influence of the synthetic process and the effect of GPI on the structure and immunological 
activity of the protein. The ligation products were characterized using SDS-PAGE and LC-
ESI-MS. CD was used for preliminary structural analysis of MSP119 with and without a GPI 
anchor.   
CD analysis of the modified proteins showed that the C-terminus modification does not affect 
the overall structure of the protein. The spectra for both MSP119-Biotin and MSP119-GPI 
presented identical profiles that corresponded to the expected random coil structure of the 
MSP119 native protein.  
A dendritic cell stimulation assay showed that both MSP119-Biotin and MSP119-GPI were 
able to activate the T-cells and release cytokines TNF-and IL-12. The DC activation and 
cytokine production was very similar for both proteins with and without GPI at low 
concentration. However, at 1 μM very high levels of TNF- and IL-12 were observed only for 
MSP119-GPI only. This study is the first immunological and structural evaluation of a 
homogeneous synthetic MSP119-GPI and shows that a GPI anchor is a dominant 
immunogenic factor indicating that MSP119-GPI is a potential target for vaccine 
development. 
Even though CD elucidated the overall structure for the protein, further studies involving 
NMR, crystallization and cryo-EM are necessary to understand the interactions of the protein 
with the glycolipid and the effect of the GPI anchor on the behaviour of the protein on 
membranes. The next steps in the evaluation of glypiated MSP1should include in vivo studies 
in a murine model to evaluate MSP119-GPI as an anti-malarial vaccine candidate. From the 
current T-cell activation results, we can expect high vaccine efficacy from MSP119-GPI. If 







3.9.1 Material and Methods of Synthetic chemistry 
All purchased chemicals were of reagent grade and all anhydrous solvents were of high-purity 
grade and used as supplied except where noted otherwise. Reactions were performed in oven-
dried glassware under an inert argon atmosphere unless noted otherwise. Reagent grade 
thiophene was dried over activated molecular sieves prior to use. Pyridine was distilled over 
CaH2 prior to use. Sodium hydride suspension was washed with hexane and THF and stored 
in an anhydrous environment. Benzyl bromide was passed through activated basic aluminum 
oxide prior to use. Metal sodium was washed with hexane and stored in hexane. Analytical 
thin layer chromatography (TLC) was performed on Merck silica gel 60 F254 plates (0.25mm). 
Compounds were visualized by UV irradiation or heating the plate after dipping in staining 
solution. The staining solutions were cerium sulfate-ammonium molybdate (CAM) solution, 
basic potassium permanganate solution, acidic ninhydrin-acetone solution, or a 3-
methoxyphenol-sulfuric acid solution (Sugar Stain). Flash column chromatography was 
carried out using a forced flow of the indicated solvent on Sigma Aldrich silica gel high purity 
grade 60 Å (230-400 mesh particle size, for preparative column chromatography). Solvents 
were removed under reduced pressure using rotary evaporator and high vacuum (<1 mbar). 
Freeze drying of the aqueous solutions was performed using Alpha 2-4 LD Lyophilizer 
(Christ, Osterode am Harz, Germany) 
1H, 13C and 31P-NMR as well as all 2D-spectra (1H-1H COSY, 1H-1H TOCSY, 1H-13C HSQC, 
1H-13C HMBC) were recorded on a Varian 400 (400 MHz), a Varian 600 (600 MHz), a 
Bruker 400 (400 MHz) and a Bruker Ascend 400 (400 MHz)  spectrometer in CDCl3 (7.26 
ppm 1H, 77.1 ppm 13C), D2O (4.79 ppm 1H), MeOD (4.87 ppm and 3.31 ppm 1H, 49.00 ppm 
13C), Acetone-d6 (2.05 ppm and 2.84 ppm 1H, 206.26 ppm and 29.84 ppm 13C)  unless 
otherwise stated. The coupling constants (J) are reported in Hertz (Hz). Splitting patterns are 
indicated as s, singlet; d, doublet; t, triplet; q, quartet; br, broad singlet; dd, doublet of 
doublets; m, multiplet; dt, doublet of triplets; h, hextet for 1H NMR data. Signals were 
assigned by means of 1H-1H COSY, 1H-1H TOCSY, 1H-13C HSQC, 1H-13C HMBC spectra 
and version thereof. ESI mass analyses were performed by Waters Xevo G2-XS Q-TOF with 










A mannose acceptor 3-6a (0.2 g, 0.52 mmol) and trimannosyl donor 3-5a (0.90 g, 0.57 mmol) 
were dissolved and co-evaporated with dry toluene three times and dried under high vacuum 
for 2 h. The reaction mixture was dissolved in dry thiophene:toluene (2:1, 10 mL) under argon 
atmosphere, followed by the addition of activated powdered molecular sieves. Then, 24 μL 
(0.1 mmol) of TBSOTf was added to the reaction mixture under argon atmosphere. After 2 h, 
the reaction was quenched by using Et3N, filtered the molecular sieves and concentrated. The 
residue was purified using column chromatography to obtain tetrasaccharide 3-15a (0.42 g, 
0.23 mmol, 50%, -anomer) 1H NMR (400 MHz, CDCl3) δ 7.35 – 7.24 (m, 3H), 7.24 (s, 
10H), 7.26 – 7.14 (m, 28H), 7.18 – 7.08 (m, 14H), 7.06 (ddd, J = 11.2, 6.6, 2.4 Hz, 7H), 6.97 
(t, J = 7.4 Hz, 1H), 5.82 – 5.69 (m, 1H), 5.49 (dd, J = 3.0, 1.8 Hz, 1H), 5.34 (dd, J = 3.3, 1.7 
Hz, 1H), 5.24 (d, J = 1.3 Hz, 1H), 5.18 (d, J = 1.4 Hz, 1H), 5.14 (d, J = 1.4 Hz, 1H), 5.10 – 
5.08 (m, 1H), 5.08 – 5.05 (m, 1H), 4.98 (d, J = 1.3 Hz, 1H), 4.86 – 4.32 (m, 26H), 4.22 (d, J = 
12.1 Hz, 1H), 4.12 – 3.98 (m, 3H), 4.03 – 3.86 (m, 7H), 3.87 (d, J = 9.6 Hz, 3H), 3.86 – 3.76 
(m, 7H), 3.79 – 3.67 (m, 3H), 3.69 – 3.51 (m, 6H), 3.55 – 3.39 (m, 3H), 2.07 (d, J = 2.9 Hz, 
3H), 2.01 (d, J = 3.5 Hz, 3H), 1.09 – 0.91 (m, 21H). 13C NMR (101 MHz, CDCl3) δ 170.35, 
170.19, 163.44, 138.78, 138.73, 138.56, 138.49, 138.34, 138.14, 138.10, 137.93, 137.80, 
133.17, 128.50, 128.41, 128.36, 128.31, 128.28, 128.21, 128.19, 128.14, 128.05, 127.98, 
127.94, 127.79, 127.77, 127.69, 127.63, 127.57, 127.51, 127.47, 127.44, 127.40, 118.24, 
100.07, 99.90, 98.82, 96.50, 91.81, 79.46, 78.60, 77.25, 75.57, 75.07(2C), 74.90, 74.60, 
74.13(2C), 73.53, 73.41, 73.13, 72.93, 72.21, 72.02, 71.84, 71.75, 71.46, 70.61, 69.06, 68.77, 
68.61, 68.51, 67.91, 66.13, 62.75, 60.45, 26.06, 21.21, 21.09, 18.16(6C), 14.23, 11.95(3C). 
ESI-MS (m/z): [M+Na]+ cald 1869.867 obs 1870.747. 
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(1→6)-2-O-acetyl-3,4-O-benzyl--D-mannopyranosyl trichloroacetamidate (3-16a) 
 
 
A solution of [IrCOD(PPh2Me)2]PF6 (5.0 mg) in THF (2 mL) was stirred under hydrogen 
atmosphere until the color of the solution turned from red to colorless to pale yellow. The 
hydrogen atmosphere was exchanged with Argon. This solution was added to a solution of 
tetrasaccharide 3-15a (0.30 g, 0.16 mmol) in THF (7 mL). After 16 h, the solvent was 
removed in vacuo and the residue was dissolved in a mixture of acetone (4 mL) and water 
(0.5 mL). Mercury (II) chloride (0.11 g, 0.41 mmol) and mercury (II) oxide (7.1 mg, 0.002 
mmol) were added. After 1 h, saturated NaHCO3 (aq) was added and the reaction mixture was 
extracted three times with CH2Cl2. The combined organic layer was dried over Na2SO4, 
filtered and concentrated. The crude product was purified by silica gel column 
chromatography to give trisaccharide hemiacetal (0.22 g, 0.12 mmol, 70 %) as colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.25 (d, J = 11.7 Hz, 21H), 7.25 – 6.96 (m, 79H), 5.51 – 5.40 
(m, 1H), 5.19 (d, J = 20.0 Hz, 3H), 4.96 (s, 1H), 4.79 (ddd, J = 13.3, 11.0, 6.2 Hz, 10H), 4.72 
– 4.51 (m, 10H), 4.55 – 4.26 (m, 20H), 4.24 – 4.02 (m, 2H), 4.02 – 3.67 (m, 28H), 3.67 – 3.34 
(m, 15H), 2.05 (s, 3H), 2.02 (s, 3H), 0.98 (d, J = 3.2 Hz, 18H). ESI-MS (m/z): [M+Na]+  cald 
1829.835 obsd 1829.833. 
To a stirred solution of hemiacetal (0.2 g, 0.11 mmol) in a anhydrous CH2Cl2 (7 mL) were 
added trichloroacetonitrile (110 µL, 1.11 mmol) and DBU (5 µL, 0.033 mmol) at 0 °C. The 
reaction mixture was stirred and warmed up to room temperature. After 2 h, volatiles were 
evaporated and the crude reaction mixture was purified using silica gel column 
chromatography to get the imidate 3-16a (0.14 g, 0.11 mmol, 64%). 1H NMR (400 MHz, 
CDCl3) δ 7.41 – 7.24 (m, 40H), 7.22 (ddd, J = 20.6, 10.9, 3.5 Hz, 26H), 7.19 – 7.03 (m, 6H), 
6.21 (d, J = 1.6 Hz, 1H), 5.58 (dd, J = 2.9, 1.8 Hz, 1H), 5.54 – 5.50 (m, 1H), 5.32 (d, J = 5.6 
Hz, 1H), 5.05 (s, 1H), 4.95 – 4.79 (m, 6H), 4.81 – 4.62 (m, 7H), 4.64 – 4.49 (m, 7H), 4.52 – 
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4.41 (m, 7H), 4.27 (d, J = 12.1 Hz, 1H), 4.13 – 3.97 (m, 7H), 4.01 – 3.91 (m, 7H), 3.95 – 3.83 
(m, 6H), 3.86 – 3.69 (m, 6H), 3.72 – 3.45 (m, 7H), 2.14 (d, J = 5.4 Hz, 3H), 2.12 (s, 2H), 1.07 
(d, J = 3.2 Hz, 28H). 13C NMR (101 MHz, CDCl3) δ 170.20, 170.03, 138.75, 138.57, 138.11, 
137.99, 137.35, 128.50, 128.39, 128.37, 128.31, 128.27, 128.24, 128.15, 128.08, 128.00, 
127.93, 127.88, 127.79, 127.68, 127.55, 127.39, 99.99, 98.66, 97.46, 94.88, 90.70, 78.60, 
77.89, 75.19, 75.08, 74.52, 74.14, 73.54, 73.49, 73.39, 73.09, 72.78, 72.18, 72.05, 71.78, 






The glucosamine imidate 2-18 (1.13 g, 2.38 mmol) and inositol acceptor 2-15 (0.75 g, 1.19 
mmol) were co-evaporated with toluene (3 x 10 mL) and dried under high vacuum for 2 h. 
The mixture was dissolved in a mixture of anhydrous diethylether and anhydrous CH2Cl2 
(1:1, 16 mL) and activated molecular sieves were added. The solution was stirred for 10 min 
at room temperature and cooled to 0 °C. The mixture was treated with TMS-OTf (43 µL, 0.24 
mmol) and stirred at 0 °C for a period of 1 h. The reaction was diluted with CH2Cl2, quenched 
with Et3N and concentrated. The crude product was purified by flash column chromatography 
to obtain disaccharide 3-12 (0.9 g, 0.95 mmol, 80%). 1H NMR (400 MHz, CDCl3) δ 7.83 (ddt, 
J = 20.7, 9.2, 4.2 Hz, 11H), 7.64 – 7.44 (m, 8H), 7.43 – 7.24 (m, 36H), 5.98 – 5.86 (m, 2H), 
5.84 (d, J = 3.6 Hz, 1H), 5.48 – 5.32 (m, 1H), 5.28 (ddd, J = 17.3, 3.0, 1.5 Hz, 2H), 5.23 – 
5.07 (m, 3H), 5.08 – 4.94 (m, 9H), 4.93 – 4.79 (m, 4H), 4.79 – 4.60 (m, 4H), 4.34 – 4.23 (m, 
3H), 4.22 – 4.13 (m, 3H), 4.14 – 4.06 (m, 6H), 4.05 – 3.91 (m, 3H), 3.71 – 3.60 (m, 1H), 3.60 
– 3.49 (m, 2H), 3.44 (dtt, J = 11.7, 5.9, 3.2 Hz, 5H), 3.32 – 3.12 (m, 2H), 2.63 (d, J = 1.5 Hz, 
1H), 2.17 – 1.81 (m, 9H). 13C NMR (101 MHz, CDCl3) δ 170.75, 170.64, 170.19, 170.00, 
169.85, 169.58, 163.54, 138.79, 138.73, 138.37, 138.32, 138.17, 136.22, 136.09, 135.27, 
134.43, 134.06, 133.18, 132.94, 128.63, 128.46, 128.38, 128.27, 128.13, 128.07, 127.92, 
127.77, 127.71, 127.66, 127.62, 127.44, 126.85, 126.65, 126.44, 126.28, 126.17, 126.05, 
125.99, 125.88, 125.78, 117.52, 117.28, 115.93, 101.11, 97.46, 83.62, 83.38, 81.98, 81.74, 
81.65, 81.44, 81.16, 80.86, 80.68, 79.80, 75.90, 75.40, 74.18, 74.08, 73.23, 73.00, 72.72, 






71.22, 70.90, 70.47, 67.83, 66.91, 60.93, 31.96, 29.73, 29.40, 22.74, 20.81, 20.77, 20.73, 







To a stirred solution of thioglycoside 3-12 (0.80 g, 0.85 mmol) in MeOH (15 mL) was added 
freshly prepared 1 M solution of NaOMe. After 1 h, the reaction was neutralized with 
Amberlite IR 120 H+ resin, filtered and concentrated to obtain crude product 3-13 (0.59 g, 
0.73 mmol, 85%). The crude product 3-13 was directly used without any further purification. 
1H NMR (400 MHz, CDCl3) δ 7.90 – 7.75 (m, 7H), 7.65 – 7.55 (m, 1H), 7.54 – 7.44 (m, 3H), 
7.44 – 7.27 (m, 16H), 7.26 (s, 3H), 6.04 – 5.88 (m, 1H), 5.67 (d, J = 3.7 Hz, 1H), 5.40 – 5.11 
(m, 3H), 5.10 – 4.98 (m, 4H), 4.94 – 4.78 (m, 2H), 4.74 – 4.60 (m, 4H), 4.40 (t, J = 9.5 Hz, 
0H), 4.35 – 4.08 (m, 3H), 4.12 – 3.99 (m, 3H), 3.93 (dd, J = 10.4, 8.9 Hz, 1H), 3.88 – 3.68 
(m, 2H), 3.65 – 3.54 (m, 1H), 3.49 – 3.36 (m, 5H), 3.34 – 3.17 (m, 3H), 3.08 (dd, J = 10.4, 3.7 
Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 138.77, 138.58, 138.43, 138.17, 136.15, 135.23, 
134.21, 128.47, 128.39, 128.04, 127.90, 127.72, 127.65, 127.27, 126.64, 126.27, 126.05, 
125.87, 117.37, 101.23, 97.52, 81.97, 81.71, 81.50, 80.87, 75.88, 75.41, 75.14, 74.14, 72.69, 
72.46, 71.53, 71.02, 69.42, 62.72, 62.49, 31.96, 29.73, 29.40, 22.73, 14.18. (NMR for mixture 
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To the solution of crude product 3-13 (0.59 g, 0.73 mmol) in ACN (15 mL) were added 
benzaldehyde dimethyl acetal (0.32 mL, 2.16 mmol) and CSA (0.04 g, 0.18 mmol). The 
reaction mixture was stirred for 3 h at room temperature. The reaction was quenched with 
aq.NaHCO3, extracted with CH2Cl2, washed with brine and dried over Na2SO4. The solvents 
were removed under reduced pressure and the crude product was purified by flash column 
chromatography to obtain benzylidene intermediate compound (0.45 g, 0.50 mmol, 68%). 
To a stirred solution of intermediate (0.4 g, 0.44 mmol) in anhydrous DMF (10 mL) was 
added NaH (0.04 g, 1.77 mmol) at 0 ˚C. After 20 min, BnBr (0.11 mL, 0.88 mmol) was added 
and the reaction was stirred overnight at room temperature. The reaction was quenched with 
MeOH and concentrated. The crude product was purified using flash chromatography to 
obtain 3-14 (0.32 g, 0.32 mmol, 73%). 1H NMR (400 MHz, CDCl3) δ 7.89 – 7.76 (m, 5H), 
7.60 (d, J = 8.6 Hz, 1H), 7.50 (dd, J = 6.2, 3.2 Hz, 3H), 7.36 (dq, J = 22.6, 9.0, 8.2 Hz, 20H), 
7.31 – 7.20 (m, 9H), 7.20 – 7.13 (m, 3H), 5.98 (ddt, J = 16.0, 10.7, 5.6 Hz, 1H), 5.77 (d, J = 
3.8 Hz, 1H), 5.51 (s, 1H), 5.29 (d, J = 17.2 Hz, 1H), 5.22 (d, J = 10.4 Hz, 1H), 5.02 (d, J = 6.5 
Hz, 3H), 4.97 (dd, J = 11.0, 7.8 Hz, 3H), 4.87 (d, J = 11.2 Hz, 1H), 4.81 (dd, J = 10.8, 4.7 Hz, 
2H), 4.74 – 4.60 (m, 2H), 4.31 (t, J = 9.5 Hz, 1H), 4.20 (td, J = 9.6, 4.0 Hz, 3H), 4.14 – 3.96 
(m, 6H), 3.64 (dt, J = 24.4, 9.8 Hz, 2H), 3.50 (t, J = 9.3 Hz, 1H), 3.45 – 3.38 (m, 3H), 3.34 
(dd, J = 10.0, 3.8 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 138.59, 138.20, 138.04, 137.92, 
137.53, 136.20, 134.26, 133.16, 132.97, 128.79, 128.45, 128.42, 128.36, 128.32, 128.27, 
128.05, 127.96, 127.91, 127.85, 127.74, 127.71, 127.67, 127.53, 127.34, 126.56, 126.23, 
126.01, 125.82, 117.30, 101.21, 97.99, 82.95, 81.97, 81.88, 81.06, 80.89, 77.25, 75.72, 75.57, 
75.33, 74.88, 74.08, 72.93, 72.71, 71.00, 68.74, 63.08, 62.41. (NMR for mixture of isomers)  






To a stirred solution of 3-14 (0.1 g, 0.10 mmol) in CH2Cl2 (6 mL) were added trifluoroacetic 
anhydride (0.04 mL, 0.30 mmol) and triethylsilane (0.08 mL, 0.5 mmol) were added at 0 °C 
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followed by trifluoroacetic acid (0.04 mL, 0.5 mmol) drop wise. The reaction mixture was 
stirred at 0 °C. After 5 h, the reaction mixture was quenched with Et3N and concentrated to 
give yellow oil that was purified by flash column chromatography to obtain disaccharide 
acceptor 3-7c (0.08 g, 0.08 mmol, 79 %) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.78 
(dd, J = 15.5, 8.8 Hz, 3H), 7.56 (d, J = 8.3 Hz, 1H), 7.49 – 7.30 (m, 11H), 7.30 – 7.16 (m, 
16H), 6.00 – 5.84 (m, 1H), 5.72 (d, J = 3.4 Hz, 1H), 5.24 (d, J = 17.5 Hz, 1H), 5.17 (d, J = 
10.2 Hz, 1H), 4.99 (q, J = 10.8 Hz, 4H), 4.86 (s, 2H), 4.79 (d, J = 10.6 Hz, 1H), 4.70 – 4.55 
(m, 4H), 4.39 (d, J = 12.0 Hz, 1H), 4.31 – 4.19 (m, 2H), 4.14 (t, J = 9.4 Hz, 1H), 4.05 (s, 1H), 
3.99 (s, 2H), 3.81 – 3.66 (m, 1H), 3.47 – 3.32 (m, 2H), 3.30 – 3.21 (m, 1H), 3.24 – 3.14 (m, 









A mixture of glycosyl acceptor 3-7c (0.05 g, 0.05 mmol) and glycosyl donor 3-16a (0.10 g, 
0.051 mmol) was dissolved and co-evaporated with dry toluene three times and dried under 
high vacuum for 2 h. The mixture was dissolved in anhydrous CH2Cl2 (5 mL) under argon 
atmosphere followed by the addition of activated powdered molecular sieves. Then, TMSOTf 
(3 µL, 0.014 mmol) was added to the reaction mixture at -40 °C. After 2 h, the reaction 
mixture was quenched with triethylamine, filtered and concentrated. The crude mixture was 
purified using column chromatography to obtain 3-17 (0.07 g, 0.025 mmol, 51%). Further 
optimization of the reaction is required. 1H NMR (400 MHz, CDCl3) δ 7.36 – 7.20 (m, 42H), 
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7.25 – 7.14 (m, 43H), 7.17 – 6.98 (m, 21H), 5.50 (dd, J = 3.1, 1.8 Hz, 2H), 5.18 (t, J = 20.3 
Hz, 2H), 4.98 (dd, J = 6.5, 1.9 Hz, 2H), 4.87 – 4.04 (m, 39H), 4.05 – 3.76 (m, 28H), 3.78 – 









To a stirred solution of pseudo-hexasaccharide 3-3 (0.130 g, 0.045 mmol) in acetic acid (2 
mL) and water (0.1 mL) were added palladium chloride (0.04 g, 0.23 mmol) and sodium 
acetate (0.04 g, 0.45 mmol) at room temperature. After 16 h, the reaction mixture was diluted 
with dichloromethane and the solution was washed with aqueous NaHCO3, brine, and water. 
The combined organic layers were dried over Na2SO4, filtered and concentrated. The crude 
product was purified by silica gel column chromatography to give pseudo-hexasaccharide 3-
18 (90 mg, 0.032 mmol, 70%) as colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.82 (d, J = 7.8 
Hz, 1H), 7.64 (dd, J = 29.1, 8.5 Hz, 4H), 7.52 – 7.38 (m, 8H), 7.40 – 7.24 (m, 87H), 7.27 – 
7.05 (m, 31H), 6.97 (t, J = 7.3 Hz, 1H), 5.51 – 5.44 (m, 3H), 5.40 (s, 1H), 5.33 (s, 1H), 5.24 
(s, 1H), 5.09 – 4.68 (m, 21H), 4.67 – 4.23 (m, 26H), 4.25 – 4.06 (m, 7H), 4.06 – 3.74 (m, 
25H), 3.75 – 3.58 (m, 8H), 3.55 – 3.36 (m, 7H), 3.37 – 3.24 (m, 5H), 3.04 (d, J = 7.0 Hz, 1H), 
2.64 – 2.52 (m, 1H), 2.45 (q, J = 6.0, 5.5 Hz, 3H), 2.05 (s, 3H), 1.47 (s, 1H), 1.40 – 1.27 (m, 
10H), 1.04 (d, J = 3.8 Hz, 18H). 13C NMR (101 MHz, CDCl3) δ 205.67, 171.83, 138.99, 
138.93, 138.84, 138.64, 138.50, 138.44, 138.37, 138.08, 137.88, 137.75, 137.58, 136.28, 
133.26, 132.77, 128.57, 128.50, 128.39, 128.35, 128.32, 128.28, 128.25, 128.20, 128.14, 
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128.09, 128.02, 127.97, 127.87, 127.84, 127.79, 127.73, 127.65, 127.61, 127.50, 127.42, 
127.37, 127.26, 127.18, 125.95, 125.63, 125.42, 100.11, 99.62, 99.03, 98.79, 97.83, 81.86, 
81.21, 80.92, 80.30, 79.99, 79.90, 79.72, 78.58, 75.84, 75.14, 75.03, 74.89, 74.73, 74.50, 
74.43, 74.29, 73.31, 73.05, 72.54, 72.31, 72.10, 72.03, 71.60, 71.41, 71.19, 70.32, 68.86, 
68.73, 64.26, 62.60, 37.76, 31.47, 30.21, 29.75, 27.92, 22.73, 18.17(6C), 11.95(3C). ESI-MS 





A mixture of 1,2-distearoyl-sn-glycerol (250 mg, 0.40 mmol) and phosphonic acid (36.1 mg, 
0.44 mmol) were dissolved and co-evaporated three times with pyridine. The resulting 
mixture was dissolved in anhydrous pyridine (10 mL) and pivaloyl chloride (0.05 mL, 0.32 
mmol) was added dropwise. The reaction mixture was stirred under nitrogen atmosphere at 
room temperature for two days. The volatiles were removed under reduced pressure and the 
resulting solid was purified by silica gel column chromatography to give H-phosphonate 3-8 
(218 mg, 0.32 mmol, 79%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.65 (s, 0.5H), 
6.06 (s, 0.5H), 5.30 – 5.16 (m, 1H), 4.38 (dd, J = 11.9, 3.6 Hz, 1H), 4.18 (dd, J = 11.9, 6.4 Hz, 
1H), 4.02 (dd, J = 7.9, 5.2 Hz, 2H), 1.64 – 1.58 (m, 5H), 1.40 (t, J = 7.3 Hz, 18H), 1.26 (s, 
47H), 0.89 (t, J = 6.8 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 173.46, 173.06, 70.26, 62.46, 
62.07, 45.65, 34.31, 34.12, 31.95, 29.74, 29.69, 29.54, 29.40, 29.34, 29.17, 29.14, 24.89, 




















The pseudo-pentasaccharide 3-18 (98 mg, 0.041 mmol) and H-phosphonate 3-8 (161 mg, 
0.203 mmol) were dissolved and co-evaporated with anhydrous pyridine (3 x 3 mL) and dried 
under high vacuum overnight. The reaction mixture was dissolved in anhydrous pyridine (2 
mL) at room temperature and pivaloyl chloride (20 µL, 0.163 mmol) was added. The resulting 
reaction mixture was stirred at room temperature for 3 h. Iodine (36.3 mg, 0.143 mmol) in a 
mixture of pyridine/water (19:1, 0.2 mL) was added to oxidize P (III) to P (V). The reaction 
mixture was further stirred for 2 h at room temperature to the complete the oxidation. The 
reaction mixture was diluted with CHCl3 and washed with aqueous Na2S2O3 solution to 
remove the excess iodine. The aqueous layer was further washed with CHCl3 and the 
combined organic layer was dried over Na2SO4, filtered and concentrated under reduced 
pressure to give the crude residue, which was subjected to flash column with Et3N-deactivated 
silica gel to give 3-19 (70 mg, 55 %) as syrup. Rf  =  0.25 (CHCl3/MeOH = 20: 1). 1H NMR 
(400 MHz, CDCl3) δ 7.84 – 7.48 (m, 4H), 7.46 – 6.98 (m, 78H), 6.90 (d, J = 7.4 Hz, 1H), 5.86 
(d, J = 3.4 Hz, 1H), 5.41 (d, J = 16.3 Hz, 1H), 5.29 (d, J = 11.6 Hz, 1H), 5.20 (d, J = 10.3 Hz, 
1H), 5.05 – 4.61 (m, 16H), 4.64 – 4.30 (m, 16H), 4.28 – 3.78 (m, 14H), 3.79 – 3.68 (m, 1H), 
3.65 – 3.38 (m, 5H), 3.37 – 3.17 (m, 2H), 3.13 – 3.05 (m, 1H), 2.53 – 2.33 (m, 2H), 2.30 – 
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2.13 (m, 2H), 1.96 (d, J = 8.1 Hz, 1H), 1.61 – 1.30 (m, 1H), 1.22 (d, J = 6.1 Hz, 71H), 0.99 (d, 
J = 4.2 Hz, 21H), 0.85 (t, J = 6.5 Hz, 7H). 31P NMR (162 MHz, CDCl3) δ -1.58. ESI-MS 










In the second step, the pseudo-pentasaccharide 3-19 (70 mg, 0.023 mmol) was passed through 
a column of Amberlite IR120 ion exchange resin (Na+ form) using CHCl3/MeOH (1:1) as 
eluent. The eluate was collected and concentrated to dryness. The obtained residue was then 
dissolved in CH3CN (2.5 mL) with a trace of H2O (100 µL). Sc(OTf)3 (55.6 mg, 0.113 mmol) 
was added to the reaction mixture and the resulting mixture was heated to 45 ºC and stirred 
overnight. The reaction mixture was cooled down to room temperature and few drops of 
pyridine was added to quench any excess Sc(OTf)3. The reaction mixture was evaporated to 
dryness and subjected to flash column chromatography with Et3N-deactivated silica gel to 
afford 3-20 (45 mg, 68 %) as a syrup. 1H NMR (400 MHz, CDCl3) δ 7.43 (td, J = 19.8, 17.0, 
9.9 Hz, 20H), 7.32 (dd, J = 13.7, 8.7 Hz, 38H), 7.28 – 6.97 (m, 171H), 5.44 (s, 1H), 5.40 – 
5.29 (m, 3H), 5.14 (d, J = 26.4 Hz, 3H), 4.97 – 4.75 (m, 18H), 4.74 – 4.50 (m, 20H), 4.54 – 
4.43 (m, 19H), 4.46 – 4.29 (m, 17H), 4.29 – 4.19 (m, 6H), 4.17 – 3.92 (m, 14H), 3.92 – 3.59 
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(m, 34H), 3.53 (dq, J = 24.6, 9.2, 8.2 Hz, 17H), 3.38 – 3.21 (m, 8H), 3.01 – 2.85 (m, 1H), 
2.43 (d, J = 6.5 Hz, 3H), 2.35 – 2.19 (m, 9H), 1.55 (dt, J = 40.9, 7.4 Hz, 12H), 1.26 (s, 105H), 
0.88 (t, J = 6.8 Hz, 6H). 31P NMR (162 MHz, CDCl3) δ -1.72. MALDI (m/z): [M-H]- cald 











The bilipidated pseudo-pentasaccharide 3-19 (40 mg, 0.014 mmol) and H-phosphonate 3-9 
(39 mg, 0.102 mmol) were dissolved and co-evaporated with anhydrous pyridine (3x3 mL) 
and dried under high vacuum overnight. The reaction mixture was dissolved in anhydrous 
pyridine (2 mL) at room temperature and pivaloyl chloride (13 µL, 0.102 mmol) was added. 
The resulting reaction mixture was stirred at room temperature for 5 h. The progress of the 
reaction was monitored by using TLC analysis. Iodine (26 mg, 0.102 mmol) in a mixture of 
pyridine/water (19:1, 0.2 mL) was added to oxidize P (III) to P (V). The reaction mixture was 
further stirred for 2 h at room temperature to complete the oxidation, diluted with CHCl3, 
washed with aqueous Na2S2O3 solution to remove the excess iodine. The aqueous layer was 
further washed with CHCl3 and the combined organic layer was dried over Na2SO4, filtered 
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and concentrated under reduced pressure to give the crude residue, which was subjected to 
flash column with Et3N-deactivated silica gel to give 3-1 (32 mg, 70 %) as a syrup. 1H NMR 
(400 MHz, Chloroform-d) δ 7.77 – 7.37 (m, 4H), 7.34 (d, J = 7.3 Hz, 7H), 7.25 (d, J = 14.9 
Hz, 15H), 7.25 – 7.09 (m, 74H), 7.02 (dd, J = 22.1, 10.4 Hz, 22H), 5.38 – 5.02 (m, 4H), 4.83 
(dddd, J = 56.9, 31.6, 18.8, 11.0 Hz, 16H), 4.63 – 4.48 (m, 9H), 4.48 – 4.25 (m, 21H), 4.24 – 
3.87 (m, 17H), 3.81 (s, 8H), 3.77 – 3.65 (m, 6H), 3.59 (d, J = 9.9 Hz, 3H), 3.44 (dt, J = 40.4, 
14.9 Hz, 10H), 3.29 – 2.99 (m, 4H), 2.81 (s, 8H), 2.52 – 2.32 (m, 1H), 2.15 (t, J = 6.9 Hz, 
4H), 1.95 (d, J = 7.8 Hz, 2H), 1.32 (s, 3H), 1.20 – 1.07 (m, 100H), 0.97 (dd, J = 26.0, 12.1 
Hz, 12H), 0.81 (t, J = 6.7 Hz, 6H). 31P NMR (162 MHz, CDCl3) δ -1.42, -1.51. ESI-MS (m/z): 









To the stirred solution of bisphosphorylated pseudo-hexasaccharide 3-1 (18.0 mg, 0.005 
mmol) in CH2Cl2 (2 mL) were added acetic acid (10 µL, 0.19 mmol), pyridine (15 µL, 0.19 
mmol) and hydrazine hydrate (2.3 µL, 0.05 mmol) sequentially. The reaction mixture was 
stirred at room temperature. After 12 h, the reaction mixture was quenched with acetone and 
concentrated to obtain crude product.  The crude product was then dissolved in mixture of 
CH2Cl2/MeOH (3:1, 5 mL) at room temperature and Pd(OH)2/C (33 mg, 0.046 mmol, 20% Pd 
Ho* 
ı \ . ı  I Ho o Ho o HO 
O Ho o HO 
o* 





\ \  O o' FQ- 
HQ OH 





content) was added. Hydrogen gas was bubbled through the solution for 15 min and the 
reaction mixture was stirred under an atmosphere of hydrogen gas for additional 16 h. The 
palladium was removed by filtration through a pad of celite and the solvents were removed 
under reduced pressure to give the crude product. 1H NMR (400 MHz, MeOD) δ 7.48 (s, 7H), 
5.13 (d, J = 25.9 Hz, 2H), 4.95 (d, J = 46.0 Hz, 4H), 4.10 – 3.92 (m, 14H), 3.90 (s, 9H), 3.79 
(dd, J = 18.2, 13.0 Hz, 10H), 3.71 – 3.31 (m, 26H), 3.15 – 2.91 (m, 2H), 2.86 – 2.68 (m, 1H), 
2.63 – 2.45 (m, 1H), 2.31 – 2.09 (m, 6H), 1.55 – 1.44 (m, 7H), 1.27 – 1.15 (m, 128H), 0.79 (t, 
J = 6.4 Hz, 17H). 31P NMR (162 MHz, MeOD) δ 0.48, 0.11. 
The debenzylated crude intermediate compound was confirmed by mass spectrometry. The 
crude material (4 mg) was then dissolved at 0 °C in a mixture of trifluoroacetic acid and 
anisole (5.5 mL, 10:1 v/v) and stirred for 5 min. Then Hg(TFA)2 (9.1 mg, 21 μmol) was 
added to the reaction mixture and stirred for an additional 30 min. the volatiles were removed 
under high vacuum at 0 °C. The resulting solid residue was dissolved in an AcOH/water 
mixture (7.5 mL, 7:3 v/v) and mercaptoethanol (400 μL, 5.7 mmol) was added at room 
temperature. The mixture was stirred at the same temperature for 10 h. The solution was dried 
on a rotary evaporator, to give a pale yellow residue. The amphiphilic nature of PfGPI 1 (2.5 
mg, 1.2 µmol, 41%) created solubility problem in only one solvent. So, the NMR was 
analysed in mixture of chloroform, methanol and water. 1H NMR (700 MHz, MeOD) δ 5.47 
(d, J = 119.0 Hz, -1H), 5.26 (s, 1H), 5.05 (d, J = 80.8 Hz, 1H), 4.27 – 3.41 (m, 33H), 3.41 (s, 
1H), 3.23 (s, 1H), 3.11 – 3.00 (m, 2H), 2.43 – 2.10 (m, 2H), 1.94 (s, 3H), 1.61 (s, 3H), 1.52 – 
1.38 (m, 1H), 1.28 (s, 45H), 0.88 (s, 7H). 31P NMR (162 MHz, MeOD) δ 0.27, -0.03. HRMS 
(m/z): [M-2H]2- cald 987.9350 obsd 988.0052. 
 
3.9.2 Material and Methods of Biochemistry 
All amino acids were purchased from IRIS Biotech (Marktredwitz, Germany) or 
Novabiochem (Darmstadt, Germany). Deionized water was obtained by purification with a 
Milli-Q purification system (Merck Millipore, Billerica, USA). 
General protocol for protein ligation 
A solution of 70 mM MMBA and 20 mM TCEP in 20 μL of ligation buffer is adjusted to pH 
7.2. To this solution, fusion protein (MSP119-NpuN) in buffer, 3 eq. of the modified 
NpuC(AA) peptide and 2 eq. of GPI (or Cys-Biotin) were added. The final volume of the 





incubated at 37 °C for three days. The reaction progress was monitored with SDS-PAGE. 
Ligation buffer contained 300 mM NaCl and 50 mM Tris at pH 7.0. 
Size Exclusion Chromatography  
Size Exclusion Chromatography (SEC) was generally applied for protein purification. In SEC, 
proteins are separated by size rather than by any interaction with the stationary phase. Smaller 
proteins and other molecules can enter into the pores of the stationary phase material which 
usually consists of small porous polymer beads such as agarose or sepharose with different 
pore sizes. Therefore, smaller molecules are retained longer during the run and elute later than 
larger proteins. Generally, all samples were centrifuged at 13.3 k rpm and / or filtered through 
a 0.2 μm syringe filter prior to loading on SEC columns. Maximum 1.5 mL of sample 
containing 0.5 – 10 mg protein was loaded onto the Superdex 75 column. 
LC-ESI-QTOF-MS 
Waters Xevo G2-XS with an Acquity H-class UPLC was used. In this instrument, the ESI 
source was coupled to a quadrupole-time-of flight (QTOF) mass analyzer. A quadrupole 
consists of four parallel metal rods. The two opposite rod pairs are connected electrically. The 
quadrupole is used to generate an oscillating electric field which can be used to filter ions of 
specific m/z ratios. In the TOF mass analyzer, the ions are further separated. 
Circular Dichroism (CD)  
Circular dichroism utilized circularly polarized light to determine the optical properties of 
chiral compounds. Circular Dichroism Spectrometer Chirascan from Applied Photophysics 
(Leatherhead, UK) was used for the analysis and Origin Pro from Originlab (Northampton, 
USA) was used to process the data. Protein samples were prepared in PBS buffer at 
concentrations ranging from 0.1 – 1 mg/mL. The protein solution was then filled into a High 
Precision Cell Quartz cuvette (light path 1 mm) and placed in the Chirascan Circular 
Dichroism Spectrometer. Circular dichroism was measured between 190 and 260 nm against 
PBS buffer as a reference and measurements were performed in triplicates. The averages of 





























 Synthesis and Structural Analysis 4





  Introduction 4.1
 
The cell membrane defines the boundary between the intracellular and extracellular space and 
is essential for many biological functions such as cell adhesion and cell signaling.  The basic 
structure of a membrane is composed of a lipid bilayer embedding proteins, glycolipids and 
other biomolecules.221 In 1972, Singer and Nicolson introduced the fluid mosaic model to 
describe cell membrane organization. This model proposes the membrane as an oriented, two-
dimensional, viscous solution of amphipathic proteins and lipids in instantaneous 
thermodynamic equilibrium, where ionic and highly polar groups protrude into the aqueous 
phase and non-polar groups are buried in the hydrophobic interior of the bilayer.222  
Although it is possible to form a lipid bilayer using a single lipid, a cell membrane generally 
contains different kind of lipids; for example, a eukaryotic membrane contains 
glycerophospholipids, sphingolipids and sterols.223 The main reason for compositional 
diversity in a membrane is to provide a stable and robust assembly to protect the cell and to 
participate in physiological events like cell signaling, metabolism and protein transport. The 
cell membrane was initially described as a continuous fluidic system. However, the presence 
of sub compartments in the membrane was observed when the membrane of Madin-Darby 
Canine Kidney (MDCK) cells could be separated into detergent-soluble and detergent-
resistant fractions.224 These observations suggested that the cell membrane is remarkably 
heterogeneous and lipids can exist in several fluidic phases in the bilayer such as gel, liquid 
ordered phase (lo) and liquid crystalline phase (lc).225 The bilayer is rigid in the gel state 
whereas in the liquid crystal phase, it is characterized as fluidic. The liquid ordered phase is 





 Lipid Raft 4.1.1
In epithelial cells, the plasma membrane is polarized into apical and basolateral domains, 
which are characterized by a differentiated composition.226 Wherein, the apical domain 
mainly consists of sphingolipids and cholesterol assemblies on the exoplasmic leaflet of the 
bilayer. The basolateral domain is characterized by an inner leaflet rich in glycerolipids and 
phosphatidylcholine.227, 228 The concept of membrane raft was introduced to explain the 
organization of sphingolipids and cholesterol on the exoplasmic leaflet of the bilayer.229 Lipid 
raft domains are usually defined as very small, highly dynamic and transient plasma 
membrane entities enriched in saturated sphingolipids, phospholipids, glycolipids, cholesterol 
and glycosylphosphatidylinositol (GPI)-anchored proteins. In rafts, the polar head groups of 
sphingolipids interact with each other through weak hydrophilic interactions occupying more 
area in the plane of bilayer compared to the lipid hydrocarbon chains. Hence, any voids 
between associating sphingolipids are filled by cholesterol, leading to close packing between 
the lipid chains and cholesterol, similar to liquid ordered phase in the model membranes. 
Cholesterol-dependent lateral segregation is also observed in the vesicle model membrane, 
where cholesterol favors the interactions with stiffer saturated lipids than with more flexible 
unsaturated lipids.98, 230, 231 This lateral segregation in the lipid systems leads to the formation 
of extended conformations and hydrophobic mismatch, resulting in a segregation of the 
membrane plane into a thicker, liquid ordered phase and a thinner, liquid disordered phase 
(figure 4.1). 232-233 
The concept of lipid raft has been controversial because they are believed to be nanoscopic 
domains in cells that are difficult to observe using conventional microscopy. 234, 235 For this 
reason, several optical tools have been developed to investigate nanoscopic structures and 
dynamics of the cell membrane. 236, 237 These methods have been used to detect lipid-mediated 
protein clustering on the surface of the cell and include photoactivated localization 
microscopy (PALM), stimulated emission depletion (STED) and near field scanning optical 








Figure 4.1: Lipid associated membrane domains.242 
 
The term lipid rafts has been applied to different membrane assemblies, such as pure lipid 
clusters including glycolipid clusters, ceramide domains and other lipid domains, and to lipid 
mediated protein clusters including GPI and RAS domains. Ordered domains can also be 
formed as a result of liquid-liquid phase separation of lipids or by protein mediated lipid 
clustering. Due to the small size and short lifetime of the raft domains in vivo, direct 
measurement of the properties on the membrane is complicated especially because many 
different domains can co-exist at the same time.243 However, computational studies have 
shown that compartmentalization of the membrane into domains, including the existence of 
lipid rafts, is important for membrane function.244 
 
 Role of Lipid Rafts 4.1.2
The role of lipid rafts in the cell function is not clear due to the difficulties in defining their 
composition and chemical and physical properties. Important functions that have been 
attributed to these lipid domains include participation in signal transduction. Immunoglobulin 
E (IgE)-mediated activation of cells was the first signaling pathway associated with lipid 
rafts.245 Studies have shown that T-cell and B-cell receptors on antigen presenting cells (APC) 
are found in the lipid fluidic part of the membrane in resting state and are shifted to lipid rafts 
during the activation process. Thereby, the lipid raft are associated with the active signaling of 
these receptors and hence, involved in innate and adaptive immune response.246-251 GPI-
anchored proteins associated with immune system are also found in lipid rafts. These include 
the receptor of lipopolysaccharide CD14252 and THY1, which is an important protein for T-
cell activation.253 
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Lipid rafts may also act as modulators for host-pathogen interactions involving viruses 
covered with large number of saturated lipids and cholesterol.254 In case of the HIV Gag 
protein, it was observed that this protein preferentially binds to the high cholesterol regions of 
the membrane of the host cell, suggesting the importance of rafts for virus budding.255, 256 
Another example of the biological role of lipid rafts is the localization of oncogenic proteins 
involved in cancer development and progression in raft-like domains.257-259 One such protein 
is the RAS protein, which is involved in breast cancer. Hence, some of the anticancer drugs 
contain the alkyl phospholipids edelfosine and perifosine, which can disrupt raft 
localizations.260, 261 Similarly, overexpression of Mucin 1 (MUC1), can lead to different forms 
of cancer and is also associated with proteins found in raft regions. 
In cardiovascular diseases, macrophages take up cholesterol and aggregate in the arteries 
clogging the blood vessels that can cause heart attack. This uptake transforms the 
macrophages into foam cells mediated by rafts containing LDL receptors, which are 
responsible for the binding of the lipids.262, 263 
 
 GPI in Lipid Raft 4.2
 
GPI-anchored proteins (GPI-APs) are the most characterized example of protein associated 
with lipid rafts. They are involved in many cellular functions such as membrane trafficking, 
immune response, adhesion and nutrient uptake.264-268 The lipid part of GPI anchors is highly 
heterogeneous and can contain the lipids that are not involved in raft formation. Domains 
containing GPI-APs have been described as detergent-resistant domains, which is a 
characteristic property of raft formation that is acquired while trafficking through the Golgi 
network during the biosynthesis. GPI-APs have been studied in cell mimics such as liposomes 
and lipid Langmuir monolayers to investigate the protein-membrane interactions.269-272 In 
these studies, the clustering of GPI-APs was attributed to protein-protein interactions. 
However, similar clustering is also observed in studies with free GPIs, which lack protein. 
Thus, interactions between GPI molecules and their interactions with other membrane 
components may be responsible for the heterogeneous distribution observed for free GPIs on 





The lipids of GPIs are structurally similar to phospholipids which interact with the 
membranes through van der Waals forces. GPIs possess bulky and flexible head groups that 
are responsible for strong hydrogen bonding between glycans. The glycans possess large in-
plane area compared lipid part. The conformational changes in these highly ordered structures 
can give rise to formation of temporary domains that can be referred to as rafts. However, the 
structural requirement and underlying reason for the formation of GPI lipid rafts is unclear.274 
Therefore, the elucidation of structural and conformational behavior of GPIs in membrane 




In 2014, our group reported the presence of molecular ordering of GPI fragments in a two-
dimensional monolayer at the air/liquid interface (figure 4.2). In order to understand the 
correlation between structure of glycan and its spatial arrangement in the monolayer, three 
fragments were designed; the commercially available glycerolipid 4-1, and two synthesized 
structures, the phosphatidylinositol 4-2 and pseudo-disaccharide 4-3, which adequately mimic 
the zwitterionic character of the GPIs. This glycolipid 4-3 features an amino and a phosphate 
group that largely determines the ionic strength/interactions of the head group.  
To understand the influence of the lipid component on the conformation of the polar head 
groups and clustering effect on the model membrane; grazing incidence X-ray diffraction 
(GIXD) pattern, Langmuir isotherm, tilt angle and lattice distortion at different lateral 
pressure were studied for the three structures. A comparative analysis showed that the alkyl 
chains of the fragment 4-1 presented smallest tilt angle at low lateral pressure (figure 4.2B) 
owing to the smallest head group and its weak interactions on the monolayer structure was 
strongly influenced by the glycerol chirality. In case of fragment 4-2, which has an additional 
phosphate and inositol, there is no substantial increase in the cross-sectional area in 
comparison to 4-1. However, the bigger head group and additional electrostatic repulsion of 
the phosphate group induce a larger tilt angle of the lipid chains. At high lateral pressure, the 
lipids are in untilted state with higher packing density. The electrostatic repulsion between the 
head group become more dominant compared to attractive van der Waals interactions 
between the alkyl chains. 
140 
 
In case of fragment 4-3, the monolayer was characterized by a large tilt angle of the lipid 
chains at the uncompressed state, which changes slightly upon compression. This behavior 
was attributed to strong hydrogen bonding interactions between the head groups. An increased 
structural rigidity of the zwitterionic fragment due to hydrogen bonding led to a highly 
ordered structure on the monolayer, characterized by an alkyl chain lattice and a head group 




Figure 4.2: A) Chemical Structure of GPI-fragments; B) monolayer structural changes of the GPI-fragments as the variation of the tilt angle of the alkyl chains (°) with the lateral surface pressure (π) on PBS at 20 °C.275 
 
 Design of Epitopes and Retrosynthesis 4.4
 
To further investigate the role of the lipid composition and the hydrogen bonding of the head 
groups in the formation of microdomains, a new set of structures having a pseudo-
disaccharide head group and different lipids were designed. These structures were designed 
bearing lipid chains with unsaturated and branched alkyl chains. In addition to delivering the 
information about the behavior of lipid chains on the model membrane, these fragments 
would provide further understanding about the importance of lipid remodeling during the 
biosynthesis and intracellular transport of GPI-APs. 
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Fragments 4-4 and 4-5 were designed to understand the effect of hydrogen bonding. In these 
molecules the amino group of the pseudo-disaccharide fragment was replaced with an N-
acetyl group to break the participation of this function in hydrogen bonding between the 
molecules on the bilayer.  
To understand the role of lipids in the formation of microdomains, fragment 4-5 was designed 
having an oleic and stearic ester at the glycerol, which is similar to the lipid composition 
reported for mammalian GPIs and is an important intermediate during the GPI biosynthesis in 
mammals. Fragment 4-6 was designed having a lipid with two branched alkyl chains at the 
sn-1 and sn-2 position of the glycerol moiety. This type of lipid modification is believed to 
have a similar effect as unsaturation (figure 4.3).  
 
 
Figure 4.3: Structures of GPI fragments designed and investigated for this study. 
 
The synthetic strategy was designed to give access to all the fragments from a common 
intermediate. The retrosynthetic analysis features a late-stage phosphorylation of the pseudo-
disaccharides 4-7a and 4-7b with the H-phosphonate (4-8, 4-9 and 4-10) as the most 
convenient disconnection. Benzyl ether was selected as the permanent protecting group for 
the synthesis of the fragments 4-3, 4-4 and 4-6. The 2-(napthyl)methyl ether was selected as 
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permanent protecting group for the synthesis of fragment 4-5 because this group can be 
cleaved under acidic conditions facilitating the incorporation of an unsaturated lipid. 
To ensure high α-selectivity, the disaccharide 4-7a can be accessed by the glycosylation of 
myo-inositol building block 4-12 with the azido-glucosamine trichloroacetimidate 4-11. Allyl 
ether was chosen as the orthogonal protecting group at 1-O position of inositol for the 




Figure 4.3: Retrosynthetic analysis of GPI-fragments 4-3, 4-4, 4-5 and 4-6 using a common intermediate. 
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 Results and Discussion  4.5
 
 Synthesis of Building Blocks 4.5.1
The process started with the synthesis of the H-phosphonate 4-9 from commercially available 
(S)-2,3-O-isopropylideneglycerol 4-14. First, the free hydroxyl group of 4-14 was temporarily 
protected with PMB ether and the isopropylidene group cleaved under acidic condition to 
obtain the diol 4-16. The primary and secondary hydroxyl groups were successively esterified 
with stearic acid and oleic acid, using DIC and DMAP as coupling reagents to obtain bilipid 
4-16. Then, the PMB group was removed using DDQ and water, and the obtained glycerolipid 




Scheme 4.1: Synthesis of H-phosphonate 4-9. a) PMBCl, NaH, DMF, rt, 2 h, 83%; b) pTSA, H2O, CH2Cl2, rt, 92%, c) Stearic acid, DIC, DMAP CH2Cl2, rt, 84%; d) Oleic acid, DIC, DMAP, CH2Cl2, rt, 75%; e) DDQ, H2O, CH2Cl2, rt, 60%; f) H3PO3, PivCl, py, rt, 70%. 
 
The synthesis of the protected myo-inositol acceptor 4-12b was performed from commercially 
available methyl -D-glucopyranoside using a modification of the method reported by the 
Fraser-Reid group in 1998.276 Starting with a trityl protection of the primary alcohol, the 
obtained triol 4-18 was transformed into 6-OH glucoside 4-20 by protecting the free hydroxyl 
groups with 2-(napthyl)methyl ether and removing the trityl in 60% yield over two steps. The 
alcohol 20 was oxidized to an aldehyde using SO3-pyridine complex and the obtained 
aldehyde was immediately converted into the acetyl enolate 4-21 by enol acetylation. A 
mercury assisted Ferrier rearrangement of 4-21 delivered the cyclic hexanone 4-22, which 
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was subjected to chelation-mediated reduction using NaBH(OAc)3 to obtain the diol 4-23 in 
68% yield over two steps. The myo-inositol 4-23 was deacetylated and regioselectively 
protected with 2-(napthyl)methyl and allyl ether at position 2-O and 1-O respectively to give 
the myo-inositol acceptor 4-12b in 63% yield. The corresponding benzylated myo-inositol 




Scheme 4.2: Synthesis of myo-inositol 4-12b. (a) NAPBr, NaH, DMF, rt, 12 h, 85%; (b) p-TsOH, MeOH, rt, 16 h, 70%; (c) i. SO3.Py, DIPEA, DMSO, CH2Cl2, 0 °C, 1 h, ii. Ac2O, K2CO3, CH3CN, reflux, 4 h, 80% (2 steps); (d) i. Hg(OTf)2, acetone/H2O, rt, 1 h, ii. NaOAc, NaCl, 0 °C to rt, 12 h, 77%; (e) NaBH(OAc)3, CH3CN, AcOH, rt, 12 h, 83%; (f) NaOMe, MeOH, rt, 30 min; (g) i. (Bu3Sn)2O, toluene, reflux, 5 h; ii. AllylBr, TBAI, C6H5CH3, 65 °C, 17 h, 65%; (h) NAPBr, NaH, DMF, -20 °C to 0 °C, 2 h, 63%. 
 
The synthesis of glucosamine donor 4-11 started with preparation of the azide 4-27, which 
was obtained from D-glucosamine by an azido transfer reaction using TfN3 and following 
acetylation in 69% yield. The acetylated 2-azidoglucoside 4-27 was transformed into the 
trichloroacetimidate donor 4-11 by removal of the anomeric acetyl group using piperidine in 
THF and following the reaction of the obtained hemiacetal 4-28 with trichloroacetonitrile in 
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Scheme 4.3: Synthesis of glucosamine building block 4-11. a) TfN3 (in CH3CN), CuSO4.5H2O, Et3N, H2O, 0 °C, 24 h, 84%; b) Ac2O, py, rt, 24 h, 69 %, c) Piperidine, THF, rt, 16 h, 68 %; d) CCl3CN, DBU, CH2Cl2, 0 °C, 4 h, 92%.  
 
 Synthesis of Pseudo-Disaccharide Fragments 4.5.2
Glycosylation of myo-inositol 4-12a with trichloroacetimidate donor 4-11 using TMSOTf in 
Et2O/CH2Cl2 at 0 °C afforded the pseudo-disaccharide 4-29 as an anomeric mixture of product  
( = 5:1) in 80% yield. The  mixture of 4-29 could not be separated using silica gel 
chromatography. Therefore, the obtained anomeric mixture of pseudo-disaccharide 4-29 was 
deacetylated using freshly prepared sodium methoxide followed by benzylation using benzyl 
bromide and sodium hydride to give the benzylated pseudo-disaccharide 4-31 in 54% yield 
over 2 steps. The disaccharide 4-31 was deallylated using PdCl2 under anhydrous conditions 
to obtain the pseudo-disaccharide 4-7a, which could be separated using silica gel column 
chromatography giving the α-isomer in 65% yield (scheme 4.4). 
 
Finally, the alcohol 4-7a was phosphitylated with the H-phosphonate 4-8 using pivolyl 
chloride and the product was oxidized with iodine and water to obtain the corresponding 
phosphate 4-32. A palladium catalyzed hydrogenation with palladium hydroxide for the 
global deprotection delivered the pseudo-disaccharide 4-3 in 50% yield after purification. 
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Scheme 4.4: Synthesis of pseudo-disaccharide 4-3. a) TMSOTf, CH2Cl2-Et2O, 0 °C, 1 h; b) NaOMe, MeOH, rt, 6 h; c) BnBr, NaH, DMF, rt, 18 h, 54% (over 3 steps); d) PdCl2, MeOH-CH2Cl2, rt, 4 h, 82%; e) i. 4-8, PivCl, py, rt, 12 h; ii. I2, H2O, rt, 2 h, 60%; f) Pd(OH)2, H2, CH2Cl2:MeOH:H2O (3:3:1), rt, 48 h, 50%. 
 
In order to obtain the GPI fragment 4-4, the azide of pseudo-disaccharide 4-31 was converted 
into an N-acetyl group (4-33) by reduction of the azide using zinc and acetic acid follwing 
acetylation of the amine using acetic anhydride and pyridine. Similar to fragment 4-3, the 
resulted disaccharide was deallylated, phosphorylated and deprotected using the same 
conditions to obtain the desired pseudo-disaccharide 4-4 in 50% yield (scheme 4.5). 
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Scheme 4.5: Synthesis of pseudo-disaccharide 4-4. a) Zn, Ac2O, AcOH, THF, rt, 4 h, 71%; b) PdCl2, MeOH-CH2Cl2, rt, 4 h, 72%; c) i. 4-8, PivCl, py, rt, 12 h; ii. I2, H2O, rt, 2 h, 60%; d) Pd(OH)2, H2, CH2Cl2:MeOH:H2O (3:3:1), rt, 48 h, 50%. 
 
To incorporate the unsaturated lipid, the synthesis of fragment 4-5 was carried out using the 
2-(napthyl)methyl ether as a permanent protecting group. Glycosylation of myo-inositol 4-12b 
with trichloroacetimidate donor 4-11 using TMSOTf in Et2O/CH2Cl2 at 0 °C afforded the 
pseudo-disaccharide 4-36 as an anomeric mixture of product  (= 6:1) in 80% yield. The 
 mixture of 4-36 could not be separated using silica gel chromatography. Therefore, the 
obtained anomeric mixture of pseudo-disaccharide 4-36 was deacetylated using freshly 
prepared sodium methoxide followed by napthylation using 2-(napthyl)methyl bromide and 
sodium hydride to give napthylated pseudo-disaccharide 4-38 in 82% yield over 2 steps. The 
azide of disaccharide 4-38 was converted into an N-acetyl group (4-39) by reduction of the 
azide using zinc and acetic acid followed by acetylation using acetic anhydride and pyridine. 
The obtained disaccharide 4-39 was deallylated using PdCl2 under anhydrous conditions to 
obtain the pseudo-disaccharide 4-40 as pure -isomer in 59% yield (scheme 4.6). The alcohol 
4-40 was phosphitylated with H-phosphonate 4-9 using pivolyl chloride activation. The 
obtained phosphodiester was chemoselectively oxidized using BrCCl3 and Et3N to obtain the 
corresponding phosphate 4-41.279 The global deprotection was carried out using a (9:1) TFA-
anisole mixture under anhydrous conditions to obtain the pseudo-disaccharide 4-5 in 70% 
yield. 
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Scheme 4.6: Synthesis of pseudo-disaccharide 4-5. a) TMSOTf, CH2Cl2-Et2O, 0 °C, 1 h, 80%; b) NaOMe, MeOH, rt, 6 h; c) NAPBr, NaH, DMF, rt, 18 h, 82%; d) Zn, Ac2O, AcOH, THF, rt, 4 h, 79%; e) PdCl2, MeOH- CH2Cl2, rt, 4 h, 59% (α); f) i. 4-9, PivCl, py, rt, 12 h; ii. BrCCl3, Et3N, CH2Cl2, rt, 2 h 61%; g) TFA-anisole (10:1), rt, 6 h, 80%. 
 
Similar to fragment 4-3, the disaccharide 4-7a was phosphitylated with the H-phosphonate 4-
10 using pivolyl chloride and the product was oxidized using iodine and water to deliver the 
phosphate 4-42. A global deprotection using palladium hydroxide under hydrogen atmosphere 
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Scheme 4.7: Synthesis of pseudo-disaccharide 4-6. a) i. 4-10, PivCl, py, rt, 12 h; ii. I2, H2O, rt, 2 h, 60%; b) Pd(OH)2, H2, CH2Cl2:MeOH:H2O (3:3:1), rt, 48 h, 52%. 
 
 Analysis of the pseudo-disaccharides in monolayers 4.5.3
With all the synthetic fragments in hand, the compounds were investigated using 2-D model 
membrane at the air/water interface by our collaborators.3  The structural changes, molecular 
ordering and phase transition in the monolayer were analyzed using grazing incidence X-ray 
diffraction (GIXD) and infrared reflection absorption spectroscopy (IRRAS). Two additional 
parameters, change of tilt angle and distortion of lattice with lateral pressure, were determined 
by extrapolation of GIXD data. 
 
                                                          
3 All the studies on monolayers were performed by Prof. Dr. Gerald Brezesinski. 
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Figure 4.3: Monolayers of GPI fragment 4-3 at 20 °C on water. (A) GIXD pattern; (B) variation of tilt angle of the alkyl chain with the lateral pressure; (C) lattice distortion; (D) IRRA spectra of OH stretching region at different lateral pressures. 
 
Previous studies showed that surface pressure/molecular area isotherms recorded on different 
subphases for fragment 4-3 were characterized as a rigid 2-D structure. The isotherm was 
typical for a liquid condensed (LC) phase even at high temperature.274 Based on the fact that 
no phase transition was observed during compression for the fragment 4-3, the GIXD pattern 
of monolayers for the fragment 4-3 was measured on water at 20 °C. The plot of the GIXD 
featured three distinct Bragg peaks (between 1.2 and 1.6 in figure 4.3A), characteristic for 
ordered alkyl chains arranged in an oblique lattice. Some very weak Bragg peaks 
corresponding to the head group ordering have been additionally observed. The large tilt 
angle of the alkyl chains observed at low lateral pressure decreases continuously during 
compression (figure 4.3B). The extrapolation yields a value of 59.3 mN/m for the tilting 
transition pressure. Above this pressure, the chains are oriented upright. However, a lattice 
distortion of -0.044 is observed in the non-tilted state (figure 4.3C). This distortion of the 
lattice supports the argument of rigid structural arrangements as a consequence of hydrogen 
bonding between the head groups. IRRA spectra showed a broad peak at 3600 cm-1 that is 
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during compression indicating an increase in layer thickness supporting the decrease of the tilt 
angle. 
Surface pressure/molecular area isotherms recorded on subphases at different pH for fragment 
4-4, containing N-acetyl glucosamine to disrupt the zwitterionic character, show only the 
phase transition from gaseous to LC phase (re-sublimation). Only a shift in the isotherm at pH 
9 was observed, which can be explained by the ionization of the phosphate group, which will 
be mostly in the deprotonated form at this pH, leading to stronger electrostatic repulsion. A 
tilting of Wilhelmy plate was observed at high surface pressure for pH 9 due to the stiffness of 
monolayer (figure 4.4). 
 
            
 
Figure 4.4: Surface pressure-molecular area of monolayers of GPI fragment 4-4 at 20 °C on different subphases. 
 
To investigate the structural changes with varying pressure for the monolayer of fragment 4-4, 
contour plots for this monolayer were recorded at different lateral pressures. The GIXD data 
revealed that monolayers were characterized by a chiral (oblique) chain lattice below ~ 12 
mN/m. Compression leads to a change to an orthorhombic lattice, and eventually to a 
hexagonal phase of non-tilted chains at the lateral pressure of ~26 mN/m (figure 4.5A). The 
correspondence of zero tilt angle with the zero distortion indicates that the lattice distortion in 
this monolayer is only caused by the tilt of the molecule and not because of any other 




HO Ha<¬ HO AcHN OH O OH OO , o  
P`OH O/ o ä 30 - 
layer - tilting of Wilhelmy plate 
25- 





30 4.0 so ob ab 








                 
                                                                                                                  
 
 
Figure 4.5: Monolayers of GPI fragment 4-4 at 20 °C on water. (A) GIXD pattern at different lateral pressure; (B) variation of tilt angle of the alkyl chain; (C) lattice distortion. 
 
The GIXD pattern for the fragment 4-5, containing an unsaturated fatty acid chain in the lipid 
part and an N-acetyl glucosamine, did not show the characteristic peaks for an ordered alkyl 
chain in an oblique or orthorhombic lattice, instead only one characteristic Bragg peak for the 
hexagonal ordered structure and a peak corresponding to an in-plane area of about 23 Å2 
(figure 4.6). This result shows that the saturated fatty acid is involved in the formation of a 
more ordered inner phase in the 2-D membrane model whereas the unsaturated fatty acid is 
present at the less ordered outer phase (figure 4.6A). The IRRA spectra showed an increase in 
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Figure 4.6: Monolayers of GPI fragment 4-5 at 20 °C on water. (A) GIXD pattern; (B) IRRAS spectra of OH stretching region at different lateral pressure. 
 
The variation of the absorption wavenumber for the alkyl chains (CH2 stretching vibration) 
was between 2925 and 2923 cm-1. The first value at low lateral pressure is typical for the 
liquid-expanded (LE) state whereas the second value corresponds to the transition state 
between LC and LE, confirming the hypothesis of the presence of partial fluid and partial 




Figure 4.7: Wavenumber vs surface pressure for GPI fragment 4-5 monolayers at 20 °C on water. 
 
The isotherm spectra of fragment 4-6 with two branched fatty acid chains were very similar at 
different pH values in contrast to the results obtained with fragment 4-4. This isotherm 
suggests again a first-order phase transition from gaseous to a LC phase. It indicates strong 
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head-group interactions due to the hydrogen bonding. The IRRAS signals were also very 
similar to the signals of fragment 4-3 having broad hydroxyl bands due to the hydrogen 
bonding between the head groups. An increase in lateral pressure also increased the hydrogen 
bonding and van der Waals interactions. 
 
      
 
Figure 4.8: Monolayers of GPI fragment 4-6 at 20 °C on water (A) IRRAS spectra of OH stretching region at different lateral pressure; (B) Surface pressure-molecular area isotherms on different subphases. 
 
Variations in the absorption wavenumber for the alkyl chain between 2926 and 2925 cm-1 
during compression for fragment 4-6 is characteristic for the liquid expanded phase (LE), and 
whereas values between 2922 and 2920 cm-1 for fragment 4-3 is characteristic for the liquid-
condensed phase (LC). It confirms that the saturation of the chains is responsible for the 
formation of micro-domains in the membrane and hence responsible for the fluidity or rigidity 
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Figure 4.8: Comparison of wavenumber vs surface pressure curve between GPI fragment 4-6 (blue) and 4-3 (black) monolayers at 20 °C on water. 
 
The disruption of the electrostatic interactions and hydrogen bonding between the phosphate 
and amine group of the GPI fragments has a drastic effect on the structural arrangement in the 
model membrane. Although the effective in-plane area of the head group is the same, the 
hydration shell and the zwitterionic effect of fragment 4-3 plays an important role in the 
formation of rigid structural arrangements of the compound in the monolayer. This result can 
be supported by the extrapolation of the distortion versus sin2(t) curve which shows a strong 
distortion in case of fragment 4-3, proving strong interactions between the head groups, and a 
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 Conclusion and Outlook 4.6
 
This study was able to provide a better insight in the role of lipid and head groups in the 
structural arrangement of GPI fragments in monolayers. To perform a comparative analysis of 
different GPI fragments in the 2-D membrane model, especially to study the role of the 
hydrogen bonding and zwitterionic effect in the head group and role of lipid composition in 
the formation of lipid rafts, four different GPI fragments with varying ionic strength and 
different lipid composition were designed. The synthetic strategy was based on the synthesis 
of pseudo-disaccharide followed by phosphorylation to generate the desired fragments. 
Benzyl was used as the permanent protecting group for the synthesis of fragment 4-3, 4-4 and 
4-6. To obtain the glycolipid fragment 4-5 with unsaturated lipid a new protecting group, 2-
(napthyl)methyl was utilized. This group was cleaved under acidic conditions without 
affecting the double bond. The NAP group was found to be an efficient protecting group 
which uses similar conditions for its installation as benzyl; it is stable during different 
reactions of the synthesis and can be easily cleaved to obtain the desired product. 
In order to obtain pseudo-disaccharides, myo-inositol building block was synthesized from 
glucose using the Ferrier type II rearrangement followed by the glycosylation with the 
glucosamine to generate the disaccharide. The glycosylation conditions were optimized to 
favor the formation of desired α stereoisomer. Phosphorylation of the disaccharides was 
carried out by using H-phosphonates of the lipids and following oxidation of the phosphonate 
using iodine and water. In case of fragment 4-5, bromotrichloromethane was used as 
oxidizing agent for the phosphonate as it selectively oxidizes the phosphonate and not the 
alkene in the lipid. Hydrogenation was carried out for the global deprotection of benzyl 
groups in case of fragments 4-3, 4-4 and 4-6. The NAP groups were cleaved using TFA in 
case of fragment 4-5 to obtain the desired deprotected disaccharide. 
The study of these compounds as monolayers showed that by breaking the zwitterionic 
properties of the glycolipid, the head group of the GPI fragment became more flexible and 
can be converted into a non-distorted hexagonal unit cell. Monolayers of fragment 4-3 formed 
a highly ordered structure characterized by two lattices, a lattice of alkyl chains and a 
molecular lattice of the head group. In contrast, monolayers of fragment 4-4 only formed a 
lattice of alkyl chains due to the disruption of interaction between the phosphate and the 





interaction in the formation of ordered structures in the membrane. These observations can 
also be directly related to the GPI biosynthesis, where the acetylation and deacetylation of the 
amine plays a crucial role. 
The presence of branching and unsaturation at the lipid had similar effect and was responsible 
for the fluidity of the membrane. Monolayers of fragment 4-5, which had one saturated and 
one unsaturated chains, were characterized by the presence of partially ordered and partially 
disordered domains. This structure had a lattice of the alkyl chains at the center forming an 
ordered domain (LC) of the saturated alkyl chains and a more flexible outer part forming a 
liquid-expanded domain (LE) as the unsaturated lipids were projected outwards making the 
membrane more fluid. In case of fragment 4-6 that contained two branched lipid chains, the 
monolayer showed a similar behavior as for the fragment with unsaturation. The membrane 
was completely fluid and did not form any ordered structure. The results were further 
confirmed by the IR wavenumber comparison between the lipid chains, which showed that 
fragment 4-6 was in complete liquid-expanded phase whereas fragment 4-5 was in partial 
liquid-expanded and liquid-condensed phase. These findings suggest that the lipids play a 
crucial role in the formation of rafts and are responsible for many cellular functions. 
They also provide important information about the hydrogen bonding interactions of different 
GPI-anchored proteins in cell membrane during lipid raft formation. However, during the 
biosynthesis of GPI-APs, there is a strong GPI remodeling involved and other lipid variants 
are produced. Some of the GPI also possess an additional lipid at the inositol residue; in order 
to understand the role of this lipid, a new fragment bearing the third lipid would provide 
insight about its role in lipid raft formation. 
The structure of GPI anchors contains an additional phosphoethanolamine. Further studies 
could also consider the incorporation of this phosphate would increase the ionic strength, 
which might change the interaction between the head groups and give a better idea about the 









 General Methods for Synthetic Chemistry 4.7.1
All purchased chemicals were of reagent grade and all anhydrous solvents were of high-purity 
grade and used as supplied except where noted otherwise. Reactions were performed in oven-
dried glassware under an inert argon atmosphere unless noted otherwise. Reagent grade 
thiophene was dried over activated molecular sieves prior to use. Pyridine was distilled over 
CaH2 prior to use. Sodium hydride suspension was washed with hexane and THF and stored 
in an anhydrous environment. Benzyl bromide was passed through activated basic aluminum 
oxide prior to use. Analytical thin layer chromatography (TLC) was performed on Merck 
silica gel 60 F254 plates (0.25mm). Compounds were visualized by UV irradiation or heating 
the plate after dipping in staining solution. The staining solutions were cerium sulfate-
ammonium molybdate (CAM) solution, basic potassium permanganate solution, acidic 
ninhydrin-acetone solution, or a 3-methoxyphenol-sulfuric acid solution (Sugar Stain). Flash 
column chromatography was carried out using a forced flow of the indicated solvent on 
Sigma Aldrich silica gel high purity grade 60 Å (230-400 mesh particle size, for preparative 
column chromatography). 
1H, 13C and 31P-NMR as well as all 2D-spectra (1H-1H COSY, 1H-1H TOCSY, 1H-13C HSQC, 
1H-13C HMBC) were recorded on a Varian 400 (400 MHz), a Varian 600 (600 MHz), a 
Bruker 400 (400 MHz) and a Bruker Ascend 400 (400 MHz)  spectrometer in CDCl3 (7.26 
ppm 1H, 77.1 ppm 13C), D2O (4.79 ppm 1H), MeOD (4.87 ppm and 3.31 ppm 1H, 49.00 ppm 
13C), Acetone-d6 (2.05 ppm and 2.84 ppm 1H, 206.26 ppm and 29.84 ppm 13C)  unless 
otherwise stated. The coupling constants (J) are reported in Hertz (Hz). Splitting patterns for 
1H NMR data are indicated as s, singlet; d, doublet; t, triplet; q, quartet; br, broad singlet; dd, 
doublet of doublets; m, multiplet; dt, doublet of triplets and h, hextet. Signals were assigned 
by means of 1H-1H COSY, 1H-1H TOCSY, 1H-13C HSQC, 1H-13C HMBC spectra and version 
thereof. ESI-MS analyses were performed on a Waters Xevo G2-XS Q-TOF spectrometer 
with an Acquity H-class UPLC. MALDI-MS were recorded on a Bruker Autoflex-speed 
MALDI-TOF spectrometer equipped with an ATR unit. Infrared (FTIR) spectra were 
recorded as thin films on a Perkin Elmer Spectrum 100 FTIR spectrophotometer. Optical 
rotations were measured with a Schmidt & Haensch UniPol L 1000 polarimeter at a 
concentration (c) expressed in g/100 mL. HPLC supported purifications were conducted using 





 Synthetic Protocols 4.7.2
(R)-3-((4-methoxybenzyl)oxy)propane-1,2-diol (4-15) 
 
To a stirred solution of (S)-2,3-O-isopropylideneglycerol 4-13 (0.50 g, 3.81 mmol) in 
anhydrous DMF (10 mL) was added NaH (0.18 g, 7.60 mmol) at 0 °C. After 20 min, PMBCl 
(0.77 mL, 5.72 mmol) was added. The reaction mixture was warmed to room temperature and 
was stirred for 12 h. The reaction was quenched with MeOH, and diluted with Et2O. The 
organic layer was extracted with water. The combined organic layers were further washed 
with brine, dried over Na2SO4 and concentrated to obtain 4-14. The crude product was 
dissolved in CH2Cl2 (12 mL), pTSA.5H2O (0.06 g, 0.3 mmol) was added and the reaction 
mixture was allowed to stir at room temperature for 12 h. The reaction was quenched with 
Et3N and concentrated. Flash chromatography was performed to obtain the diol 4-15 (0.60 g, 
2.83 mmol, 75%) as colorless oil. Rf = 0.30 (EtOAc/hexane 2:1); 1H NMR (400 MHz, CDCl3) 
δ 7.27 (d, J = 7.4 Hz, 2H), 6.91 (d, J = 8.3 Hz, 2H), 4.51 (s, 2H), 3.90 (td, J = 5.8, 2.9 Hz, 
1H), 3.83 (s, 3H), 3.73 (dd, J = 11.4, 3.9 Hz, 1H), 3.65 (dd, J = 11.4, 5.3 Hz, 1H), 3.56 (qd, J 
= 9.6, 5.0 Hz, 2H).  13C NMR (101 MHz, CDCl3) δ 159.41, 129.71, 129.51(2C), 113.91(2C), 
73.29, 71.57, 70.52, 64.15, 55.32.  
 
(S)-1-((4-methoxybenzyl)oxy)-3-(stearoyloxy)propan-2-yl octadec-9-enoate (4-16) 
 
To a stirred solution of diol 4-15 (0.50 g, 2.36 mmol) in CH2Cl2 (15 mL) were added DMAP 
(0.28 g, 2.36 mmol), stearic acid (0.67 g, 2.36 mmol) and DIC (0.37 mL, 2.36 mmol). The 
mixture was stirred at room temperature for 5 h. The reaction was extracted with CH2Cl2, 
washed with brine, dried over Na2SO4 and concentrated. The residue was purified by flash 
column chromatography to obtain monoacylated glycerol and was subjected to second 
coupling. The intermediate alcohol (0.67 g, 1.43 mmol) was dissolved in CH2Cl2 (10 mL), 
DMAP (0.17 g, 1.41 mmol), oleic acid (0.48 mL, 1.54 mmol) and DIC (0.24 mL, 1.54 mmol) 
were added and reaction mixture was stirred at room temperature for 12 h. The reaction was 









product was purified by flash column chromatography to obtain 4-16 (0.78 g, 1.05 mmol, 
75%) as white solid. Rf = 0.40 (EtOAc/hexane 1:4); 1H NMR (400 MHz, CDCl3) δ 7.26 (d, J 
= 8.2 Hz, 2H), 6.90 (d, J = 8.4 Hz, 2H), 5.37 (qq, J = 8.7, 5.3, 4.5 Hz, 2H), 5.25 (dd, J = 6.2, 
4.0 Hz, 1H), 4.55 – 4.43 (m, 2H), 4.35 (dd, J = 11.9, 3.8 Hz, 1H), 4.19 (dd, J = 11.9, 6.4 Hz, 
1H), 3.83 (s, 3H), 3.58 (d, J = 5.5 Hz, 2H), 2.32 (dt, J = 17.1, 7.5 Hz, 4H), 2.03 (q, J = 6.6 Hz, 
4H), 1.62 (h, J = 7.3 Hz, 4H), 1.39 – 1.25 (m, 49H), 0.90 (t, J = 6.6 Hz, 6H). 13C NMR (101 
MHz, CDCl3) δ 173.47, 173.14, 159.29, 130.02, 129.73, 129.33(2C), 113.80(2C), 72.96, 
70.01, 67.87, 62.70, 55.27, 34.34, 34.14, 31.96, 31.94, 29.80, 29.74, 29.70, 29.67, 29.56, 
29.53, 29.40, 29.36, 29.33, 29.24, 29.16, 29.13, 29.09, 27.25, 27.20, 24.97, 24.91, 22.73, 
14.17. ESI-MS (m/z): [M+Na]+ cald 765.600, obsd 765.2. 
 
(S)-1-hydroxy-3-(stearoyloxy)propan-2-yl octadec-9-enoate (4-17) 
 
To a stirred solution of bilipid 4-16 (0.60 g, 0.81 mmol) in 10:1 mixture of CH2Cl2 and water 
was added DDQ (0.18 g, 1.61 mmol) at room temperature. After 12 h, sat. NaHCO3 solution 
was added. The mixture was extracted with CH2Cl2, dried over Na2SO4 and concentrated. The 
crude product was purified by flash column chromatography to obtain 4-17 (0.30 g, 
0.48 mmol, 60%). Rf = 0.35 (EtOAc/hexane 2:3); 1H NMR (400 MHz, CDCl3) 5.42 – 5.31 
(m, 2H), 5.11 (p, J = 5.0 Hz, 1H), 4.43 – 4.22 (m, 2H), 3.75 (t, J = 5.8 Hz, 2H), 2.36 (q, J = 
8.0 Hz, 4H), 2.12 – 1.94 (m, 4H), 1.73 – 1.61 (m, 2H), 1.30 (d, J = 20.0 Hz, 51H), 0.94 – 0.87 





Glycerol bilipid 4-17 (0.20 g, 0.32 mmol) and phosphorus acid (0.13 g, 1.61 mmol) were 
dissolved and co-evaporated with anhydrous pyridine three times and dried under high 
vacuum for 2 h. The mixture was dissolved in anhydrous pyridine (5 mL) and a solution of 
HO 
o 
I O!\(CH2)16CH3 o\",(cH2)7cH=cH(cH2)7cH3 
O 
O la Ho" H\O 
o 






pivaloyl chloride (0.20 mL, 1.61 mmol) in pyridine (2 mL) was added. The solution was 
stirred for 16 h at room temperature. After the completion of reaction, the reaction mixture 
was concentrated and purified by Et3N deactivated silica gel column chromatography to 
obtain H-phosphonate 4-9 (0.15 g, 0.22 mmol, 70%) as a white solid. Rf = 0.7 (MeOH/ 
CH2Cl2 = 1:9) ; 1H NMR (400 MHz, CDCl3) δ 12.38 (s, 1H), 5.47 – 5.31 (m, 2H), 5.24 (s, 
1H), 4.48 – 3.96 (m, 3H), 3.10 (s, 5H), 2.32 (q, J = 7.6 Hz, 4H), 2.03 (q, J = 6.4 Hz, 3H), 1.33 
– 1.21 (m, 44H), 0.90 (t, J = 6.7 Hz, 6H). 31P NMR (162 MHz, CDCl3) δ 4.66. ESI-MS (m/z): 
[M-H]- cald 685.52, obsd 685.0.  
 




To a stirred solution of 4-19 (10 g, 11.67 mmol) in MeOH (50 mL) was added p-TsOH.H2O 
(0.56 g, 2.92 mmol) at room temperature. After 12 h, the reaction mixture was quenched with 
Et3N and concentrated. The crude product was purified by flash column chromatography to 
obtain alcohol 4-20 (5.02 g, 8.17 mmol, 70%) as white solid. Rf = 0.2 (EtOAc/hexane = 1:2) 
1H NMR (400 MHz, CDCl3) δ 7.77 – 7.57 (m, 13H), 7.52 – 7.28 (m, 10H), 7.29 (d, J = 1.7 
Hz, 1H), 5.12 (d, J = 11.2 Hz, 1H), 4.96 (dd, J = 11.3, 6.8 Hz, 2H), 4.89 (d, J = 12.2 Hz, 1H), 
4.77 (dd, J = 17.2, 11.8 Hz, 2H), 4.53 (d, J = 3.6 Hz, 1H), 4.05 (t, J = 9.2 Hz, 1H), 3.72 (dt, J 
= 9.1, 4.6 Hz, 1H), 3.69 – 3.59 (m, 2H), 3.59 – 3.49 (m, 2H), 3.31 (s, 3H). 13C NMR (101 
MHz, CDCl3) δ 136.30, 135.60, 135.53, 133.37, 133.25, 133.21, 133.12, 132.98, 128.40, 
128.27, 128.16, 128.00, 127.97(2C), 127.74, 127.71(2C), 127.09, 126.68, 126.54, 126.24, 
126.14, 126.10, 126.05, 126.02(2C), 126.00, 125.93, 125.86, 125.85, 98.20, 82.02, 79.91, 
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To a stirred solution of alcohol 4-20 (9 g, 14.64 mmol) and SO3.Py (9.51 g, 58.6 mmol) in 
CH2Cl2 (100 mL) at 0 °C was added DIPEA (12.8 mL, 73.2 mmol). The reaction mixture was 
stirred at 0 °C for 10 min and DMSO (15.6 mL, 220 mmol) was added. After 1 h at 0 °C, the 
reaction was diluted with aq. NaHCO3, extracted with Et2O, washed with brine, dried over 
Na2SO4 and concentrated (EtOAc/hexane= 2:3, Rf = 0.15). The crude compound was 
dissolved in CH3CN (100 mL). Then, Ac2O (8.3 mL, 88 mmol) and K2CO3 (8.12 g, 58.8 
mmol) were added. The reaction mixture was refluxed (85 °C) for 4 h and allowed to cool to 
room temperature, diluted with aq.NaHCO3, extracted with Et2O, washed with brine, dried 
over Na2SO4, and concentrated. The crude product was purified by flash column 
chromatography to obtain enolate 4-21 (7.7 g, 11.76 mmol, 80%) as white solid. Rf  = 0.28 
(EtOAc/hexane = 1:3) 1H NMR (400 MHz, CDCl3) δ 7.88 – 7.69 (m, 13H), 7.72 – 7.63 (m, 
1H), 7.56 – 7.39 (m, 10H), 5.14 – 4.80 (m, 7H), 4.73 (d, J = 3.4 Hz, 1H), 4.08 (d, J = 6.3 Hz, 
2H), 3.69 (dq, J = 9.4, 6.2, 4.8 Hz, 1H), 3.50 (s, 3H), 2.16 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 167.36, 136.04, 135.36, 135.10, 135.06, 134.97, 133.32, 133.23, 133.18, 133.04, 
132.98, 128.41, 128.29, 128.11, 128.03, 127.99, 127.94, 127.70, 127.68(2C), 127.08, 126.81, 
126.57, 126.25, 126.13, 126.09,126.06, 126.01, 125.97, 125.94, 125.90, 125.84, 123.17, 
99.81, 81.36, 79.07, 77.68, 75.78, 74.55, 73.89, 56.36, 20.66. ESI-MS (m/z): [M+Na]+ cald 
677.2515, obsd 677.2507. 
 
D-1-O-Acetyl-3,4,5-tri-O-(2-naphthyl)methyl-myo-inositol (4-23)  
  To the stirred solution of enolate 4-21 (5.6 g, 8.5 mmol) in a mixture of acetone/water (v/v = 
5:1, 85 mL) was added Hg(OTf)2 (4.38 g, 10.3 mmol) at r. t.. After 1 h, the reaction mixture 
was cooled to 0 °C and aq. NaOAc (3M, 8.6 mL) was added, immediately followed by 
addition of brine (17 mL). The reaction was slowly warmed to room temperature and stirred 
for 12 h. The reaction mixture was diluted with aq.NaHCO3 and extracted with EtOAc. The 
combined organic layer was washed with brine, dried over Na2SO4, concentrated. The crude 
product was crystalized from CH2Cl2/Et2O (1:50) to obtain ketone 4-22 (4.2 g, 6.6 mmol, 
77%) as white solid. Rf = 0.20 (EtOAc/hexane= 2:3)  
The solution of ketone 4-22 (4.2 g, 6.6 mmol) in CH3CN (40 ml) was slowly transferred to a 
cooled (0 °C) solution of NaBH(OAc)3 (6.95 g, 32.8 mmol) in a mixture of AcOH/CH3CN 
(v/v = 1:1, 80 mL). The reaction was allowed to warm to room temperature and stirred for 12 





h. The reaction mixture was diluted with aq.NaHCO3 and extracted with EtOAc. The 
combined organic layer was washed with brine, dried over Na2SO4 and concentrated. The 
crude product was crystalized by CH2Cl2/Et2O to give diol 4-23 (3.5 g, 5.45 mmol, 83%) as 
white solid. Rf = 0.20 (EtOAc /hexane = 1:1) 1H NMR (400 MHz, CDCl3) δ 7.77 – 7.69 (m, 
5H), 7.66 (dd, J = 15.6, 8.4 Hz, 6H), 7.61 – 7.55 (m, 1H), 7.38 (dtt, J = 8.4, 6.4, 3.4 Hz, 9H), 
5.05 (d, J = 11.3 Hz, 2H), 4.96 (d, J = 11.1 Hz, 1H), 4.88 (d, J = 11.4 Hz, 1H), 4.85 – 4.75 (m, 
2H), 4.71 (dd, J = 10.2, 2.7 Hz, 1H), 4.30 (d, J = 2.9 Hz, 1H), 4.12 (td, J = 9.8, 2.8 Hz, 1H), 
3.98 (t, J = 9.5 Hz, 1H), 3.60 (dd, J = 9.5, 2.7 Hz, 1H), 3.40 (td, J = 8.2, 7.2, 4.7 Hz, 1H), 2.10 
(s, 3H). 13C NMR (101 MHz, CDCl3) δ 135.98, 135.75, 134.79, 133.26, 133.19, 133.00, 
132.94, 128.43, 128.37, 128.09, 127.92(3C), 127.64(2C), 126.80, 126.63, 126.44, 126.24, 
126.11, 126.01, 125.93, 125.90, 125.82, 125.76, 125.73, 82.88, 80.94, 80.05, 75.87, 75.72, 
73.08, 72.88, 70.49, 67.79, 21.08. ESI-MS (m/z): [M+Na]+ cald 665.2515, obsd 665.2525. 
 
D-1-O-Allyl-3,4,5-tri-O-(2-naphthyl)methyl-myo-inositol (4-25)  
  The diol 4-23 (2 g, 3.11 mmol) was stired at room temperature for 30 min in the presence of 
NaOMe (0.04 g, 0.63 mmol) in MeOH/CH2Cl2 (v/v = 1:1, 60 mL). Then, the reaction was 
neutralized with Amberlite IR 120 H+ resin, filtered and concentrated. A mixture of triol 4-24 
(1.7 g, 2.8 mmol) and bis(tributyltin)oxide (1.9 mL, 3.7 mmol) in toluene (50 mL) was 
refluxed for 5 h using a Dean-Stark trap. TBAI (1.05 g, 2.8 mmol) and allyl bromide (1.2 mL, 
14.2 mmol) were added. The mixture was stirred under anhydrous condition at 65 °C for 16 h. 
The reaction mixture was concentrated and purified by flash column chromatography to 
obtain 4-25 (1.2 g, 1.87 mmol, 65%) as white solid. Rf = 0.35 (EtOAc/hexane= 1:2) 1H NMR 
(400 MHz, CDCl3) δ 7.84 – 7.59 (m, 12H), 7.51 – 7.38 (m, 9H), 5.91 (ddt, J = 16.5, 11.0, 5.9 
Hz, 1H), 5.24 (dt, J = 17.2, 1.5 Hz, 1H), 5.21 – 5.11 (m, 1H), 5.11 – 4.94 (m, 4H), 4.91 (d, J = 
2.4 Hz, 2H), 4.28 (d, J = 3.0 Hz, 1H), 4.26 – 4.13 (m, 1H), 4.15 – 4.03 (m, 3H), 3.52 (dd, J = 
9.6, 2.7 Hz, 1H), 3.44 (t, J = 9.4 Hz, 1H), 3.17 (dd, J = 9.7, 2.7 Hz, 1H), 2.52 – 2.45 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 136.20, 136.09, 135.29, 134.38, 133.29, 133.18, 133.02, 
132.91, 128.31, 128.20, 128.02, 127.92, 127.88, 127.67, 127.63, 126.68, 126.50, 126.17, 
126.04, 126.02, 125.98, 125.93, 125.90, 125.83, 125.78, 125.74, 117.85, 82.72, 80.97, 79.88, 
78.87, 75.91, 75.44, 72.80, 72.32, 71.33, 67.02. ESI-MS (m/z): [M+Na]+ cald 663.2723, obsd 
663.2733. 
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D-1-O-Allyl-2,3,4,5-tetra-O-(2-naphthyl)methyl-myo-inositol (4-12b)   
   To the stirred solution of inositol 4-25 (0.35 g, 0.55 mmol) in DMF (10 mL) was added NaH 
(0.03 g, 1.2 mmol) at 0 °C, in one portion. After strirring for 30 min at 0 °C, the reaction 
mixture was cooled to -20 °C, 2-naphthylmethyl bromide (0.12 g, 0.55 mmol) in DMF was 
added dropwise, and the reaction was stirred for 2 h allowing it to warm to 0 °C. The reaction 
was quenched with MeOH and extracted with EtOAc and the combined organic layers were 
washed with brine and dried over Na2SO4. The solvents were removed under reduced pressure 
and the crude residue was purified by flash column chromatography to obtain acceptor 4-12b 
(0.27 g, 0.34 mmol, 63%) as white solid. R f = 0.28 (EtOAc/hexane = 1:3) 1H NMR (400 
MHz, CDCl3)  7.86-7.72 (m, 13H), 7.70-7.60 (m, 3H), 7.54-7.42 (m, 12H), 5.98-5.85 (m, 
1H), 5.29-5.22 (m, 1H), 5.21-5.15 (m, 2H), 5.13-5.08 (m, 5H), 4.90 & 4.84 (q, J = 11.9 Hz, 
2H), 4.33-4.23 (m, 2H), 4.19-4.16 (m, 1H), 4.12-3.98 (m, 2H), 3.58-3.50 (m, 2H), 3.22-3.15 
(m, 1H); 13C NMR (100 MHz, CDCl3) 136.5, 136.4, 135.9, 134.6, 133.44, 133.36, 133.3, 
133.1, 133.0, 128.29, 128.26, 128.2, 128.1, 128.0, 127.80, 127.78, 127.75, 126.7, 126.6, 
126.4, 126.30, 126.28, 126.26, 126.08, 126.06, 126.0, 125.87, 125.85, 117.6, 83.5, 81.6, 81.2, 
80.0, 76.0, 75.5, 74.2, 73.4, 73.2, 73.0, 71.4. ESI-MS (m/z): [M+Na]+ cald 803.3349, obsd 
803.3372. 
 




To a stirred solution of hemiacetal 4-28 (1.4 g, 4.23 mmol) in CH2Cl2 (15 mL) at 0 °C were 
added CCl3CN (4.2 mL, 42.3 mmol) and DBU (0.13 mL, 0.85 mmol). The reaction mixture 
was stirred for 4 h at 0 °C. The resulting mixture was concentrated and purified by flash 
column chromatography to obtain imidate 4-11 (1.85 g, 3.9 mmol, 92%) as yellowish solid. Rf 
= 0.4 (EtOAc/hexane = 2:3) 1H NMR (400 MHz, CDCl3) δ 8.86 (s, 1H), 6.51 (d, J = 3.6 Hz, 
1H), 5.58 – 5.51 (m, 1H), 5.18 (t, J = 9.8 Hz, 1H), 4.30 (dd, J = 12.4, 4.2 Hz, 1H), 4.25 – 4.21 
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(m, 1H), 4.13 (dd, J = 12.3, 1.9 Hz, 1H), 3.80 (dd, J = 10.5, 3.6 Hz, 1H), 2.14 (s, 3H), 2.09 (s, 
4H), 2.08 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 170.57, 169.90, 169.71, 160.54, 94.01, 






 To a stirred solution of triol 4-30 (0.29 g, 0.38 mmol) in anhydrous DMF (12 mL) was added 
NaH (0.09 g, 3.78 mmol) at 0 °C. After 20 min, BnBr (0.45 mL, 3.78 mmol) was added; the 
reaction was warmed to room temperature and stirred for 16 h. The reaction was quenched 
with MeOH and concentrated. The crude product was purified by flash chromatography to 
obtain 4-31 (0.3 g, 0.29 mmol, 77%). To a stirred solution of 4-31 (0.28 g, 0.27 mmol) in 
MeOH/CH2Cl2 (3:1, 7 mL) was added PdCl2 (0.01 g, 0.054 mmol) at room temperature. The 
reaction was stirred for 12 h and quenched with Et3N and concentrated. The crude residue was 
purified by flash column chromatography to obtain 4-7a (0.22 g, 0.22 mmol, 82%). Rf = 0.4 
(EtOAc/hexane = 1:1) 1H NMR (400 MHz, Chloroform-d) δ 7.48 – 7.02 (m, 51H), 5.42 (d, J 
= 3.6 Hz, 1H), 5.07 – 4.31 (m, 20H), 4.16 – 3.84 (m, 8H), 3.76 – 3.31 (m, 9H), 3.25 – 3.14 
(m, 2H), 3.05 – 2.97 (m, 1H).13C NMR (101 MHz, CDCl3) δ 138.55, 138.45, 138.41, 138.19, 
138.07, 137.77, 128.44, 128.43, 128.40, 128.33, 128.26, 128.24, 128.21, 128.20, 128.04, 
128.00, 127.94, 127.90, 127.83, 127.75, 127.70, 127.65, 127.61, 127.59, 127.43, 127.31, 
98.37, 81.97, 81.10, 80.89, 80.72, 80.43, 78.05, 77.32, 77.20, 77.00, 76.68, 75.82, 75.44, 
75.23, 74.74, 73.52, 73.33, 72.88, 72.39, 70.79, 67.37, 64.07. ESI-MS (m/z): [M+Na]+ cald 
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Disaccharide 4-7a (0.05 g, 0.05 mmol) and H-phosphonate 4-8 (0.05 g, .08 mmol) were co-
evaporated with pyridine for three times and dried under high vacuum for 2 h. The mixture 
was dissolved in anhydrous pyridine (5 mL) and a solution of pivolyl chloride (0.01 mL, 0.08 
mmol) in pyridine (1 mL) was added. The solution was stirred for 48 h at room temperature. 
After 48 h, iodine (0.06 g, 0.25 mmol) and water (0.2 mL) were added and reaction was 
stirred for 4 h. The reaction mixture was quenched with Na2S2O3 and extracted with CH2Cl2. 
The organic layer were concentrated and purified by Et3N deactivated silica gel flash column 
chromatography to obtain bilipidated disaccharide 4-32 (0.05 g, 0.03 mmol, 60%). R f = 0.7 
(MeOH/CH2Cl2 = 1:9)  1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 7.1 Hz, 2H), 7.40 – 7.29 
(m, 23H), 7.29 – 7.18 (m, 20H), 7.18 – 6.97 (m, 6H), 5.87 (d, J = 3.7 Hz, 1H), 5.26 (dt, J = 
8.8, 4.4 Hz, 1H), 5.00 (dd, J = 32.9, 11.3 Hz, 4H), 4.88 (s, 2H), 4.83 – 4.70 (m, 6H), 4.60 (dd, 
J = 35.6, 11.8 Hz, 2H), 4.49 – 4.24 (m, 6H), 4.19 – 3.99 (m, 8H), 3.78 – 3.71 (m, 1H), 3.59 
(dd, J = 9.8, 2.1 Hz, 1H), 3.55 – 3.46 (m, 3H), 3.43 – 3.34 (m, 3H), 3.23 (dd, J = 10.3, 3.7 Hz, 
1H), 3.03 (dt, J = 11.1, 5.5 Hz, 10H), 2.27 (dp, J = 10.2, 5.7, 5.1 Hz, 6H), 1.58 (s, 8H), 1.27 
(d, J = 4.7 Hz, 73H), 0.90 (t, J = 6.8 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 173.46, 173.09, 
139.80, 138.77, 138.48, 138.45, 138.13, 138.08, 138.00, 128.41, 128.29, 128.27, 128.25, 
128.20, 128.17, 128.09, 128.07, 127.96, 127.86, 127.76, 127.67, 127.57, 127.52, 127.44, 
127.40, 127.29, 127.15, 127.00, 96.77, 81.88, 80.98, 79.77, 78.35, 76.09, 75.65, 75.16, 74.78, 
74.71, 73.29, 72.26, 69.95, 67.96, 63.80, 63.17, 62.75, 52.91, 45.57, 34.30, 34.09, 31.96, 
29.76, 29.71, 29.59, 29.58, 29.41, 29.38, 29.19, 24.93, 24.89, 22.73, 14.18, 8.53, 8.00. 31P 
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To the stirred solution of pseudo-disaccharide 4-32 (20.0 mg, 0.012 mmol) in mixture of 
CH2Cl2/MeOH/H2O (3:3:1, 5 mL) at room temperature was added Pd(OH)2 on C (17 mg, 
0.024 mmol, 20% Pd content). Hydrogen gas was bubbled through the solution for 15 min 
and the reaction mixture was stirred under an atmosphere of hydrogen gas for additional 24 h. 
The Pd(OH)2 was removed by filtration through a pad of celite and the solution was 
concentrated. The crude product was purified by size exclusion chromatography on a LH20 
column using CH2Cl2/MeOH/H2O (3:3:1) as the solvent mixture to obtain the bilipidated 
disaccharide 4-3 (6.0 mg, 0.006 mmol, 50%) 31P NMR (162 MHz, MeOD) δ -0.69. ESI-MS 







Activated zinc (0.11 g, 1.73 mmol) was suspended in THF (10 mL) and transferred to the 
pseudodisaccharide 4-31 (0.12 g, 0.12 mmol). Ac2O (0.033 mL, 0.35 mmol) and AcOH 
(0.007 mL, 0.115 mmol) were added and reaction mixture was stirred at room temperature for 
4 h. The reaction mixture was filtered through celite and washed with saturated NaHCO3 
twice. The organic phase was dried over Na2SO4 and concentrated. The crude product was 
purified by flash column chromatography to obtain 4-33 (0.087 mg, 0.082 mmol, 71%). R f = 
0.3 (EtOAc/hexane = 1:1) 1H NMR (400 MHz, CDCl3) δ 7.33 (dd, J = 14.5, 7.4 Hz, 4H), 7.27 
– 7.00 (m, 60H), 5.66 (ddt, J = 16.4, 10.3, 6.1 Hz, 1H), 5.18 (d, J = 3.3 Hz, 1H), 5.16 – 5.15 
(m, 1H), 5.13 – 5.05 (m, 3H), 4.94 – 4.75 (m, 7H), 4.76 – 4.63 (m, 10H), 4.63 – 4.60 (m, 3H), 
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4.60 – 4.53 (m, 4H), 4.42 (dd, J = 24.7, 11.4 Hz, 3H), 4.35 – 4.18 (m, 2H), 4.19 – 3.98 (m, 
3H), 3.99 – 3.90 (m, 11H), 3.82 (dd, J = 12.0, 6.0 Hz, 2H), 3.75 – 3.64 (m, 4H), 3.64 – 3.48 
(m, 4H), 3.47 – 3.18 (m, 5H), 3.11 (dd, J = 10.0, 2.0 Hz, 2H), 1.76 (s, 3H). 13C NMR (101 
MHz, CDCl3) δ 169.91, 138.75, 138.61, 138.43, 138.29, 138.22, 138.13, 133.52, 128.49, 
128.38, 128.35, 128.28, 128.24, 128.09, 128.03, 127.90, 127.82, 127.78, 127.68, 127.60, 
127.54, 127.40, 119.11, 100.30, 83.12, 81.99, 81.20, 80.84, 79.73, 79.19, 78.23, 75.82, 75.54, 
74.99, 74.79, 74.25, 73.41, 73.04, 72.83, 72.09, 71.13, 68.75, 53.49, 23.29. ESI-MS (m/z): 








To a stirred solution of 4-33 (0.07 g, 0.062mmol) in MeOH/ CH2Cl2 (3:1) was added PdCl2 (4 
mg, 0.019 mmol) at room temperature. The reaction was stirred for 12 h, quenched with TEA 
and concentrated. The crude product was purified by flash column chromatography to obtain 
4-34 (0.04 g, 0.04 mmol, 72%) Rf = 0.35 (EtOAc/hexane = 3:2). Disaccharide 4-34 (0.04 g, 
0.04 mmol) and H-phosphonate 4-8 (0.09 g, 0.13 mmol) were co-evaporated with pyridine for 
three times and dried under high vacuum for 2 h. The mixture was dissolved in anhydrous 
pyridine (7 mL) and a solution of pivolyl chloride (0.016 mL, 0.13 mmol) in pyridine (1 mL) 
was added. The solution was stirred for 48 h at room tmeperature. After 48 h, iodine (0.11 g, 
0.44 mmol) and water (0.3 mL) were added and the reaction was stirred for 4 h. The reaction 
mixture was quenched with Na2S2O3 and extracted with CH2Cl2. The organic layers were 
concentrated and the crude product was purified with Et3N deactivated silica gel flash column 
chromatography to obtain bilipidated disaccharide 4-35 (0.045 g, 0.027 mmol, 60%). R f = 0.6 
(MeOH/ CH2Cl2 = 1:9) 1H NMR (400 MHz, CDCl3) δ 7.49 – 7.09 (m, 40H), 5.50 (d, J = 2.4 
Hz, 2H), 5.32 (d, J = 3.4 Hz, 1H), 5.21 (dd, J = 6.6, 3.0 Hz, 1H), 5.05 – 4.89 (m, 2H), 4.88 – 
4.61 (m, 7H), 4.47 (dd, J = 23.7, 11.5 Hz, 1H), 4.42 – 4.24 (m, 4H), 4.22 – 3.88 (m, 8H), 3.83 
– 3.66 (m, 1H), 3.47 – 3.34 (m, 3H), 2.33 – 2.15 (m, 4H), 2.07 (s, 3H), 1.53 (s, 2H), 1.25 (d, J 
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= 9.5 Hz, 51H), 0.89 (t, J = 6.8 Hz, 6H). 31P NMR (162 MHz, CDCl3) δ -1.12. ESI-MS (m/z): 







To a stirred solution of pseudodisaccharide 4-35 (30.0 mg, 0.018 mmol) in mixture of 
CH2Cl2/MeOH/H2O (3:3:1, 5 mL) at room temperature was added Pd(OH)2 on C (17 mg, 
0.024 mmol, 20% Pd content). Hydrogen gas was bubbled through the solution for 15 min 
and the reaction mixture was stirred under an atmosphere of hydrogen gas for additional 24 h. 
The Pd(OH)2 was removed by filtration through a pad of celite and the solution was 
concentrated. The crude product was purified by size exclusion chromatography on a LH20 
column using CH2Cl2/MeOH/H2O (3:3:1) as the solvent mixture to obtain the bilipidated 
disaccharide 4-4 (9.0 mg, 0.009 mmol, 50%). 1H NMR (400 MHz, Methanol-d4) δ 7.27 (s, 
1H), 5.04 (d, J = 5.6 Hz, 2H), 4.01 (ddd, J = 23.1, 11.1, 5.5 Hz, 2H), 3.94 – 3.61 (m, 5H), 
3.65 – 3.41 (m, 8H), 3.41 – 3.25 (m, 3H), 3.09 (q, J = 7.3 Hz, 5H), 2.96 – 2.73 (m, 0H), 2.32 
– 2.22 (m, 3H), 2.21 (dd, J = 13.4, 7.5 Hz, 1H), 2.00 – 1.91 (m, 1H), 1.53 (s, 2H), 1.17 (s, 
44H), 1.03 (d, J = 6.5 Hz, 4H), 0.83 – 0.71 (m, 6H). 31P NMR (162 MHz, MeOD) δ 0.44. 
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To the stirred solution triol 4-37 (0.3 g, 0.31 mmol) in anhydrous DMF (12 mL) was added 
NaH (0.045 g, 1.86 mmol) at 0 °C. After 20 min, NAPBr (0.27 g, 1.24 mmol) was added; the 
reaction was warmed to room temperature and stirred for 24 h. The reaction was quenched 
with MeOH and concentrated. The crude product was purified with flash chromatography to 
obtain 4-38 (0.35 g, 0.25 mmol, 82%). Activated zinc (0.1 g, 0.1 mmol) was suspended in 
THF and transferred to the pseudodisaccharide 4-38. Ac2O (0.03 mL, 0.33 mmol) and AcOH 
(0.006 mL, 0.011mmol) were added and reaction mixture was stirred at room temperature for 
4 h. The reaction mixture is filtered through celite and washed with saturated NaHCO3 twice. 
Organic phases were dried over Na2SO4 and concentrated. The crude residue was purified 
with flash column chromatography to obtain 4-39 (0.12 g, 0.086 mmol, 79%). Rf = 0.2 
(EtOAc/hexane = 1:1) 1H NMR (400 MHz, CDCl3) δ 7.90 – 7.31 (m, 109H), 7.21 (ttd, J = 
16.6, 8.3, 1.4 Hz, 4H), 5.74 – 5.60 (m, 1H), 5.44 (d, J = 3.4 Hz, 1H), 5.36 – 5.23 (m, 1H), 
5.23 – 5.10 (m, 5H), 5.10 – 4.95 (m, 11H), 4.91 (dd, J = 23.6, 12.3 Hz, 5H), 4.88 – 4.57 (m, 
5H), 4.50 (td, J = 10.1, 3.4 Hz, 1H), 4.45 – 4.20 (m, 5H), 4.23 – 4.01 (m, 4H), 3.98 – 3.78 (m, 
5H), 3.77 – 3.55 (m, 7H), 3.54 – 3.44 (m, 3H), 3.26 (dd, J = 10.0, 2.0 Hz, 1H), 1.88 (s, 2H). 
13C NMR (101 MHz, CDCl3) δ 169.95, 136.27, 136.18, 136.07, 135.87, 135.68, 135.58, 
135.46, 133.32, 133.23, 133.18, 133.12, 133.00, 132.95, 132.91, 132.89, 132.83, 128.30, 
128.13, 128.09, 128.04, 127.98, 127.94, 127.92, 127.86, 127.75, 127.68, 127.62, 126.65, 
126.57, 126.44, 126.40, 126.27, 126.24, 126.19, 126.13, 126.10, 126.08, 126.03, 125.98, 
125.90, 125.84, 125.81, 125.76, 125.66, 118.90, 116.02, 100.37, 83.16, 82.03, 81.10, 80.63, 
79.95, 78.91, 78.45, 77.28, 75.90, 75.65, 75.05, 74.79, 74.30, 73.55, 73.17, 72.72, 72.12, 
71.18, 68.81, 60.47, 53.47, 29.76, 23.47, 21.14, 14.26.  
 
3,4,6–Tri-O-(2-naphthyl)methyl-2-acetamide-2-deoxy--D-glucopyranosyl-(1→6)-
2,3,4,5-tetra-O-(2-naphthyl)methyl -D-myo-inositol (4-40) 
 
 
To a stirred solution of 4-39 (0.12 g, 0.086 mmol) in MeOH/ CH2Cl2 (3:1) was added PdCl2 
(6 mg, 0.034 mmol) at room temperature. The reaction was stirred for 12 h and quenched with 
Et3N and concentrated. The crude residue was purified with flash column chromatography to 
obtain 4-40 (0.07 g, 0.05 mmol, 59%). R f = 0.25 (EtOAc/hexane = 3:2) 1H NMR (400 MHz, 





CDCl3) δ 7.80 – 7.68 (m, 17H), 7.70 – 7.63 (m, 13H), 7.61 (d, J = 8.6 Hz, 13H), 7.61 – 7.36 
(m, 43H), 7.40 – 7.32 (m, 13H), 7.34 – 7.21 (m, 12H), 7.19 (s, 9H), 6.94 (dd, J = 8.4, 1.3 Hz, 
2H), 6.04 (d, J = 9.1 Hz, 1H), 5.27 (d, J = 3.4 Hz, 1H), 5.16 (d, J = 11.8 Hz, 1H), 5.07 (d, J = 
11.0 Hz, 2H), 5.05 – 4.60 (m, 17H), 4.44 (t, J = 12.4 Hz, 3H), 4.23 (td, J = 9.7, 3.4 Hz, 2H), 
4.14 (t, J = 9.6 Hz, 2H), 4.05 (d, J = 12.3 Hz, 2H), 3.91 (d, J = 5.2 Hz, 3H), 3.74 (dt, J = 25.5, 
9.1 Hz, 3H), 3.48 (d, J = 9.9 Hz, 1H), 3.37 – 3.30 (m, 6H), 3.26 (d, J = 9.1 Hz, 1H), 1.61 (s, 
4H) 13C NMR (101 MHz, CDCl3) δ 170.20, 135.98, 135.88, 135.66, 135.42, 135.35, 133.21, 
133.09, 132.87, 132.82, 128.68, 128.43, 128.10, 127.94, 127.91, 127.81, 127.76, 127.64, 
127.14, 126.77, 126.61, 126.55, 126.49, 126.38, 126.32, 126.22, 126.11, 125.99, 125.96, 
125.93, 125.85, 125.79, 125.73, 98.99, 81.45, 80.76, 80.31, 78.01, 77.25, 75.88, 75.04, 74.82, 
74.63, 73.35, 72.57, 71.55, 68.16, 53.10, 23.35. ESI-MS (m/z): [M+Na]+ cald 1385.6 obsd 







Disaccharide 4-40 (0.03 g, 0.022 mmol) and H-phosphonate 4-9 (0.045 g, 0.066 mmol) were 
co-evaporated with pyridine for three times and dried under high vacuum for 2 h. The mixture 
was dissolved in anhydrous pyridine (4 mL) and a solution of pivolyl chloride (0.007 mL, 
0.064 mmol) in pyridine (0.5 mL) was added. The solution was stirred for 48 h at room 
temperature. After 48 h, reaction mixture is concentrated and redissolved in CH2Cl2. To the 
stirred solution of crude phosphonate in CH2Cl2 (5 mL) was added BrCCl3 (0.03 g, 0.088 
mmol)  and Et3N (0.03 g, 0.18 mmol)  and the reaction was stirred for 3 h. Reaction mixture 
was concentrated and purified using Et3N quenched flash column chromatography to obtain 
bilipidated disaccharide 4-41 (0.03 g, 0.013 mmol, 61%). R f = 0.55 (MeOH/DCM = 2:9). 31P 
NMR (162 MHz, CDCl3) δ -1.55(-0.44 rotamer). MALDI-MS (m/z): [M-H]- cald 2048.617 
obsd 2048.488.  
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To the stirred solution of disaccharide 4-41 (0.02 g, 0.01 mmol) in a mixture of TFA/anisole 
(v/v = 10:2, 3.0 mL) at 0 ºC for 2 h, was warmed to room temperature and stirred for 
additional 3 h. The mixture was diluted with toluene (2 mL), concentrated. The crude product 
was purified by Sephadex LH-20 size exclusion chromatography (CHCl3/MeOH/H2O = 3:3:1) 
to give the pseudodisaccharide 4-5 (8.3 mg, 0.008 mmol, 80%). 31P NMR (162 MHz, MeOD) 
δ 0.09, MALDI-MS (m/z): [M+Na]+ cald 1090.641 obsd 1090.670, [M+2Na-H]+ cald 








Disaccharide 4-7a (0.03 g, 0.03 mmol) and H-phosphonate 4-10 (0.06 g, 0.09 mmol) were co-
evaporated with pyridine for three times and dried under high vacuum for 2 h. The mixture 
was dissolved in anhydrous pyridine (5 mL) and a solution of pivolyl chloride (0.01 mL, 0.09 
mmol) in pyridine (1 mL) was added. The solution was stirred for 48 h at room temperature. 
After 48 h, iodine (0.04 g, 0.15 mmol) and water (0.2 mL) were added and reaction was 
stirred for 4 h. The reaction mixture was quenched with Na2S2O3 and extracted with CH2Cl2. 
The organic layer were concentrated and purified with Et3N quenched flash column 
chromatography to obtain bilipidated disaccharide 4-42 (0.03 mg, 0.003 mmol, 55%). R f = 
0.6 (MeOH/DCM = 1:9) 1H NMR (400 MHz, CDCl3) δ 7.43 (dd, J = 22.7, 7.9 Hz, 2H), 7.34 
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(s, 5H), 7.31 (d, J = 5.8 Hz, 7H), 7.25 (d, J = 12.9 Hz, 8H), 7.06 (s, 2H), 5.25 (dt, J = 11.7, 5.8 
Hz, 1H), 5.05 – 3.95 (m, 23H), 3.78 – 3.21 (m, 8H), 3.07 – 2.96 (m, 3H), 2.29 (dq, J = 12.3, 
7.5 Hz, 5H), 1.63 – 1.56 (m, 7H), 1.30 (d, J = 7.2 Hz, 43H), 1.12 – 1.06 (m, 7H), 0.91 (t, J = 
6.6 Hz, 6H), 0.85 (dd, J = 6.3, 2.8 Hz, 8H).31P NMR (162 MHz, CDCl3) δ -1.87. MALDI-MS 







To the stirred solution of pseudodisaccharide 4-42 (21.0 mg, 0.013 mmol) in mixture of 
CH2Cl2/MeOH/H2O (3:3:1, 5 mL) at room temperature was added Pd(OH)2 on C (17 mg, 
0.024 mmol, 20% Pd content). Hydrogen gas was bubbled through the solution for 15 min 
and the reaction mixture was stirred under an atmosphere of hydrogen gas for additional 24 h. 
The Pd(OH)2 was removed by filtration through a pad of celite and the solution was 
concentrated. The crude product was purified by LH20 size exclusion chromatography with 
CH2Cl2/MeOH/H2O (3:3:1) as the solvent mixture to obtain the bilipidated disaccharide 4-6 
(6.6 mg, 0.007 mmol, 52%). 1H NMR (400 MHz, MeOD) δ 5.50 (d, J = 31.7 Hz, 1H), 5.28 (s, 
1H), 4.44 (d, J = 11.7 Hz, 3H), 4.26 – 4.16 (m, 3H), 4.09 (s, 3H), 4.04 – 3.91 (m, 2H), 3.84 
(d, J = 10.6 Hz, 3H), 3.71 (dd, J = 14.4, 10.2 Hz, 1H), 3.50 – 3.38 (m, 4H), 3.18 (q, J = 7.3 
Hz, 2H), 2.35 (dt, J = 15.3, 7.5 Hz, 6H), 1.61 (s, 4H), 1.29 (d, J = 11.2 Hz, 44H), 1.13 – 1.07 
(m, 7H), 0.90 (d, J = 6.6 Hz, 6H), 0.85 (d, J = 6.5 Hz, 9H). 13C NMR (101 MHz, MeOD) δ 
174.30, 174.01, 95.34, 77.84, 77.52, 77.20, 73.05, 72.53, 72.32, 70.97, 70.15, 69.77, 62.79, 
54.13, 46.57, 37.02, 34.15, 34.04, 32.69, 31.83, 29.92, 29.68, 29.61, 29.58, 29.26, 29.13, 
26.98, 24.90, 24.81, 22.56, 19.48, 19.43, 13.81, 13.77, 8.30, 6.74, -19.42. 31P NMR (162 












 Material and Methods for Biophysical Studies 4.7.3
For the monolayer experiments, 1 mM solutions of all the fragments were prepared in a 
mixture of chloroform (Merck, Germany; purity >99.8%), methanol (Merck, Germany; purity 
>99.9%) and ultrapure water (Millipore, resistivity of 18 MΩ cm) in a 6:2:0.2 volume ratios. 
 
Surface Pressure – Area Isotherms   
The pressure/area (π/A) isotherms were recorded during compression of the monolayer on a 
computer-interfaced Langmuir trough (R&K, Potsdam, Germany) including a surface 
pressure microbalance with filter paper Wilhelmy plate. The results were plotted as surface 
pressure (π) versus the area per molecule. The bare water surface was checked for purity by 
compression before each measurement. The temperature of the Milli-Q Millipore water 
subphase was maintained at 20 °C by an external thermostat. The Langmuir layers were 
prepared by spreading the chloroform: methanol: water solutions of the fragments at the 
air/water interface. Before compression, the monolayers were left to equilibrate for 15 
minutes in order to allow the evaporation of the spreading solvents. Each measurement was 
repeated at least two times to prove the reproducibility of results. In order to avoid dust 
contamination of the interface and to ensure a constant humidity, the Langmuir trough was 
placed in a sealed box.  
 
Grazing Incidence X-ray Diffraction (GIXD)  
The grazing incidence X-ray diffraction measurements were carried out at the undulator 
beamline P08 using the Langmuir trough GID setup at PETRA III, DESY (Hamburg, 
Germany). The setup is equipped with a temperature controlled Langmuir trough (R&K, 
Potsdam, Germany), which is enclosed in a sealed, helium-filled container. The synchrotron 
X-ray beam is monochromated to an energy of 15 keV (wavelength of 0.827 Å) and is 
adjusted to strike the helium/water interface at a grazing incidence angle αi = 0.07° 
illuminating approximately 1 × 50 mm2 of the monolayer surface. A MYTHEN detector 
(DECTRIS Ltd., Switzerland) measures the diffracted signal and is rotated to scan the in-
plane Qxy component values of the scattering vector. A Soller collimator in front of the 
MYTHEN restricted the in-plane divergence of the diffracted beam to 0.09°. The vertical 
strips of the MYTHEN measure the out-of-plane Qz component of the scattering vector 
between 0.0 and 0.75 Å-1. The diffraction data consist of Bragg peaks at diagnostic Qxy values 
obtained by summing the diffracted intensity over a defined vertical angle or Qz-window. The 





from the Bragg peak positions: d = 2π/Qxy. To estimate the extent of the crystalline order in 
the monolayer, the in-plane coherence length Lxy, is approximated from the full-width at half-
maximum (fwhm) of the Bragg peaks using Lxy~ 0.9(2π)/fwhm(Qxy) using the measured 
fwhm(Qxy) corrected for the instrumental resolution. Integrating the diffracted intensity 
normal to the interface over the Qxy window of the diffraction peak yields he corresponding 
Bragg rod. The thickness of the scattering unit is estimated from the fwhm of the Bragg rod 
using 0.9(2π)/fwhm(Qz).  
 
Infrared Reflection Absorption Spectroscopy (IRRAS) 
Infrared reflection absorption spectra were recorded using the Vertex 70 FT-IR spectrometer 
(Bruker, Germany), equipped with a liquid-nitrogen cooled MCT detector and coupled to a 
Langmuir film balance, which was placed in a sealed container (an external air/water 
reflection unit (XA 5 511, Bruker)) to guarantee a constant vapor atmosphere. Using a KRS-5 
(thallium bromide and iodide mixed crystal) wire grid polarizer, the IR-beam was polarized 
parallel (p) or vertical (s) and focused on the fluid subphase at an angle of incidence of 40°. A 
computer controlled ‘trough shuttle system’ enables us to choose between the compartment 
with the sample (subphase with spread layer) and a reference compartment (pure subphase). 
The single-beam reflectance spectrum from the reference trough was taken as background for 
the single-beam reflectance spectrum of the monolayer in the sample trough to calculate the 
reflection absorption spectrum as -log(R/R0) in order to eliminate the water vapor signal. 
FTIR spectra were collected at a resolution of 8 cm-1 using 200 scans for s-polarized light and 
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3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-N-phthalimido--D-glucopyranosyl trichloroacetimidate (2-13) 
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1-O-(6-thiobenzyl)hexyl-3,6-O-benzyl-2-deoxy-2-N-phthalimido--D-glucopyranoside (2-14)  
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mannopyranosyl-(1→4)-2-amino-2-deoxy--D-glucopyranoside (GPI 1) 
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mannopyranosyl-(1→6)--D-mannopyranosyl-(1→4)-2-deoxy-2-amino--D-glucopyranoside (GPI 2) 
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mannopyranosyl-(1→6)--D-mannopyranosyl-(1→4)-2-deoxy-2-amino--D-glucopyranoside (GPI 3) 
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3,4,6-tri-O-benzyl-α-D-mannopyranosyl-(1→2)-3,4-di-O-benzyl-6-O-(2-(N-(tert-butoxycarbonyl)-S-(tert-butyl)-L-cysteinyl)aminoethyl phosphonato)-α-D-mannopyranosyl-(1→2)-3,4,6-tri-O-benzyl-α-D-mannopyranosyl-(1→6)-2-O-levulinyl-3,4-di-O-benzyl-α-D-mannopyranosyl-(1→4)-2-azido-3,6-di-O-benzyl-2-deoxy-α-D-glucopyranosyl-(1→6)-1-O-(1,2-dimyristoyl-sn-glyceryl-phosphonato)-2,3,4,5-tetra-O-benzyl-D-myo-inositol (3-1) 
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α-D-mannopyranosyl-(1→2)-6-O-(N-(S-S-mercaptoethanol-L-cysteinyl)aminoethanol-phosphonato)-α-D-mannopyranosyl-(1→2)-α-D-mannopyranosyl-(1→6)-α-D-mannopyranosyl-(1→4)-2-amino-2-deoxy-α-D-glucopyranosyl-(1→6)-1-O-(1,2-dimyristoyl-sn-glyceryl-phosphonato)-D-myo-inositol (PfGPI 1) 
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(S)-1-((4-methoxybenzyl)oxy)-3-(stearoyloxy)propan-2-yl octadec-9-enoate (4-16) 
 
 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
f 
I 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
.JUUUU 
PMEIO O G J I \ \ . D ¶ ' f * " l f \ l O O \ I \ I " 1 O O C O I I \ t \ \ D < I ' l \ J 1 - I O C O † f ¬ " ) ( \ l l \ l O I " 1 O C D I I \ f \ l ¬ - l O O W  ı . n < ı - m m m m n ı m - ı - ı o o L n m m m m m m m m m o a o o o u o m m m m m m c n ø o  ¬ - I 1 - 1 1 - < 1 - I O O O O O  28000 
0 













Iı 2000 II I iM J 
'T' *r 1-1 0: 
1-1 
'T' |\ eo N 
Ego -2000 




*r 'T' 3 3 M M 
I 2 I -2 I 16 14 I 13 I 8 7 6 f f  (ppm) 
I 5 
v**<*m*< f \ l l D ! ¶ ' l \ O  °ı°±°ı°=z°ı v - ıOOf \ I v -4
I 4 I 3 
o Q LD 
I 1 I 0 I -1 I -3 
Q Q Ü U U U Q Q O U U U 1-1 m m ı.n 1-1 
5 w  ocnow M A N  .-<.-<.-. \I/ 
1-1 on m 1-1 1-1 
l \  ı.n m |\ I \ I  OO 1-1 m o | \  m o on l`\ g 
ın ın ı 
-2200 < r u ¬ L o < r o < r ¬ - ı ¬ - ı r ~ r - m ¬ - ı \ o m < r u o c ¬ u ¬ c › r \ ¬ - ı m m r ~  M H $ $ ® ß ß ß © M M † M M N ﬁ O N N $ @ ß ß ﬁ  
† † H H ® ® ® @ ® ® ® O @ ® ® @ ® h h † † N N †  
La-Jı=ıı' ¦ T . K " J " " J "  _ I r - - -  
|\ N KD N o |\ N |\ \ n |\ N o Q v / 
O 














I 700 I 
600 
I 500 I 
400 
I I I 
I I 300 




I I I I I I I I I I I I 210 I 200 I 190 180 I 170 I 160 
ı 
150 140 I 130 I 120 
ı 
110 100 90 f f  (ppm) 
Ju 









(S)-1-hydroxy-3-(stearoyloxy)propan-2-yl octadec-9-enoate (4-17) 
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(2R)-1-((hydroxyhydrophosphoryl)oxy)-3-(stearoyloxy)propan-2-yl octadec-9-enoate (4-9) 
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3,4,6–Tri-O-acetyl-2-azido-2deoxy--D-glucopyranosyl trichloroacetimidate (4-11) 
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3,4,6–Tri-O-benzyl-2-azido-2-deoxy--D-glucopyranosyl-(1→6)-1-O-(1,2-O-distearoyl-sn-glycerol)-phosphate-2,3,4,5-tetra-O-benzyl--myo-inositol (4-32)  
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3,4,6–Tri-O-benzyl-2-acetamide-2-deoxy--D-glucopyranosyl-(1→6)-1-O-allyl-2,3,4,5-tetra-O-benzyl-D-myo-inositol (4-33)  
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3,4,6–Tri-O-benzyl-2-acetamide-2-deoxy--D-glucopyranosyl-(1→6)- 1-O-(1,2-O-distearoyl-sn-glycerol)-phosphate -2,3,4,5-tetra-O-benzyl-D-myo-inositol (4-35)  
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3,4,6–Tri-O-(2-naphthyl)methyl -2-acetamide-2-deoxy--D-glucopyranosyl-(1→6)- 1-O-allyl-2,3,4,5-tetra-O-(2-naphthyl)methyl -D-myo-inositol (4-39) 
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3,4,6–Tri-O-(2-naphthyl)methyl-2-acetamide-2-deoxy--D-glucopyranosyl-(1→6)-2,3,4,5-tetra-O-(2-naphthyl)methyl -D-myo-inositol (4-40) 
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3,4,6–Tri-O-(2-naphthyl)methyl-2-acetamide-2-deoxy--D-glucopyranosyl-(1→6)- 1-O-(1-O-stearoyl-2-O-oleoyl-sn-glycerol)-phosphate-2,3,4,5-tetra-O-(2-naphthyl)methyl -D-myo-inositol (4-41)  
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